<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>a2191551zex-2_1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 2.1</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXECUTION
VERSION</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SHARE
PURCHASE AGREEMENT</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMONG</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">VERTEX
PHARMACEUTICALS INCORPORATED, as the Parent,</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman"><font style="font-size:10.0pt;font-weight:bold;">VERTEX PHARMACEUTICALS (CANADA) INCORPORATED</font>, as the Purchaser,</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">-
AND -</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">VIROCHEM
PHARMA INC., as the Corporation,</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">-
AND -</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THE
SECURITYHOLDERS OF</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">VIROCHEM
PHARMA INC., as Vendors</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">-
AND -</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FRAN&#199;OIS LEGAULT,</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AS REPRESENTATIVE</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OF CERTAIN OF THE SECURITYHOLDERS OF</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">VIROCHEM
PHARMA INC.</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MADE
THIS</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3</font></b><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;position:relative;top:-3.0pt;">rd</font>&#160;DAY OF MARCH, 2009</b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">McCarthy
T&#233;trault LLP</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=1,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=93673,FOLIO='',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-01_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:26 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TABLE
OF CONTENTS</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="6%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="87%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="5%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Page</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">ARTICLE&nbsp;1
  - INTERPRETATION</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">2</font></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.01</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Definitions</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.02</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Headings</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.03</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Extended Meanings</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.04</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Statutory References</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.05</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounting Principles</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.06</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Actions on Non-Business Days</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.07</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Currency</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.08</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Control</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.09</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedules</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">ARTICLE&nbsp;2
  - SALE AND PURCHASE</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">14</font></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.01</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shares to be Sold and Purchased</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.02</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase Price</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.03</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Payment of Purchase Price</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.04</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase Price Adjustment</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.05</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Share Consideration Adjustment</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.06</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;116 Withholding</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.07</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;1097 Withholding</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">ARTICLE&nbsp;3
  - REPRESENTATIONS AND WARRANTIES</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">22</font></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.01</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vendors&#146; Representations and
  Warranties</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.02</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporation&#146;s Representations and
  Warranties</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.03</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Representations and Warranties of
  the Purchaser and Parent</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">ARTICLE&nbsp;4
  - COVENANTS</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">43</font></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.01</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Covenants of the Vendors and of the
  Corporation</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">43</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.02</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Covenants of Parent</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">45</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.03</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Covenants of all Parties</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">45</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.04</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Directors&#146; and Officers&#146; Liability
  Insurance</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.05</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tax Matters</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.06</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Confidentiality</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">48</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.07</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Release of Claims</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">ARTICLE&nbsp;5
  - CONDITIONS AND TERMINATION</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">49</font></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.01</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Conditions to Closing of Each Party</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.02</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Conditions for the Benefit of the
  Purchaser and the Parent</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.03</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Conditions for the Benefit of the
  Vendors</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.04</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Waiver of Condition</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">52</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">i</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=2,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=89350,FOLIO='',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-01_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:26 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.05</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Termination</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">52</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.06</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Effect of Termination</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">ARTICLE&nbsp;6
  - CLOSING ARRANGEMENTS</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">54</font></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.01</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Closing</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">54</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.02</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deliveries</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">54</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">ARTICLE&nbsp;7
  &#150; SURVIVAL OF REPRESENTATIONS AND WARRANTIES AND INDEMNIFICATION</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">57</font></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.01</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Survival of Representations and
  Warranties</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">57</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.02</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indemnification by the Vendors and
  ViroChem Employees</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.03</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indemnification by the ESOP Holders</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">61</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.04</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indemnification by the Purchaser
  and the Parent</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">62</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.05</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Claims for Fraud</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">63</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.06</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indemnification Procedures</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">63</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.07</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exclusive Remedy</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">65</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.08</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adjustment to Purchase Price</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">65</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.09</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Securityholders&#146; Representative</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">65</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">ARTICLE&nbsp;8
  - GENERAL</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">67</font></p>
  </td>
 </tr>
 <tr>
  <td width="94%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:94.22%;">
  <p style="margin:0in 0in .0001pt;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-transform:uppercase;"><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.01</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Further Assurances</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">67</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.02</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Time of the Essence</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">67</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.03</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fees and Commissions</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">67</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.04</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Public Announcements</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">67</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.05</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Benefit of the Agreement</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">68</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.06</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Entire Agreement</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">68</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.07</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amendments and Waivers</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">68</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.08</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Assignment</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">68</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.09</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notices</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">69</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.10</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Remedies Cumulative</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">73</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.11</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No Third Party Beneficiaries</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">73</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.12</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Governing Law</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">74</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.13</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attornment</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">74</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.14</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Severability</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">74</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.15</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Representation by Counsel</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">74</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.16</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Construction</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">74</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.17</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Counterparts</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">75</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.34%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.18</font></p>
  </td>
  <td width="87%" valign="top" style="padding:0in .7pt 0in .7pt;width:87.88%;">
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Electronic Execution</font></p>
  </td>
  <td width="5%" valign="top" style="padding:0in .7pt 0in .7pt;width:5.78%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">75</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ii</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=3,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=1027447,FOLIO='',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-01_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:26 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SHARE
PURCHASE AGREEMENT</font></u></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">THIS AGREEMENT
is made as of March&nbsp;3, 2009</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AMONG:</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 1.0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">VERTEX
PHARMACEUTICALS INCORPORATED</font></b>, a corporation
incorporated under the laws of The Commonwealth of Massachusetts (the &#147;<b>Parent</b>&#148;),</p>

<p style="margin:0in 1.0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">- and -</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 1.0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">VERTEX
PHARMACEUTICALS (CANADA) INCORPORATED </font></b>, a
corporation incorporated under the laws of the Province of British Columbia,
Canada (the &#147;<b>Purchaser</b>&#148;),</p>

<p style="margin:0in 1.0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">- and -</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 1.0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">VIROCHEM
PHARMA INC.</font></b>, a corporation incorporated
under the laws of Canada (the &#147;<b>Corporation</b>&#148;),</p>

<p style="margin:0in 1.0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">- and -</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 1.0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The persons
and entities who are listed in <b>Schedule&nbsp;A</b>
hereto under the caption &#147;Vendors&#148; (collectively, the &#147;<b>Vendors</b>&#148;).</font></p>

<p style="margin:0in 1.0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">- and -</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FRAN&#199;OIS LEGAULT</font></b>, as representative of certain of the
securityholders of ViroChem Pharma Inc. (the &#147;<b>Securityholders&#146; Representative</b>&#148;)</p>

<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS the
Vendors are the beneficial and registered owners of the Shares;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS the
ViroChem Trust (as such term is defined hereinafter) holds the ViroChem Shares
(as such term is defined hereinafter) in trust for and on behalf of the
ViroChem Employees (as such term is defined hereinafter) and has the power to
execute this Agreement (as such term is defined hereinafter) for and on behalf
of itself and the ViroChem Employees who will have exercised, after the date
hereof and prior to the Time of Closing (as such term is defined hereinafter),
their options under the Trust ESOP (as such term is defined hereinafter) to
acquire shares of the Corporation which are held by the ViroChem Trust at the
time of execution of this Agreement and who will have intervened hereto by
executing the intervention provided for in Section&nbsp;6.02(2)(a)&nbsp;hereof;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS the
ESOP Holders (as such term is defined hereinafter) are those Persons (as such
term is defined hereinafter) who will have exercised their options under the
ESOP (as such term is defined hereinafter) after the date hereof and prior to
the Time of Closing, will therefore</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=4,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=26552,FOLIO='',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-01_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:26 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">hold the ESOP
Shares (as such term is defined hereinafter) at the Time of Closing and will
have intervened hereto by executing the intervention provided for in Section&nbsp;6.02(2)(b)&nbsp;hereof;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AND WHEREAS
the Purchaser desires to purchase, and the Vendors, including the ViroChem
Trust, on its own behalf and for and on behalf of the ViroChem Employees, and
the ViroChem Employees and the ESOP Holders desire to sell, the Shares (as such
term is defined hereinafter), the ViroChem Shares and the ESOP Shares, which
will constitute all of the issued and outstanding equity capital of the
Corporation at the Time of Closing, upon and subject to the terms and
conditions set out in this Agreement;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW THEREFORE,
in consideration of the covenants and agreements herein contained, the parties
agree as follows:</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:avoid;text-align:center;text-decoration:underline;text-transform:uppercase;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">ARTICLE&nbsp;1 - INTERPRETATION</font></u></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:avoid;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.01</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Definitions</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In this
Agreement, unless something in the subject matter or context is inconsistent
therewith:</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>2008 Audited Financial Statements</b>&#148; means the audited
financial statements of the Corporation, prepared in accordance with Canadian
generally accepted accounting principles, consisting of a balance sheet and
statements of income, retained earnings and cash flows for each of the three
years ended December&nbsp;31, 2008, 2007 and 2006, together with the reports of
Deloitte and Touche LLP, chartered accountants, thereon and the notes thereto.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Affiliate</b>&#148; means, with respect to any person, any other
person that controls or is controlled by or is under common control with the
referent person.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Agreement</b>&#148; means this agreement, including its recitals and
schedules, as amended from time to time.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Applicable Law</b>&#148; means, with respect to any Person, property,
transaction, event or other matter, (i)&nbsp;any foreign or domestic
constitution, treaty, law, statute, regulation, code, ordinance, principle of
common law or equity, rule, municipal by-law, order or other requirement
(including a requirement arising at common law) having the force of law, and (ii)&nbsp;any
policy, practice, protocol, standard or guideline of any Governmental Authority
having the force of law relating or applicable to such Person, property,
transaction, event or other matter.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Asset Purchase Agreement</b>&#148; means the asset purchase agreement
dated April&nbsp;7, 2004 between Shire and the Corporation, as amended on June&nbsp;28,
2007.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Audits</b>&#148; has the meaning set out in Section&nbsp;3.02(16)(d).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Audited Financial Statements</b>&#148; has the meaning set out in Section&nbsp;3.02(5)(b).</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=5,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=453358,FOLIO='2',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-01_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:26 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>BDC</b>&#148; means BDC Capital Inc.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Benefit Plans</b>&#148; has the meaning set out in Section&nbsp;3.02(9)(a).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Business Day</b>&#148; means a day other than a Saturday, Sunday or
statutory holiday in the Province of Qu&#233;bec, Canada or in Boston,
Massachusetts.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>CDPQ</b>&#148; means Caisse de d&#233;p&#244;t et
placement du Qu&#233;bec.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Canadian Purchase Price</b>&#148; means the portion of the Closing
Purchase Price allocated to each Non-Resident Vendor notionally converted into
Canadian dollars, using the noon exchange rate of the Bank of Canada on the
Closing Date, as set out in Column&nbsp;36 on the attached <b>Schedule&nbsp;2.02(2)</b>.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Claims</b>&#148; means all losses, damages, expenses, liabilities
(whether accrued, actual or contingent), claims and demands of whatever nature
or kind including all reasonable legal fees and disbursements, but excluding
any indirect, incidental, consequential, special or punitive damages or loss of
profits (except to the extent awarded by a court of competent jurisdiction in
any Third Party Proceedings) and with respect to a Claim that arises directly
or indirectly out of or results from any inaccuracy or misrepresentation in the
representations and warranties contained in Section&nbsp;3.02(19) (<i>Tax Matters</i>), the amount of such Claim shall be computed
after applying all the tax attributes of the Corporation (including any
undeducted research and development expenditures, capital cost allowance,
deductions, tax credits, non-capital losses, capital losses) actually available
and valid at the Closing Date to reduce the amount of the Claim otherwise
determined.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Closing Balance Sheet</b>&#148; has the meaning set out in Section&nbsp;2.04(5).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Closing Date</b>&#148; means the first Business Day following the
date on which the conditions set forth in Article&nbsp;5 are satisfied (other
than those conditions which by their nature are satisfied at closing) or
waived, or such other date as mutually agreed by the Corporation and the
Purchaser.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Closing Purchase Price</b>&#148; means the amount equal to the sum of
(i)&nbsp;the product of the (x)&nbsp;the volume-weighted average per share
price of the Parent Shares as reported on The NASDAQ Stock Market on the
trading day immediately prior to the Closing Date, and (y)&nbsp;the number of
the Consideration Shares, as adjusted pursuant to Section&nbsp;2.05, and (ii)&nbsp;the
portion of the Purchase Price payable in cash pursuant to Section&nbsp;2.03(2).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Closing Reference Price</b>&#148; means </font>the volume weighted average price of the Parent Shares as reported on The
NASDAQ Stock Market during the following period: (i)&nbsp;if there are
seventeen (17) or more trading days between the Public Announcement Date and
the Closing Date, the period commencing on (and including) the seventeenth (17<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>) trading
day prior to the Closing Date and ending on (and including) the third (3<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">rd</font>) trading
day prior to the Closing Date, and (ii)&nbsp;if there are fewer than seventeen
(17) trading days between the Public Announcement Date and the Closing Date,
the period commencing on </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=6,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=190026,FOLIO='3',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-01_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:26 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">(and including) the Public Announcement
Date and ending on (and including) the trading day prior to the Closing Date.</font>.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Confidentiality Agreement</b>&#148; means the confidentiality agreement
between the Corporation and the Parent dated March&nbsp;18, 2008.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Consideration Shares</b>&#148; has the meaning set out in Section&nbsp;2.03(1).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Corporation</b>&#148; has the meaning set out in the recitals to the
Agreement.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>CRA</b>&#148; means the Canada Revenue Agency.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Encumbrance</b>&#148; means any lien, pledge, security interest,
charge, claim, mortgage, hypothec, assignment, reservation of ownership, deed
of trust, option, warrant, purchase right, right of first refusal or similar
right, lease, easement or other encumbrance.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Environmental Law</b>&#148; means any Applicable Law in respect of
the natural environment, public or occupational health or safety, or the
manufacture, importation, handling, transportation, storage, disposal and
treatment of any Hazardous Substance.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Environmental Permit</b>&#148; means any license, permit,
authorization, certificate, approval or other similar documents issued or
granted by any Governmental Authority pursuant to any Environmental Law.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Escrow Agent</b>&#148; means Computershare Trust Company of Canada.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Escrow Agreement</b>&#148; means the escrow agreement to be executed
on or before the Closing Date among the Non-Resident Vendors, the Purchaser and
the Escrow Agent in the form attached as <b>Schedule&nbsp;6.02(1)(e)</b>.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>ESOP</b>&#148; has the meaning set forth in Section&nbsp;3.02(2)(e).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>ESOP Holder</b>&#148; means the holders of options under the ESOP as
of the date hereof listed (with their aggregate options) in <b>Schedule&nbsp;A</b>,<b>  </b>plus any
additional options issued between the date hereof and the Time of Closing, who
will have exercised such options for ESOP Shares prior to the Time of Closing.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#147;<b>ESOP Shares</b>&#148;
means all of the shares in the share capital of the Corporation issued to the
ESOP Holders pursuant to outstanding options under the ESOP as of the date
hereof or options issued between the date hereof and the Time of Closing, which
shares will have been issued by the Corporation to ESOP Holders upon exercise
of such options prior to the Time of Closing.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Estimated Closing Balance Sheet</b>&#148; means the unaudited balance
sheet prepared by the Corporation showing an estimate of the assets and
liabilities of the Corporation as at the Closing Date prepared in accordance
with Canadian generally accepted accounting principles, applied on a basis
consistent with prior periods.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=7,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=455876,FOLIO='4',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-01_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:26 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Estimated Final Net Amount</b>&#148; means, without duplication of
any items, (i)&nbsp;all cash on hand (including, for avoidance of doubt, the
subscription price received for the issuance of the ESOP Shares), short-term
investments, and GST and QST receivables shown on the Estimated Closing Balance
Sheet, <u>minus</u> (ii)&nbsp;(a)&nbsp;all Indebtedness, (b)&nbsp;all
Transaction Expenses not paid as of the Time of Closing as shown on the
Estimated Closing Balance Sheet, and (c)&nbsp;<strong><b><font face="Times New Roman" style="font-weight:normal;">the aggregate amount set forth in Column 14 of </font></b></strong><b><font style="font-weight:bold;">Schedule 2.02(2)</font><strong><b><font face="Times New Roman">&nbsp;</font></b></strong></b><strong><b><font face="Times New Roman" style="font-weight:normal;">payable to holders of
options under the ESOP who have not exercised their options under the ESOP for
ESOP Shares prior to the Time of the Closing</font></b></strong>. For
the avoidance of doubt, the Estimated Final Net Amount may be either positive
or negative after giving effect to the foregoing sentence.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Exchange Act</b>&#148; has the meaning set out in Section&nbsp;3.01(10)(e).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>FDA</b>&#148; means the United States Food and Drug Administration.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Federal Withheld Amount</b>&#148; has the meaning set out in Section&nbsp;2.06(2).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Final Net Amount</b>&#148;<b>  </b>means, without duplication of any items, (i)&nbsp;all cash
on hand (including, for avoidance of doubt, the subscription price received for
the issuance of the ESOP Shares), short-term investments, and GST and QST
receivables shown on the Closing Balance Sheet, <u>minus</u> (ii)&nbsp;(a)&nbsp;all
Indebtedness, (b)&nbsp;all Transaction Expenses not paid as of the Time of
Closing, and (c)&nbsp;<strong><b><font face="Times New Roman" style="font-weight:normal;">the aggregate amount set forth in Column 14 of </font></b></strong><b><font style="font-weight:bold;">Schedule 2.02(2)</font><strong><b><font face="Times New Roman">&nbsp;</font></b></strong></b><strong><b><font face="Times New Roman" style="font-weight:normal;">payable to holders of
options under the ESOP who have not exercised their options under the ESOP for
ESOP Shares prior to the Time of the Closing</font></b></strong>. For
the avoidance of doubt, the Final Net Amount may be either positive or negative
after giving effect to the foregoing sentence.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Financial Statements</b>&#148; has the meaning set out in Section&nbsp;3.02(5)(b).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Fonds</b>&#148; means Fonds de solidarit&#233; des
travailleurs du Qu&#233;bec (F.T.Q.).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Form&nbsp;8-K Financial Statements</b>&#148; means the financial
statements of the Corporation required for Parent to comply with the
requirements of Item&nbsp;9.01 of Form&nbsp;8-K and Regulation S-X under the
Securities Act in connection with the preparation and filing of the Shelf
Registration Statement.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Governmental Authority</b>&#148; means any domestic or foreign
legislative, executive, judicial, regulatory or administrative authority,
agency, commission, instrumentality, body or other governmental authority
having or purporting to have jurisdiction in the relevant circumstances.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>GST</b>&#148; has the meaning set out in Section&nbsp;3.02(19)(h).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Hazardous Substance</b>&#148; means any substance, matter, waste,
pollutant, hazardous substance, or contaminant as prohibited, regulated or
reportable under any Environmental Law.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>HCV Products</b>&#148; means, collectively, VCH-759, VCH-916, and
VCH-222.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=8,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=307790,FOLIO='5',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-01_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:26 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>HIV Products</b>&#148; means VCH-286.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Holdback Amount</b>&#148; means an amount equal to ten per cent (10%)
of the Purchase Price, consisting of 25% in cash and the balance in such number
of Parent Shares as calculated in the same manner as the Consideration Shares
in Section&nbsp;2.03(1). Each Vendor&#146;s portion and ViroChem Employee&#146;s portion
of the Holdback Amount is equal to the sum of the amounts set forth in
Columns&nbsp;18 and 30 of <b>Schedule&nbsp;2.02(2).</b></font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Holdback Escrow Agent</b>&#148; means Computershare Trust Company of
Canada.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Holdback Escrow Agreement</b>&#148; means the holdback escrow
agreement to be executed on the Closing Date among the Vendors,
Securityholders&#146; Representative, the ViroChem Trust, the Purchaser and the
Holdback Escrow Agent in the form attached as <b>Schedule
6.02(1)(d)</b>.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Holdback Period</b>&#148; means a period of twelve (12) months from
the Closing Date for the Vendors and the ViroChem Employees.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>IFML</b>&#148; means Les Investissements F.M. Legault Inc.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Indebtedness</b>&#148; means (i)&nbsp;the amount of principal and
accrued interest on indebtedness for borrowed money; (ii)&nbsp;the amount of
principal and accrued interest on indebtedness evidenced by bonds, debentures,
notes or similar instruments; (iii)&nbsp;the amount of obligations under
conditional sale or other title retention agreements; or (iv)&nbsp;the amount
of principal and accrued interest on indebtedness of others secured by (or for
which the holder of such liabilities has an existing right, contingent or
otherwise, to be secured by) any lien or security interest on property owned or
acquired by the Person in question whether or not the amount of principal and
accrued interest on indebtedness secured thereby have been assumed.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Intellectual Property</b>&#148; means intellectual property of any
nature and kind including all domestic and foreign trade-marks, business names,
trade names, domain names, trading styles, patents, trade secrets, software,
industrial designs and copyrights, whether registered or unregistered, and all
applications for registration thereof, and inventions (whether patentable or
not), compounds, formulae, recipes, product formulations, processes and
processing methods, technology and techniques, and know-how.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Interim Financial Statements</b>&#148; has the meaning set out in Section&nbsp;3.02(5)(b).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Investment Canada Act</b>&#148; means the <i>Investment
Canada Act </i>(Canada).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Knowledge of the Corporation</b>&#148; and all permutations thereof
shall mean, with respect to any matter in question, the actual knowledge of
Domenic De&nbsp;Luca, Gervais Dionne, Dani&#232;le Ethier, Celine Locas<b>, </b>Fran&#231;ois Legault and Louise Proulx.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Latest Balance Sheet</b>&#148; has the meaning set out in Section&nbsp;3.02(5)(b).</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=9,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=624771,FOLIO='6',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-01_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:26 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Legal Proceeding</b>&#148; means any litigation, action, application,
suit, investigation, hearing, claim, deemed complaint, grievance, civil,
administrative, regulatory or criminal, arbitration proceeding or other similar
proceeding, before or by any court or other tribunal and includes any appeal or
review thereof and any application for leave for appeal or review.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>License Agreements</b>&#148;<b>  </b>has the
meaning set out in Section&nbsp; 3.02(10)(d).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Licensed Intellectual Property</b>&#148; means all material
Intellectual Property (other than shrink-wrap or click-wrap software) that is
licensed to the Corporation under a license agreement and which is used or held
for use in, or is necessary for, the operation of the business of the
Corporation as presently conducted.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Material Adverse Effect</b>&#148; means, when used in connection with
the Corporation, Parent or the Purchaser, any change, event, violation,
inaccuracy, circumstance or effect that is materially adverse to the business,
operations, financial condition, assets, or liabilities of the Corporation,
Parent or the Purchaser, as applicable, taken as a whole; <i>provided,
however</i>, that in no event shall any of the following, alone or in
combination, be taken into account in determining whether there has been or is
likely to be a Material Adverse Effect: (i)&nbsp;changes generally adversely
affecting any of the Canadian, United States, European or worldwide economy or
financial or securities markets (except to the extent that the Corporation,
Parent or the Purchaser, as applicable, is disproportionately and materially
affected thereby as compared to other similarly situated companies); (ii)&nbsp;changes
adversely affecting the industry (or any segment thereof) in the United States,
Canada, Europe or worldwide in which the Corporation, Parent or the Purchaser,
as applicable, operates (except to the extent that the Corporation, Parent or
the Purchaser, as applicable, is disproportionately and materially affected
thereby as compared to other similarly situated companies); (iii)&nbsp;the
announcement or pendency of the transactions contemplated by this Agreement; (iv)&nbsp;the
effect of any changes after the date hereof in Applicable Laws or accounting
principles not uniquely relating to the Corporation, Parent or the Purchaser,
as applicable; or (v)&nbsp;acts of war or terrorism or the outbreak of
hostilities.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Material Contracts</b>&#148; has the meaning set out in Section&nbsp;3.02(15)(a).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Non-Resident Vendor</b>&#148; has the meaning set out in Section&nbsp;2.06(1).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Notice of Dispute</b>&#148; has the meaning set out in Section&nbsp;2.04(7).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Owned Intellectual Property</b>&#148; means all material<b>  </b>Intellectual Property that is owned by the Corporation and
which is used or held for use in or necessary for the operation of the business
of the Corporation as presently conducted.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;Parent&#148;</font></b> has the meaning set out in the recitals to the Agreement.</p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Parent Shares</b>&#148; means shares of common stock in the capital
of Parent.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=10,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=650288,FOLIO='7',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-01_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:26 2009' -->



<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Person</b>&#148; means an individual, corporation, partnership,
association, trust, unincorporated organization, limited liability company or
other legal entity.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Permits</b>&#148; means all permits, consents, waivers, licenses,
certificates, approvals, authorizations, registrations, franchises, rights,
privileges, quotas and exemptions, or any item with a similar effect, issued or
granted by any Person.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Power</b>&#148; means Power Corporation of Canada.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Private Issuer</b>&#148; has the meaning set forth in
section&nbsp;2.4 of National Instrument 45-106 &#151; <i>Prospectus
and Registration Exemptions</i>.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Product Permits</b>&#148; has the meaning set out in Section&nbsp;3.02(16)(b).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Products</b>&#148; has the meaning set out in Section&nbsp;3.02(16)(a).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Public Announcement Date</b>&#148; means the trading day on The
NASDAQ Stock Market on which the transactions contemplated by this Agreement
are first announced to the public, provided that if the announcement is made
after the closing of the market, the Public Announcement Date shall be the next
succeeding trading day.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Purchase Price</b>&#148; has the meaning set out in Section&nbsp;2.02(1).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Purchase Price Increase</b>&#148; has the meaning set out in Section&nbsp;2.04(10).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Purchase Price Reduction</b>&#148; has the meaning set out in Section&nbsp;2.04(10).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Purchaser&#148;</b> has the meaning set out in the recitals to the
Agreement.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Purchaser Indemnitees</b>&#148; has the meaning set out in Section&nbsp;7.02(1).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>QST</b>&#148; has the meaning set out in Section&nbsp;3.02(19)(h).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>QTA</b>&#148; means the <i>Taxation Act</i> (</font>Qu&#233;bec).</p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Quebec Withholding Amount</b>&#148; has the meaning set out in Section&nbsp;2.07(2).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Reference Share Price</b>&#148; means $</font>30.2148.</p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Registration Rights Agreement</b>&#148; means the registration rights
agreement to be executed on or before the Closing Date by Parent and each of
the Vendors, the ViroChem Employees<b>  </b>and the ESOP
Holders<b>  </b>in the form attached as <b>Schedule 6.02(1)(c)(i)</b>.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>SEC</b>&#148; means the United States Securities and Exchange
Commission.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>SEC Reports</b>&#148; has the meaning set out in Section&nbsp;3.03(g).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Securities Act</b>&#148; has the meaning set forth in Section&nbsp;3.01(10).</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=11,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=614795,FOLIO='8',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-03_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:29 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Securityholders&#146; Representative</b>&#148; has the meaning set out in
the recitals to the Agreement.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Shareholders Agreement</b>&#148; means the shareholders agreement
dated April&nbsp;7, 2004 between Picchio Holdings Inc., CDPQ, Fonds, BDC,
Gervais Dionne, IFML, Shire, ViroChem Trust and Therapeutic Trust and the
Corporation, to which have intervened, among others, Franklin M. Berger, Dr.&nbsp;Francesco
Bellini, Vitus and Power.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Shares</b>&#148; means all of the outstanding shares of the
Corporation held by the Vendors as at the date hereof, but excluding the
ViroChem Shares and the ESOP Shares.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Shelf Registration Statement</b>&#148; shall have the meaning set
forth in the Registration Rights Agreement.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Shire</b>&#148; means Shire Canada Inc. (a successor to Shire BioChem
Inc.).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Straddle Period</b>&#148; shall mean any period that begins prior to
the Closing Date and ends after the Closing Date for which Tax Returns are
required to be prepared and filed with any relevant Taxation Authority.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Stub Period Returns</b>&#148; has the meaning set out in Section&nbsp;4.05(3).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Tax Act</b>&#148; means the <i>Income Tax Act</i>
(Canada).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Tax Returns</b>&#148; means all returns, reports, declarations,
statements, bills, schedules, forms, remittances, information returns, reports,
documents or written information of, or in respect of, Taxes that are, or are
required to be, filed with or supplied to any Taxation Authority.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Taxation Authority</b>&#148; means any Governmental Authority that is
entitled to impose Taxes or to administer any applicable Tax legislation.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Taxes</b>&#148; means all federal, state, provincial, territorial,
county, municipal, local or foreign taxes, duties, imposts, levies,
assessments, tariffs and other charges imposed, assessed or collected by a
Governmental Authority including, (i)&nbsp;any gross income, net income, gross
receipts, business, royalty, capital, capital gains, goods and services,
harmonized sales tax, value added, severance, stamp, franchise, occupation,
premium, capital stock, sales and use, real property, land transfer, personal
property, ad valorem, transfer, license, profits, windfall profits,
environmental, payroll, employment, employer health, pension plan,
anti-dumping, countervail, excise, severance, stamp, occupation, or premium
tax, (ii)&nbsp;all withholdings on amounts paid to or by the relevant person, (iii)&nbsp;all
employment insurance premiums, Canada, Qu&#233;bec and any other pension plan
contributions or premiums, (iv)&nbsp;any instalment in respect of any such
amounts required to be made, (v)&nbsp;any fine, penalty, interest, or addition
to tax, (vi)&nbsp;any tax imposed, assessed, or collected or payable pursuant
to any tax-sharing agreement or any other contract relating to the sharing or
payment of any such tax, levy, assessment, tariff, duty, deficiency, or fee, (vii)&nbsp;any
liability for any of the foregoing as a transferee, successor, </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=12,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=181522,FOLIO='9',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-03_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:29 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">guarantor, or
by contract or by operation of law; and (viii)&nbsp;any interest, fines and
penalties imposed by any Governmental Authority in respect of any of the
foregoing.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Therapeutic Renaissance Trust Agreement</b>&#148; means the deed of
settlement of trust of the Shire BioChem Renaissance Trust done and passed on March&nbsp;15,
2004, as amended.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Therapeutic Trust</b>&#148; means the Therapeutic Renaissance Trust.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Therapeutic Trustees</b>&#148; means, collectively, Daniel Johnson,
Fran&#231;ois Legault and Gervais Dionne.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Third Party Auditors</b>&#148; has the meaning set out in Section&nbsp;2.04(7).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Third Party Claim</b>&#148; has the meaning set out in Section&nbsp;7.06(2).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Time of Closing</b>&#148; means 10:00&nbsp;a.m. (Montreal time) on
the Closing Date, or such other time as mutually agreed by the Corporation and
the Purchaser.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Transaction Expenses</b></font>&#148; means (i)&nbsp;the aggregate of any and all costs and expenses incurred
and payable by the&nbsp;Corporation or on its behalf in connection with or
related to the structuring, authorization, preparation, negotiation, execution
and performance of this Agreement and related agreements, including, without
limitation, all fees and disbursements of counsel, accountants, financial
advisors, experts, and consultants; plus (ii)&nbsp;the
liability of the Corporation for Quebec health service fund contributions or
other Taxes, if any, payable by the Corporation in respect of the exercise of
all stock options under the ESOP or the Trust ESOP exercised in contemplation
of or in connection with this transaction (including any net exercise, cash out
or similar disposition).&#160;
For greater certainty, &#147;Transaction Expenses&#148; shall not include the
costs and expenses incurred in connection with the preparation of the Form&nbsp;8-K
Financial Statements.</p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Trust ESOP</b>&#148; has the meaning set forth in Section&nbsp;3.02(2)(c).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Trusts</b>&#148; means, collectively, the ViroChem Trust and the
Therapeutic Trust and &#147;<b>Trust</b>&#148; means
any one of them.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Trustees</b>&#148; means, collectively, the ViroChem Trustees and the
Therapeutic Trustees, and &#147;<b>Trustee</b>&#148; means
any one of them.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Vendor Indemnitees</b>&#148; has the meaning set out in Section&nbsp;7.04(1).</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Vendors</b>&#148; has the meaning set out in the recitals to the
Agreement.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>ViroChem Employees</b>&#148; means the holders of options under the
Trust ESOP as of the date hereof listed (with their aggregate options) in <b>Schedule&nbsp;A</b>, who will have exercised such options for
ViroChem Shares prior to the Time of Closing.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>ViroChem Renaissance Trust Agreement</b>&#148; means the deed of
settlement of trust of ViroChem Trust done and passed on March&nbsp;15, 2004.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=13,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=196322,FOLIO='10',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-03_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:29 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>ViroChem Shares</b>&#148; means all of the shares held by the
ViroChem Trust subject to outstanding options under the Trust ESOP as of the
date hereof, all of which shares will have been transferred by the ViroChem
Trust to ViroChem Employees upon their exercise of such options by ViroChem
Employees prior to the Time of Closing.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>ViroChem Trust</b>&#148; means the ViroChem Renaissance Trust.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>ViroChem Trustees</b>&#148; means, collectively, Daniel Johnson,
Fran&#231;ois Legault and Gervais Dionne.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Vitus</b>&#148; means Vitus Investments III Private Limited.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.02</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Headings</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The division
of this Agreement into Articles and Sections and the insertion of a table of
contents and headings are for convenience of reference only and do not affect
the construction or interpretation of this Agreement. The terms &#147;hereof&#148;,
&#147;hereunder&#148; and similar expressions refer to this Agreement and not to any
particular Article, Section&nbsp;or other portion hereof. Unless something in
the subject matter or context is inconsistent therewith, references herein to
Articles, Sections and Schedules are to Articles and Sections of and Schedules
to this Agreement.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.03</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Extended Meanings</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In this
Agreement words importing the singular number only include the plural and vice
versa, and words importing any gender include all genders. The term &#147;including&#148;
means &#147;including without limiting the generality of the foregoing&#148; and the term
&#147;third party&#148; means any Person other than the Vendors, ViroChem Employees, the
ESOP Holders, the Corporation, Parent and the Purchaser.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.04</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Statutory References</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In this
Agreement, unless something in the subject matter or context is inconsistent
therewith or unless otherwise herein provided, a reference to any statute is to
that statute as now enacted or as the same may from time to time be amended,
re-enacted or replaced and includes any regulations made thereunder.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.05</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Accounting Principles</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Wherever in
this Agreement reference is made to a calculation to be made or an action to be
taken in accordance with generally accepted accounting principles, such
reference will be deemed to be to the generally accepted accounting principles
from time to time approved by the Canadian Institute of Chartered Accountants,
or any successor institute, with respect to the Corporation and the Vendors,
and generally accepted accounting principles in the United States and in Canada
with respect to Parent and the Purchaser, respectively, as applicable as at the
date on which such calculation or action is made or taken or required to be
made or taken.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=14,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=708971,FOLIO='11',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-03_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:29 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.06</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Actions on Non-Business Days</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If any payment
is required to be made or other action (including the giving of notice) is
required to be taken pursuant to this Agreement on a day which is not a
Business Day, then such payment or action shall be considered to have been made
or taken in compliance with this Agreement if made or taken on the next
succeeding Business Day.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.07</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Currency</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as
specifically noted, all references to currency herein are to lawful money of
the United States of America.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.08</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Control</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; For the purposes of this Agreement,</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a Person controls a body corporate if securities of the body
corporate to which are attached more than 50% of the votes that may be cast to
elect directors of the body corporate are beneficially owned by the Person and
the votes attached to those securities are sufficient, if exercised, to elect a
majority of the directors of the body corporate;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a Person controls an unincorporated entity, other than a limited
partnership, if more than 50% of the ownership interests, however designated,
into which the entity is divided are beneficially owned by that Person and the
Person is able to direct the business and affairs of the entity; and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the general partner of a limited partnership controls the limited
partnership.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; A Person who controls an entity is
deemed to control any entity that is controlled, or deemed to be controlled, by
the entity.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; A Person is deemed to control, within
the meaning of this Section&nbsp;1.08(1)(a)&nbsp;or 1.08(1)(b), an entity if
the aggregate of:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any securities of the entity that are beneficially owned by that
Person; and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any securities of the entity that are beneficially owned by any
entity controlled by that Person.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">is such that,
if that Person and all of the entities referred to in this Section&nbsp;1.08(3)(b)&nbsp;that
beneficially own securities of the entity were one Person, that Person would
control the entity.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.09</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Schedules</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following are the Schedules to this Agreement:</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="84%" style="border-collapse:collapse;margin-left:35.1pt;width:84.66%;">
 <tr>
  <td width="153" valign="top" style="padding:0in 0in 0in 0in;width:114.6pt;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;page-break-after:avoid;"><!-- SET mrlNoTableShading -->Schedule A </p>
  </td>
  <td width="27" valign="top" style="padding:0in 0in 0in 0in;width:20.2pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="430" valign="top" style="padding:0in 0in 0in 0in;width:322.35pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Share
  Ownership of the Corporation</font></p>
  </td>
 </tr>
 <tr>
  <td width="153" valign="top" style="padding:0in 0in 0in 0in;width:114.6pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  2.02(2)</font></p>
  </td>
  <td width="27" valign="top" style="padding:0in 0in 0in 0in;width:20.2pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="430" valign="top" style="padding:0in 0in 0in 0in;width:322.35pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Allocation
  of Purchase Price</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=15,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=258875,FOLIO='12',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-03_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:29 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="92%" style="border-collapse:collapse;margin-left:35.1pt;width:92.66%;">
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  2.03(1)(a)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Holdback Escrow
  Agent Trust Account</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  2.03(2)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">McCarthy
  T&#233;trault Trust Account</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  2.03(2)(c)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Escrow Agent
  Trust Account</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.01(5)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No Conflict,
  Violation, Consents</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.01(10)(a)(i)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Definition
  of U.S. Person</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.01(10)(b)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Definition
  of an Accredited Investor</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(1)(b)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Articles of
  Incorporation and By-Laws of the Corporation, as Amended</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(2)(e)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ESOP</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(5)(b)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financial
  Statements</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(6)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Undisclosed
  Liabilities</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule 3.02(7)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Changes and
  Unusual Transactions</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(8)(a)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">List of
  Directors, Officers, Employees, Consultants and Independent Contractors of
  the Corporation</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(8)(b)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">List of
  Employment, Consulting and Independent Contractor Agreements</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(9)(a)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Benefit
  Plans</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(a)(i)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registered
  and Applied for Owned Intellectual Property</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(a)(ii)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rights of
  Others in the Owned Intellectual Property</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(b)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registration,
  Maintenance and Fees for Owned Intellectual Property</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10(d)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">License
  Agreements</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(e)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consents
  Required to License or Sub-License</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(f)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sufficiency
  of Intellectual Property</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(g)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Infringement
  of Third Party Intellectual Property Rights</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(h)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Infringement
  of Corporation Owned Intellectual Property</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(i)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Validity and
  Enforceability of Owned Intellectual Property</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(11)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Lease
  Agreement and Related Agreements</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(14)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Insurance
  Policies</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(15)(a)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Material
  Contracts</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(16)(a)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">List of
  Products</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule </font>3.02(16)(c)(i)</p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">List of
  Clinical Trials Conducted or Being Conducted in Canada or the United States</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule </font>3.02(16)(c)(ii)</p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">List of
  Other Clinical Trials Planned or Contemplated</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule </font>3.02(16)(c)(iii)</p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Protocols
  for Clinical Trials</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(16)(d)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">List of
  Notices Disclosed to Purchaser</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(17)(a)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Environmental
  Permits</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(19) </font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tax Matters</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(20)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financial
  Advisor</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  6.02(1)(c)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of
  Registration Rights Agreement</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  6.02(1)(d)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of
  Holdback Escrow Agreement</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  6.02(1)(e)&nbsp;</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of
  Escrow Agreement</font></p>
  </td>
 </tr>
 <tr height="14" style="height:10.35pt;">
  <td width="170" height="14" valign="top" style="height:10.35pt;padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  6.02(2)(a)</font></p>
  </td>
  <td width="30" height="14" valign="top" style="height:10.35pt;padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" height="14" valign="top" style="height:10.35pt;padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of
  Intervention of the ViroChem Employees</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  6.02(2)(b)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of
  Intervention of the ESOP Holders</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  6.02(2)(j)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of
  Legal Opinion of McCarthy T&#233;trault LLP</font></p>
  </td>
 </tr>
 <tr>
  <td width="170" valign="top" style="padding:0in 0in 0in 0in;width:127.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  6.02(3)(e)</font></p>
  </td>
  <td width="30" valign="top" style="padding:0in 0in 0in 0in;width:22.45pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="468" valign="top" style="padding:0in 0in 0in 0in;width:350.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of
  Legal Opinion of Purchaser&#146;s Counsel</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=16,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=576391,FOLIO='13',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-03_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:29 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:avoid;text-align:center;text-decoration:underline;text-transform:uppercase;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">ARTICLE&nbsp;2 - SALE AND PURCHASE</font></u></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:avoid;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.01</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Shares to be Sold and Purchased</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Upon and subject to the terms and
conditions hereof, at the Time of Closing, the Vendors will sell the Shares,
the ViroChem Employees will sell the ViroChem Shares, and the ESOP Holders will
sell the ESOP Shares, in each case, to the Purchaser, and the Purchaser will
purchase from each Vendor, ViroChem Employee and ESOP Holder the Shares,
ViroChem Shares and ESOP Shares, respectively, set forth opposite each name under
the heading &#147;Number of Shares&#148; in <b>Schedule&nbsp;A</b>.<b>  </b>The obligations of the Vendors, the ViroChem Employees and
the ESOP Holders under this Article&nbsp;2 shall be individual and separate,
not joint or solidary.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.02</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Purchase Price</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The aggregate purchase price (the &#147;<b>Purchase Price</b>&#148;) for the Shares, ViroChem Shares and ESOP
Shares shall be Four Hundred Million U.S. Dollars (US$400,000,000), subject to
adjustment, if any, pursuant to Sections 2.04 and 2.05 of this Agreement.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Purchase Price shall be allocated
between the Vendors, ViroChem Employees and ESOP Holders, pro rata based on
their ownership of the outstanding shares of the Corporation at the Time of
Closing, as set forth in Column 6 on <b>Schedule 2.02(2)</b>,
with the amount set forth next to each Vendor&#146;s, ViroChem Employee&#146;s and ESOP
Holder&#146;s name on Column 6 of <b>Schedule 2.02(2)</b>.
The portion of the Purchase Price which constitutes the Holdback Amount shall
be allocated between the Vendors and ViroChem Employees as set forth in
Sections 2.03(1)(a) and 2.03(2)(a). <b>Schedule 2.02(2) </b>shall
be updated to reflect the Estimated Final Net Amount and for any changes in the
names of, or the outstanding shares held by, the Vendors, ViroChem Employees or
ESOP Holders between the date of this Agreement and the Closing Date, as
mutually agreed by the Corporation, the Parent and the Purchaser, including to
revise such <b>Schedule 2.02(2) </b>following the
calculation of the Estimated Final Net Amount and to remove the options under
the ESOP reflected in Column 5 of <b>Schedule 2.02(2) </b>which
have not been exercised prior to the Time of Closing.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.03</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Payment of Purchase Price</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Three
Hundred Million U.S. Dollars (US$300,000,000) of the Purchase Price shall be
paid to the Vendors, ViroChem Employees and ESOP Holders, pro rata based on
their ownership of the outstanding shares of the Corporation immediately prior
to the Time of Closing in consideration for the number of whole Shares,
ViroChem Shares and ESOP Shares, respectively, as set forth in Columns&nbsp;1,
2A and 5A of <b>Schedule 2.02(2)&nbsp;</b>by the
delivery of such number of Parent Shares (the &#147;<b>Consideration
Shares</b>&#148;) determined by dividing Three Hundred Million U.S. Dollars
(US$300,000,000) by the Reference Share Price, the whole subject to adjustment,
if any, upon the terms of Section&nbsp;2.05; provided, however, that any
fractional share to be issued shall be rounded down to the nearest whole share,
with the number of Parent Shares set forth next to each Vendor&#146;s, ViroChem
Employee&#146;s and ESOP Holder&#146;s name on Column&nbsp;32 of <b>Schedule
2.02(2)</b>, provided that:</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=17,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=215441,FOLIO='14',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-03_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:29 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the share portion of the Holdback Amount shall be withheld from the
Consideration Share portion of the Purchase Price payable to the Vendors and
the ViroChem Employees with the portion of such amount attributed to each
Vendor and ViroChem Employee set forth in Column&nbsp;33 of <b>Schedule 2.02(2)</b>, and delivered to the Holdback Escrow Agent
in trust at the Time of Closing by delivering the share certificates
representing same to the Holdback Escrow Agent to be dealt with by the Holdback
Escrow Agent in accordance with the provisions of the Holdback Escrow
Agreement. Each Vendor and ViroChem Employee shall contribute that portion of
the Consideration Shares to be delivered to the Holdback Escrow Agent equal to
such Person&#146;s proportionate share of the total number of the Shares and
ViroChem Shares held by the Vendors and ViroChem Employees.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>in the event that the cash amount withheld pursuant to Section&nbsp;2.03(2)(c)&nbsp;below
is less than the amount required to be withheld in respect of Non-Resident
Vendors as provided for in Section&nbsp;2.06 and Section&nbsp;2.07, then such
number of Consideration Shares equal to the quotient of (x)&nbsp;the amount of
such shortfall, and (y)&nbsp;the volume-weighted average per share price of the
Parent Shares as reported on The NASDAQ Stock Market on the trading day
immediately prior to the Closing Date, rounded up to the nearest whole share,
shall be delivered to the Escrow Agent in trust at the Time of Closing by
delivering the share certificates representing same to the Escrow Agent to be
dealt with in accordance with the provisions of the Escrow Agreement.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The $100,000,000 balance of the
Purchase Price shall be paid in cash at the Time of Closing for the benefit of
the Vendors, ViroChem Employees and ESOP Holders, pro rata based on their
ownership of the outstanding shares of the Corporation at the Time of Closing,
in consideration for the number of whole Shares, ViroChem Shares and ESOP
Shares, respectively, as set forth in Columns&nbsp;1, 2B and 5B of <b>Schedule 2.02(2)</b>, by delivering immediately available funds,
in the amount set forth next to each Vendor&#146;s, ViroChem Employee&#146;s and ESOP
Holder&#146;s name on Column&nbsp;17 of <b>Schedule 2.02(2)</b>,
by wire transfer to the McCarthy T&#233;trault Trust Account set out in <b>Schedule&nbsp;2.03(2)</b>, subject to the following:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the cash portion of the Holdback Amount shall be withheld from the
cash portion of the Purchase Price payable to the Vendors and the ViroChem
Employees in such amounts attributed to each Vendor and ViroChem Employee set
forth in Column&nbsp;18 of <b>Schedule 2.02(2)</b>,
and paid to the Holdback Escrow Agent in trust at the Time of Closing by wire
transfer to the trust account set out in <b>Schedule&nbsp;2.03(1)(a)&nbsp;</b>to
be dealt with by the Holdback Escrow Agent during the Holdback Period in
accordance with the provisions of the Holdback Escrow Agreement. Each Vendor
and ViroChem Employee shall contribute that portion of the cash to be paid to
the Holdback Escrow Agent equal to such Person&#146;s proportionate share of the
total number of the Shares and ViroChem Shares held by the Vendors and ViroChem
Employees;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>from the proportional share of the cash portion of the Purchase
Price payable to the ESOP Holders, the Purchaser shall remit to the Corporation
a portion of the </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=18,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=572462,FOLIO='15',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-03_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:29 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase Price equal to the loan made by the
Corporation to the ESOP Holders to fund the payment of the exercise price
payable by each ESOP Holder in connection with the subscription to the ESOP Shares
sold by it hereunder, the whole as set forth in Column&nbsp;9 of <b>Schedule 2.02(2)</b>, as converted into U.S. dollars using the
noon exchange rate of the Bank of Canada on the Closing Date; and</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Federal Withheld Amount and the Quebec Withholding Amount, if
any, in respect of Non-Resident Vendors, as set forth in Column&nbsp;26 of <b>Schedule 2.02(2)</b>, shall be withheld as provided for in Section&nbsp;2.06
and Section&nbsp;2.07 and paid to the Escrow Agent in trust at the Time of
Closing by wire transfer to the trust account set out in <b>Schedule
2.03(2)(c)&nbsp;</b>to be dealt with by the Escrow Agent in accordance
with the provisions of the Escrow Agreement.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Parent
shall take all actions necessary to cause the Consideration Shares to be
approved for listing on The NASDAQ Stock Market as at the Closing Date, subject
to official notice of issuance.</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Immediately
prior to the&nbsp;Time of Closing, the&nbsp;Corporation shall pay the
Transaction Expenses, or reflect them on the flow of funds to be distributed,
out of the Purchase Price at the Time of Closing (and the Corporation shall
accrue any Transaction Expenses that will not have been paid at or prior to the
Time of Closing as expenses on the Estimated Closing Balance Sheet and Closing
Balance Sheet).</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Parent or
the Purchaser shall not be required to deliver to any Vendor,
ViroChem Employee or&nbsp;ESOP Holder any consideration for any&nbsp;such
holder&#146;s outstanding&nbsp;equity interest in the Corporation, or any other
payments pursuant to this Article&nbsp;2, until such Vendor,
ViroChem Employee or&nbsp;ESOP Holder has delivered to Parent or the Purchaser
certificates or other evidence of ownership of such Vendor&#146;s,
ViroChem Employee&#146;s or&nbsp;ESOP Holder&#146;s Shares, as applicable, duly endorsed in blank for transfer, and such other documentation as may
be reasonably satisfactory to Parent. The Purchaser
shall hold in trust the portion of the Purchase Price payable to or for the
benefit of the holder of any certificate not presented at the Time of Closing,
provided that no interest will be paid on the cash portion of the Purchase
Price.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.04</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Purchase Price Adjustment</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>At least
three (3)&nbsp;Business Days prior to the anticipated Closing Date, the
Corporation will, in good faith based on the most current information available
to the Corporation and in accordance with the terms of this Section&nbsp;2.04(1),
prepare and deliver to the Parent and the Purchaser the Estimated Closing
Balance Sheet<strong><b><font face="Times New Roman">  </font></b></strong>determined as of 11:59&nbsp;p.m.
(Montreal time) on the Business Day immediately preceding the Closing Date; <i>provided, however</i> that all&nbsp;transactions occurring on
the Closing Date but prior to the Time of Closing, including but not limited to
the exercise of any options to acquire shares of the Corporation, shall be
deemed to have occurred at 11:58&nbsp;p.m. (Montreal time) on the Business Day immediately
preceding the Closing Date, which Estimated Closing Balance Sheet shall include
(i)&nbsp;a reasonably detailed estimation of Estimated Final Net Amount as of
11:59&nbsp;p.m. (Montreal time) on the Business Day immediately preceding the
Closing Date, and (ii)&nbsp;a schedule setting forth the Transaction Expenses
as of the Closing Date, the payees under such Transaction Expenses </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=19,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=959426,FOLIO='16',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-03_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:29 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and wiring instructions therefor. The
Corporation and the Parent shall seek to agree, in good faith, upon the
Estimated Final Net Amount; <i>provided, however,</i>
in the event that the Corporation and the Parent fail or are unable to so agree
on the Estimated Final Net Amount, the Purchase Price payable on the Closing
Date shall be increased based upon the Estimated Final Net Amount furnished by
the Corporation (which shall be deemed to be the Estimated Final Net Amount for
purposes hereof) and any dispute concerning the amounts thereof shall be
resolved after the Closing Date in accordance with Section&nbsp;2.04(7).</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>On the
Closing Date, immediately before the payments described in Section&nbsp;2.04(3),
Shire may exchange its Class&nbsp;B shares in the capital of the Corporation
for Class&nbsp;A shares or Class&nbsp;C shares of the Corporation, on a
one-for-one basis, and each of the ViroChem Trust and the Therapeutic Trust may
exchange their Class&nbsp;C shares in the capital of the Corporation for Class&nbsp;A
shares or Class&nbsp;B shares of the Corporation on a one-for-one basis.&#160; The Vendors hereby consent to the foregoing
and waive their pre-emptive rights relating thereto pursuant to Section&nbsp;5
of the Shareholders Agreement.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>On the
Closing Date, immediately after giving effect to the issuance of the ESOP
Shares and the transactions described in Section&nbsp;2.04(2)&nbsp;but before
the Time of Closing, the Corporation shall (i)&nbsp;reduce its stated capital
pursuant to section&nbsp;38(1)(b)&nbsp;of the <i>Canada
Business Corporations Act</i> by an amount and/or (ii)&nbsp;pay a
dividend in an amount, in either or both cases in aggregate amounts which shall
be equal to the Estimated Final Net Amount, which shall be paid to the Vendors,
ViroChem Employees and ESOP Holders prorated based on their ownership of the
outstanding shares of the Corporation immediately before the Time of Closing as
set forth in Column&nbsp;6 of <b>Schedule&nbsp;2.02(2)&nbsp;</b>by
delivering immediately available funds by wire transfer to the McCarthy
T&#233;trault Trust Account set out in <b>Schedule&nbsp;2.03(2)</b>.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>At the Time
of Closing, the Purchaser shall contribute to the stated capital account of the
Class&nbsp;A Shares of the Corporation an amount of $5,000,000.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Forthwith after the Closing Date, the
Securityholders&#146; Representative and the Corporation shall prepare an unaudited
balance sheet showing the assets and liabilities of the Corporation </font>determined as of 11:59&nbsp;p.m. (Montreal time) on the Business Day
immediately preceding the Closing Date (the &#147;<b>Closing
Balance Sheet</b>&#148;); <u>provided</u>, <u>however</u>, that all
transactions occurring on the Closing Date but prior to the&nbsp;Time of
Closing, including but not limited to the exercise of any options to acquire
shares of the Corporation, shall be deemed to have occurred at 11:58&nbsp;p.m.
(Montreal time) on the Business Day immediately preceding the Closing Date,
which Closing Balance Sheet shall include a reasonably detailed calculation
of&nbsp;Final Net Amount as of 11:59&nbsp;p.m. (Montreal time) on the Business
Day immediately preceding the Closing Date. The Closing
Balance Sheet shall be prepared in accordance with Canadian generally accepted
accounting principles, applied on a basis consistent with prior periods. The
Securityholders&#146; Representative shall forward to the Purchaser the Closing
Balance Sheet within thirty (30) calendar days after the Closing Date, together
with appropriate supporting documentation consistent in scope and content with
that which would be required for a reasonable auditor to perform an audit of
same, taking into account, <i>inter alia</i>,
appropriate thresholds.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=20,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=723594,FOLIO='17',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-03_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:29 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Purchaser undertakes to provide
the adequate access to the required members of management of the Corporation
and to instruct them accordingly in order to prepare with the Securityholders&#146;
Representative the Closing Balance Sheet as contemplated in the foregoing
paragraph.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If the Purchaser wishes to dispute
any matter in the Closing Balance Sheet, it may do so by notice (&#147;<b>Notice of Dispute</b>&#148;) to the Securityholders&#146; Representative
given within ten (10)&nbsp;Business Days of the delivery of the Closing Balance
Sheet to the Purchaser. A Notice of Dispute shall specify the basis for each
objection and the dollar amount involved. The parties shall use their
commercially reasonable efforts to amicably resolve any matters identified in a
Notice of Dispute as promptly as practicable. If any such dispute shall not
have been resolved within ten (10)&nbsp;Business Days following the date on
which the Notice of Dispute is given, then either party may refer such
unresolved matters to KPMG LLP (the &#147;<b>Third Party Auditors</b>&#148;)
for resolution. The Third Party Auditors shall decide on the item(s)&nbsp;in
dispute as follows:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Third Party Auditors shall have regard to the specifications of
this Agreement, in particular the standards referred to in the second paragraph
of this Section&nbsp;2.04. The Purchaser shall make available all documents and
information to the Third Party Auditors for their decision.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Third Party Auditors shall give the parties the opportunity to
discuss the item(s)&nbsp;in dispute and explain their position prior to
rendering their decision. Each of the parties shall have the right to request
the Third Party Auditors to hold an oral hearing.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Third Party Auditors shall give their decision together with
their reasoning in writing to each party as soon as reasonably practicable but
no later than thirty (30) calendar days after the matter has been referred to
them.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If no Notice of Dispute is given
within the delay prescribed above, then the Closing Balance Sheet shall be
final and binding on the parties as of and from the date of the delivery to the
Purchaser. If a Notice of Dispute is given in accordance with this Section&nbsp;2.04,
then the Securityholders&#146; Representative and the Corporation, as applicable,
shall, forthwith after having amicably resolved all matters identified in the
Notice of Dispute or forthwith following the decision of the Third Party
Auditors, as applicable, amend the Closing Balance Sheet to reflect their
amicable resolution of all matters identified in the Notice of Dispute or the
decision of the Third Party Auditors and deliver the Closing Balance Sheet to
the Purchaser and such Closing Balance Sheet shall be final and binding on the
Parties as of and from the date of such delivery.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(9)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The fees and disbursements of the
Third Party Auditors shall be shared equally by the Purchaser and the Vendors,
with the Vendors&#146; portion to be deducted from their pro rata share of the cash
portion of the Holdback Amount as set forth on Column&nbsp;18 of <b>Schedule 2.02(2)</b>.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(10)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Purchase Price shall be reduced
(the &#147;<b>Purchase Price Reduction</b>&#148;) by the amount,
if any, by which the Final Net Amount is lower than the Estimated Final Net
Amount. </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=21,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=114605,FOLIO='18',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-03_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:29 2009' -->



<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Purchase
Price shall be increased (the &#147;<b>Purchase Price Increase</b>&#148;)
by the amount, if any, by which the Final Net Amount is greater than the
Estimated Final Net Amount. Any applicable Purchase Price Reduction shall be
payable to the Purchaser by a reduction of the Holdback Escrow Amount in
accordance with the Holdback Escrow Agreement and any applicable Purchase Price
Increase shall be payable in cash by the Purchaser to the Vendors, the ViroChem
Employees and the ESOP Holders pro rata based on their ownership of the
outstanding Shares, ViroChem Shares and ESOP Shares, respectively, as set forth
in Column&nbsp;6 of <b>Schedule 2.02(2)&nbsp;</b>within
five (5)&nbsp;Business Days of the date on which the Closing Balance Sheet
becomes final and binding on the parties by delivering immediately available
funds by wire transfer to the McCarthy T&#233;trault Trust Account set out in <b>Schedule&nbsp;2.03(2)</b>.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.05</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Share Consideration Adjustment</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If </font>the Closing Reference Price&nbsp;is less
than the Reference Share Price and greater than 90% of the Reference Share
Price, then the number of Consideration Shares issuable at closing shall be
determined by dividing $300,000,000 by the Closing Reference Price.</p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If
the Closing Reference Price is equal to 90% of the Reference Share Price or
less, then the number of Consideration Shares issuable at closing shall be
determined by dividing $300,000,000 by 90% of the Reference Share Price.</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subject
to Section&nbsp;2.05(4), if the Closing Reference Price is equal or superior to
the Reference Share Price, then no adjustment to the number of Consideration
Shares issuable at closing shall be made.</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If
as a result of an increase in the trading price of the Parent Shares on The
NASDAQ Stock Market following the date hereof, the Corporation anticipates that
the &#147;cost of the Corporation&#148;, as of the Closing Date, determined in accordance
with U.S. generally accepted accounting principles, would exceed, with respect
to Parent, the condition of significance in the definition of significant
subsidiary in Rule&nbsp;1-02(w)(1)&nbsp;of Regulation&nbsp;S-X under the
Securities Act at the 50% percent level, if the Vendors unanimously so request,
in their sole discretion, in writing at least three (3)&nbsp;Business Days
prior to the Closing Date, the number of Consideration Shares issuable at the
Time of Closing shall be reduced by the number of Consideration Shares
specified in such notice.</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; During
the period during which the Closing Reference Price is determined, Purchaser
shall not (and shall not announce any intention to) acquire any Parent Shares
in the open market or take any action that is prohibited under Regulation M
under the Exchange Act in connection with a distribution of securities.</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.06</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Section&nbsp;116 Withholding</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; On or before the Closing Date,
Franklin M. Berger, Vitus, and all ESOP Holders and all ViroChem Employees who
are non-residents of Canada, subject to Section&nbsp;2.06(2), for purposes of
the Tax Act (each a &#147;<b>Non-Resident Vendor</b>&#148;)
will each deliver to the Purchaser a certificate in form and substance
reasonably satisfactory to the Purchaser in respect of the sale and purchase of
its respective Shares, ViroChem Shares or ESOP Shares, as applicable, issued
pursuant to subsection 116(2)&nbsp;of the Tax Act, specifying a certificate
limit in an amount that is </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=22,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=784824,FOLIO='19',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-05_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:32 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">not less than
the Canadian Purchase Price allocated to such Non-Resident Vendor and setting
out the correct name and address of the Non-Resident Vendor and the Purchaser
and description of the Shares, ViroChem Shares or ESOP Shares, as applicable,
disposed of by the Non-Resident Vendor.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;page-break-after:avoid;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If,
on or before the Closing Date,</font></p>

<p align="left" style="margin:0in 0in .0001pt;page-break-after:avoid;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>no certificate under section&nbsp;116 of the Tax Act described at Section&nbsp;2.06(1)&nbsp;or
2.06(2)(b)&nbsp;is delivered to the Purchaser by a Non-Resident Vendor, the
Purchaser shall withhold from the portion of the Purchase Price payable to such
Non-Resident Vendor in cash (pursuant to Section&nbsp;2.03(2)(c)) and, to the
extent of any shortfall in such amount, in Consideration Shares (pursuant to Section&nbsp;2.03(1)(b)),
an amount equal to 25% of the Canadian Purchase Price allocated to such
Non-Resident Vendor, or</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a certificate is issued by the CRA pursuant to subsection 116(2)&nbsp;of
the Tax Act in respect of the disposition by a Non-Resident Vendor of the
Shares, the ViroChem Shares or the ESOP Shares, as applicable, setting out the
correct name and address of the Non-Resident Vendor and the Purchaser and
description of the Shares, ViroChem Shares or ESOP Shares, as applicable,
disposed of by the Non-Resident Vendor, but specifying a certificate limit in
an amount that is less than the Canadian Purchase Price allocated to its
respective Shares, ViroChem Shares or ESOP Shares, as applicable, and otherwise
reasonably acceptable to the Purchaser, is delivered to the Purchaser, then the
Purchaser shall withhold from the portion of the Purchase Price payable to such
Non-Resident Vendor in cash (pursuant to Section&nbsp;2.03(2)(c)) and, to the
extent of any shortfall in such amount, in Consideration Shares (pursuant to Section&nbsp;2.03(1)(b)),
an amount equal to 25% of the amount by which the Canadian Purchase Price
allocated to such Non-Resident Vendor exceeds the certificate limit specified
on the certificate delivered to the Purchaser</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt .5in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(any
such amount referred to as the &#147;<b>Federal Withheld Amount</b>&#148;
for the Non-Resident Vendor).</font></p>

<p align="left" style="margin:0in 0in .0001pt .5in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Purchaser will pay any such
Federal Withheld Amount to the Escrow Agent on the Closing Date, to be held by
the Escrow Agent in accordance with the terms of the Escrow Agreement, and the
amount so paid will be credited to the Purchaser as payment on account of a
portion of the Purchase Price.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Where
the Purchaser assigns the right to purchase the Shares, ViroChem Shares and
ESOP Shares to an Affiliate of Purchaser, the Purchaser shall so notify the Non-Resident
Vendors at least ten (10)&nbsp;days before the Closing Date and the
Non-Resident Vendors shall notify the CRA that such Affiliate of the Purchaser,
and not the Purchaser, is the Purchaser of the Shares, ViroChem Shares and ESOP
Shares. In the event the Purchaser assigns the right to purchase the Shares,
ViroChem Shares and ESOP Shares to an Affiliate of the Purchaser and the
Purchaser duly notifies the Non-Resident Vendors of such assignment at least
ten (10)&nbsp;days before the Closing Date, the provisions of this Section&nbsp;2.06
shall apply as if the references to </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=23,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=148684,FOLIO='20',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-05_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:32 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 5.75pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the Purchaser were references to such Affiliate of the
Purchaser. In the event that the Purchaser fails to notify the Non-Resident
Vendors of an assignment of its rights to purchase the Shares, ViroChem Shares
and ESOP Shares in accordance with this paragraph, a certificate issued under
subsection 116(2)&nbsp;of the Tax Act shall be valid for purposes of this Section&nbsp;2.06
if it is issued under the name of the Purchaser. If such a notification is
received by the Purchaser after the above-mentioned delay, the Non-Resident
Vendors will nevertheless take the necessary steps to obtain another
certificate issued under subsection 116(2)&nbsp;or subsection 116(4)&nbsp;of
the Tax Act that correctly identifies such Affiliate as the &#147;purchaser.&#148;</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The foregoing provisions will apply <i>mutatis mutandis</i> to any amount paid to a Non-Resident Vendor
in respect of a Purchase Price Increase pursuant to Section&nbsp;2.04.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.07</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Section&nbsp;1097 Withholding</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; On or before the Closing Date, Vitus
will deliver to the Purchaser a certificate issued pursuant to section 1097 of
the QTA in respect of the sale and purchase of its respective Shares,
specifying a certificate limit in an amount that is not less than the Canadian
Purchase Price allocated to Vitus and setting out the correct name and address
of Vitus and the Purchaser and description of the Shares disposed of by Vitus.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If, on or before the Closing Date,</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>no
certificate issued by the ministre du Revenu du Qu&#233;bec pursuant to section 1097
of the QTA described at Section&nbsp;2.07(1)&nbsp;or 2.07(2)(b)&nbsp;is
delivered to the Purchaser by Vitus, then the Purchaser shall withhold from the
portion of the Purchase Price payable to Vitus in cash (pursuant to Section&nbsp;2.03(2)&nbsp;(c))
and, to the extent of any shortfall in such amount, in Consideration Shares
(pursuant to Section&nbsp;2.03(1)(b)), an amount equal to 12% of its portion of
the Canadian Purchase Price allocated to Vitus; or</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a
certificate is issued by the ministre du Revenu du Qu&#233;bec pursuant to section
1097 of the QTA in respect of the disposition by Vitus of its respective Shares
setting out the correct name and address of Vitus and the Purchaser and
description of the Shares disposed of by Vitus, but specifying a certificate
limit in an amount that is less than the Canadian Purchase Price allocated to
its Shares, is delivered to the Purchaser, then the Purchaser shall withhold
from the portion of the Purchase Price payable to Vitus in cash (pursuant to Section&nbsp;2.03(2)(c))
and, to the extent of any shortfall in such amount, in Consideration Shares
(pursuant to Section&nbsp;2.03(1)(b)), an amount equal to 12% of the amount by
which the Canadian Purchase Price allocated to Vitus exceeds the certificate
limit specified on the certificate delivered to the Purchaser</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 42.0pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(any such amount referred to as the &#147;<b>Quebec
Withholding Amount</b>&#148; for Vitus).</font></p>

<p align="left" style="margin:0in 0in .0001pt 42.0pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Purchaser will pay any such
Quebec Withholding Amount to the Escrow Agent on the Closing Date, to be held
by the Escrow Agent in accordance with the terms of the Escrow Agreement, and
the amount so paid will be credited to the Purchaser as payment on account of a
portion of the Purchase Price.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=24,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=306242,FOLIO='21',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-05_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:32 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Where the Purchaser
assigns the right to purchase the Shares to an Affiliate of Purchaser,
Purchaser shall so notify Vitus at least ten (10)&nbsp;days before the Closing
Date and Vitus shall notify the ministre du Revenu du Qu&#233;bec that such
Affiliate of the Purchaser, and not the Purchaser, is the Purchaser of its
Shares. In the event the Purchaser assigns the right to purchase the Shares to
an Affiliate of the Purchaser and the Purchaser duly notifies Vitus of such
assignment at least ten (10)&nbsp;days before the Closing Date, the provisions
of this Section&nbsp;2.07 shall apply as if the references to the Purchaser
were references to such Affiliate of the Purchaser. In the event that the
Purchaser fails to notify Vitus of an assignment of its rights to purchase the
Shares in accordance with this paragraph, a certificate issued under 1097 of
the QTA shall be valid for purposes of this Section&nbsp;2.07 if it is issued
under the name of the Purchaser. If such a notification is received by the
Purchaser after the above-mentioned delay, Vitus will nevertheless take the
necessary steps to obtain another certificate issued under 1097 or 1100 of the
QTA that correctly identifies such Affiliate as the &#147;purchaser.&#148;</p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The foregoing provisions will apply <i>mutatis mutandis</i> to any amount paid to Vitus in respect of a
Purchase Price Increase pursuant to Section&nbsp;2.04 hereof.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:avoid;text-align:center;text-decoration:underline;text-transform:uppercase;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">ARTICLE&nbsp;3- REPRESENTATIONS AND WARRANTIES</font></u></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:avoid;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.01</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Vendors&#146; Representations and Warranties</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each Vendor
individually and separately and not jointly or solidarily represents and warrants
to the Purchaser as follows in this Section&nbsp;3.01. For greater certainty,
each Vendor is providing the representations and warranties in this Section&nbsp;3.01
only with respect to itself and its Shares and not with respect to any other
Vendor or any other Vendor&#146;s Shares:</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Vendor&#146;s Shares.</u> The Vendor is
the beneficial and registered owner of that number of Shares as set out
opposite its name on <b>Schedule&nbsp;A</b>
(other than in the case of the ViroChem Trust which is the registered owner of
that number of Shares as set out opposite its name on <b>Schedule A</b>
for the benefit of the ViroChem Employees which shall become the beneficial
owners of such Shares upon exercise of their options under the Trust ESOP). All
such Shares are owned free and clear of all liens, hypothecs, charges,
encumbrances and any other rights of others (other than pursuant to this
Agreement, the Shareholders Agreement, applicable securities laws, the ViroChem
Trust and the Trust ESOP, as applicable), and such Vendor does not directly or
indirectly own any shares of capital stock or other securities of the
Corporation, or any option, warrant or other right to acquire (by purchase,
conversion or otherwise) any shares of capital stock or other securities of the
Corporation, other than as set forth on <b>Schedule A</b>.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Power, Authority, Right.</u> The
Vendor has the power, authority and right to enter into and deliver this
Agreement and to transfer the legal and beneficial title and ownership of its
Shares to the Purchaser free and clear of all liens, hypothecs, charges,
encumbrances and any other rights of others. Each Trustee has the power and
authority to enter into, perform its obligations under and complete the
transactions contemplated by this Agreement on behalf of the Trust for which it
is a trustee.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=25,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=459329,FOLIO='22',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-05_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:32 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Establishment and Incorporation.</u></font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Shire represents and warrants that it is a corporation duly
incorporated, organized and subsisting in good standing under the Laws of
Canada.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>CDPQ represents and warrants that it is a corporation duly
incorporated, organized and subsisting in good standing under <i>An Act respecting the Caisse de d&#233;p&#244;t et placement du Qu&#233;bec</i>.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Fonds represents and warrants that it is an entity duly
incorporated, organized and subsisting in good standing under <i>An Act to establish the Fonds de solidarit&#233; des travailleurs du Qu&#233;bec
(F.T.Q.)</i>.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>BDC represents and warrants that it is a corporation duly
incorporated, organized and subsisting in good standing under the Laws of
Canada.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>IFML represents and warrants that it is a corporation duly
incorporated, organized and subsisting in good standing under the laws of
Qu&#233;bec.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Power represents and warrants that it is a corporation duly
incorporated, organized and subsisting in good standing under the Laws of
Canada.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Vitus represents and warrants that it is a corporation duly
incorporated, organized and subsisting in good standing under the laws of
Singapore.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each Trustee represents and warrants that the Trust of which it is
the trustee has been established and settled and is validly existing under the
Laws of the Province of Qu&#233;bec.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Agreements.</u> There is no
agreement, contract, option, understanding, commitment or any other right of
another, binding upon or which at any time in the future may become binding
upon the Vendor to sell, transfer, assign, pledge, charge, mortgage or in any
other way dispose of or encumber any of its Shares other than pursuant to the
provisions of this Agreement, the Shareholders Agreement, the ViroChem Trust
and Trust ESOP, as applicable, in each case, except as would not prevent the
Vendor from performing its obligations hereunder. Except for the Shareholders
Agreement and with respect to the ViroChem Trust and the Trust ESOP, no Vendor
is bound by any shareholders agreement, pooling agreement, voting trust or
other similar agreement with respect to the ownership or voting of any of its
Shares in each case, except as would not prevent the Vendor from performing its
obligations hereunder.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Conflict, Violation, Consents.</u>
Except as set forth in </font><b>Schedule&nbsp;3.01(5)</b>,<b>  </b>neither
the entering into nor the delivery of this Agreement nor the completion of the
transactions contemplated in this Agreement by the Vendor will (i)&nbsp;result
in the violation or breach, (ii)&nbsp;give rise to any material termination
rights or material payment obligations under, or (iii)&nbsp;require the Vendor
to obtain any consent, authorization or approval of any third party or
Governmental Authority under any provision of:</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any contract or other instrument to which the Vendor is a party or
by which the Vendor is bound or to which any of its Shares is subject;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=26,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=605401,FOLIO='23',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-05_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:32 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>in the case of each of IFML, CDPQ, Fonds, BDC, Shire, Power and
Vitus, its articles, by-laws or any other organizational documents of such
company;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>in the case of the Trusts, the declaration of trust or any other
document settling and/or establishing the relevant Trust; or</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any Applicable Law in respect of which the Vendor must comply in
each case, except as would not prevent the Vendor from performing its
obligations hereunder.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No
Insolvency.</u> The Vendor is not insolvent within the meaning of the <i>Bankruptcy and Insolvency Act</i> (Canada) nor has committed any
act of bankruptcy, proposed any compromise or arrangement or taken any
proceedings with respect thereto and no encumbrance or receiver has taken
possession of any of the Vendor&#146;s property nor is any of the foregoing pending
or threatened.</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Legal
Proceedings.</u> There is no Legal Proceeding pending or, to the knowledge of
such Vendor, threatened, which affects the Vendor&#146;s ability to transfer good
and valid title to the Vendor&#146;s Shares to the Purchaser. There is no order,
directive, judgment, decree, injunction, decision, ruling, award or writ of any
Governmental Authority outstanding affecting the Vendor&#146;s ability to transfer
good and valid title to the Vendor&#146;s Shares to the Purchaser.</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Binding Obligation.</u> This
Agreement constitutes the valid and legally binding obligation of the Vendor,
enforceable against the Vendor in accordance with its terms, subject to
applicable bankruptcy, insolvency, reorganization and other laws of general
application limiting the enforcement of creditors&#146; rights generally and to the
fact that specific performance is an equitable remedy available only in the
discretion of a court.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(9)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Not a Non-Resident.</u> Except for
Franklin M. Berger and Vitus, none of the Vendors is a non-resident of Canada
for purposes of the Tax Act or a partnership that is not a Canadian partnership
for purposes of section&nbsp;102 of the Tax Act, and, except for Vitus, the
Shares will not constitute &#147;taxable Qu&#233;bec property&#148; contemplated in section
1097 of the QTA.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">(10)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Investment in Parent&#146;s Shares.</u> Each
Vendor acknowledges that it has been informed that Vendors who are not U.S.
Persons, as that term is defined in Regulation S under the Securities Act of
1933, as amended (the &#147;<b>Securities Act</b>&#148;),
will receive their Parent Shares pursuant to the exemption from registration
provided in Rule&nbsp;903 of Regulation S under the Securities Act as partial
consideration for the Vendor&#146;s Shares. Franklin M. Berger acknowledges that he
has been informed that he will receive his Parent Shares pursuant to the
exemption from registration provided in section&nbsp;4(2)&nbsp;of the
Securities Act and, as deemed appropriate, the rules&nbsp;promulgated
thereunder. Each Vendor acknowledges that the information supplied by the
Vendors in the representations contained herein will be relied upon by the
Purchaser in concluding that the Parent Shares have been issued </font>pursuant to Regulation S or
another exemption from the U.S. securities registration requirements.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each Vendor represents and warrants to the
Purchaser with respect to itself only that:</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=27,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=1017898,FOLIO='24',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-05_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:32 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>such Vendor (A)&nbsp;is knowledgeable, sophisticated and experienced
in making, and is qualified to make, decisions with respect to investments such
as would be involved in making a decision to accept the Parent Shares in the
manner contemplated by this Agreement, (B)&nbsp;has the knowledge and
experience in financial and business matters as to be capable of evaluating the
merits and risks of an investment in the Parent Shares, and such Vendor&#146;s
financial situation is such that such Vendor can afford to bear the economic
risks of holding the Parent Shares for an indefinite period of time and suffer
complete loss of the investment, (C)&nbsp;has requested, received, reviewed and
considered all information it deems relevant in making an informed decision to
acquire the Parent Shares, (D)&nbsp;has, in connection with its decision to
acquire the Parent Shares, relied solely upon an independent investigation made
by such Vendor and its advisors and the representations and warranties of the
Purchaser and the Parent contained herein, and (E)&nbsp;is acquiring the Parent
Shares hereunder solely for its own account and not with a view to, or for
resale in connection with, any distribution or disposition thereof other than
pursuant to an effective registration statement under the Securities Act or an
exemption thereunder.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>With the exception of Franklin M. Berger, such Vendor has reviewed <b>Schedule 3.01(10)(a)(i) </b>hereto and determined it is not a
U.S. Person, as that term is defined in Rule 902(k) of Regulation S.</p>

<p align="left" style="margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Franklin M. Berger has reviewed <b>Schedule&nbsp;3.01(10)(b)&nbsp;</b>hereto
and determined that he is an &#147;accredited investor&#148; within the meaning of Rule&nbsp;501(a)&nbsp;of
Regulation D promulgated under the Securities Act.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Such Vendor understands that the Parent Shares are being offered and
sold to it in reliance upon specific exemptions from the registration
requirements of the Securities Act and the rules&nbsp;and regulations
promulgated thereunder and Purchaser is relying upon the truth and accuracy of,
and such Vendor&#146;s compliance with, the representations, warranties, agreements,
and acknowledgments of such Vendor.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Such Vendor acknowledges that the Parent Shares to be delivered to
Vendor under this Agreement will not, at the time of delivery, be registered
under the Securities Act or under the securities laws of any state or other
jurisdiction. Such Vendor further acknowledges that the Parent Shares issued
under this Agreement will be &#147;restricted securities&#148; (as defined in Rule&nbsp;144
under the Securities Act) and may not be sold or transferred, except in
accordance with the terms of the legend set forth below. Such Vendor
acknowledges that any certificate or certificates evidencing the Parent Shares
issued hereunder to that Vendor will bear a legend until the first to occur of
the events described in clauses (A)&nbsp;or (D)&nbsp;of the legend set forth
below with respect to such Parent Shares, at which time Parent, when and as
requested by each Vendor, shall deliver at no charge an unlegended certificate
with respect to such Parent Shares) substantially to the effect set forth below
and that a stop transfer order may be placed with respect thereto.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=28,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=42166,FOLIO='25',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-05_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:32 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;THE SHARES
REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE UNITED
STATES SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), OR ANY
APPLICABLE SECURITIES LAWS OF ANY JURISDICTION AND MAY&nbsp;NOT BE SOLD,
ASSIGNED OR TRANSFERRED OR USED IN HEDGING TRANSACTIONS UNLESS (A)&nbsp;A
REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND SUCH APPLICABLE SECURITIES
LAWS SHALL BE EFFECTIVE WITH REGARD THERETO OR (B)&nbsp;THE SHARES ARE
PERMITTED TO BE RESOLD UNDER RULE 144 OR (C)&nbsp;THE RESALE IS MADE OUTSIDE
THE UNITED STATES IN ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT AND
THE APPLICABLE LAWS OF SUCH NON-US JURISDICTION OR (D)&nbsp;IN THE OPINION OF
COUNSEL IN FORM, SUBSTANCE AND SCOPE REASONABLY ACCEPTABLE TO VERTEX
PHARMACEUTICALS INCORPORATED, REGISTRATION UNDER SUCH SECURITIES ACT AND SUCH
APPLICABLE SECURITIES LAWS IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED
TRANSFER.&#148;</font></p>

<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Such Vendor represents and warrants to Purchaser that it will not,
directly or indirectly, offer, sell, pledge, sell short, transfer or otherwise
dispose of (or solicit any offers to buy, purchase or otherwise acquire or take
a pledge of) any Parent Shares except in compliance with the Securities Act,
the Securities Exchange Act of 1934, as amended (the &#147;<b>Exchange Act</b>&#148;),
and the rules&nbsp;and regulations promulgated thereunder and any other
Applicable Laws.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.02</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Corporation&#146;s Representations and Warranties</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Corporation represents and warrants as
follows:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Establishment, Incorporation,
Corporate Power.</u></font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Corporation is a corporation duly incorporated, organized and subsisting
in good standing under the Laws of Canada with the corporate power to own,
lease and operate the property and assets now owned, leased or operated by it
and to carry on its business. The Corporation conducts business only in the
Province of Quebec.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Schedule</b>&nbsp;<b>3.02(1)(b)&nbsp;</b>contains a true and complete copy of the
Corporation&#146;s articles of incorporation and by-laws, as amended, in force as of
the date hereof and there are no undertakings to amend such articles or
by-laws.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Corporation is a Private Issuer and is not a reporting issuer
under Canadian securities legislation; there is no published market for the
Shares, the ViroChem Shares or the ESOP Shares; on the date hereof, the
aggregate number of holders of the Shares, the ViroChem Shares and the ESOP
Shares is not more than fifty (50), exclusive of holders who (i)&nbsp;are in
the employment of the Corporation or an Affiliate of the Corporation, or (ii)&nbsp;were
formerly in the employment of the </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=29,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=782293,FOLIO='26',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-05_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:32 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporation or in the employment of an entity that was
an Affiliate of the Corporation at the time of that employment, and who while
in that employment were, and have continued after that employment to be,
security holders of the Corporation.</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Corporation has the power, authority and right to enter into and
deliver this Agreement and perform its obligations hereunder. This Agreement
constitutes a valid and legally binding obligation of the Corporation,
enforceable in accordance with its terms, subject to applicable bankruptcy,
insolvency, reorganization and other laws of general application limiting the
enforcement of creditors&#146; rights generally and to the fact that specific
performance is an equitable remedy available only in the discretion of the court.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;page-break-after:avoid;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Capitalization.</u></font></p>

<p align="left" style="margin:0in 0in .0001pt;page-break-after:avoid;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;page-break-after:avoid;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The authorized capital of the Corporation consists of an unlimited
number of Class&nbsp;A Shares, 725,000 Class&nbsp;B Shares and an unlimited
number of Class&nbsp;C Shares.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;page-break-after:avoid;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The issued capital of the Corporation as at the date hereof together
with the name of each beneficial and registered shareholder and the number of
shares held by each shareholder is included on <b>Schedule A</b>
under the caption &#147;Vendors&#148; and the Shares have been validly issued, are
outstanding and are fully paid and non-assessable and have been issued in
compliance with (i)&nbsp;all Applicable Laws, and (ii)&nbsp;all requirements
set forth in any applicable contracts.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except for the ViroChem Renaissance Trust Agreement and the employee
stock option plan relating thereto (the &#147;<b>Trust ESOP</b>&#148;),
the Therapeutic Renaissance Trust Agreement and the Shareholders Agreement,
there are no shareholders&#146; agreements, pooling agreements, voting trusts or
other similar agreements or understandings to which the Corporation is a party
or, to the Knowledge of the Corporation, with respect to the ownership or
voting of the shares of the Corporation or restricting any person from
purchasing, selling, pledging or otherwise disposing of (or granting any option
or similar right with respect to) any shares of the Corporation.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The ViroChem Employees are the only holders of options to acquire
shares held by the ViroChem Trust and are detailed on <b>Schedule A </b>under
the caption &#147;ViroChem Employees&#148;.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>There is no contract, option, other convertible security or any
other right of another binding upon or which at any time in the future may
become binding upon the Corporation to allot or issue any of the unissued
shares in the share capital of Corporation or to create any additional class of
shares except under the &#147;ViroChem Pharma Inc. Stock Option Plan for Employees,
Non-Employee Directors and Consultants&#148; (the &#147;<b>ESOP</b>&#148;),
a copy of which is attached hereto as <b>Schedule 3.02(2)(e)</b>.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=30,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=377206,FOLIO='27',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-05_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:32 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The only options, warrants or other rights to acquire (by purchase,
conversion or otherwise) any shares of capital stock or other securities of the
Corporation presently issued and outstanding are the options held by the ESOP
Holders as detailed on <b>Schedule A</b>
under the caption &#147;ESOP Holders.&#148; Prior to the Time of Closing (i)&nbsp;each
such option will have been exercised or cancelled with the written consent of
the holder of such option, or (ii)&nbsp;the aggregate amount set forth in
Column 14 of <b>Schedule 2.02(2)</b>&nbsp;payable to
holders of options under the ESOP who have not exercised their options under
the ESOP for ESOP Shares prior to the Time of the Closing shall be included in
the Estimated Final Net Amount. Upon exercise as contemplated under this
Agreement, the ESOP Shares will be validly issued, outstanding and fully paid
and non-assessable and will have been issued in compliance with (i)&nbsp;all
Applicable Laws, and (ii)&nbsp;all requirements set forth in any applicable
contracts, including the ESOP.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>At the Time of Closing, the options under the Trust ESOP will be
exercised or cancelled. Upon exercise of the options under the Trust ESOP and
the transfer of the Shares held by the ViroChem Trust to the ViroChem Employees
as contemplated under this Agreement, the ViroChem Shares will be validly
issued, outstanding and fully paid and non-assessable and will have been issued
in compliance with (i)&nbsp;all Applicable Laws, and (ii)&nbsp;all requirements
set forth in any applicable contracts, including the ViroChem Trust and the
Trust ESOP.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Conflict, Violation, Consents.</u>
Neither the entering into nor the delivery of this Agreement nor the completion
of the transactions contemplated in this Agreement by the Corporation will (i)&nbsp;result
in the violation or breach, (ii)&nbsp;give rise to any termination rights or
material payment obligation under, or (iii)&nbsp;require any consent,
authorization or approval of any third party or Governmental Authority under
any provision of:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Corporation&#146;s articles of incorporation and by-laws, as amended,
in force as of the date hereof;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any agreement or other instrument to which the Corporation is a
party or by which the Corporation is bound, except as could not
reasonably be expected to individually or in the aggregate have a Material
Adverse Effect; and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any Applicable Law in respect of which the Corporation must comply, except
as could not reasonably be expected to individually or in the aggregate have a
Material Adverse Effect.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Subsidiaries.</u> The Corporation
does not have any subsidiaries or any agreements, options or commitments to
acquire any shares or securities of any corporation, partnership or trust.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=31,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=562720,FOLIO='28',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-05_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:32 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;page-break-after:avoid;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Financial
Statements.</u></font></p>

<p align="left" style="margin:0in 0in .0001pt;page-break-after:avoid;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;page-break-after:avoid;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
accounting and financial books and records of the Corporation are complete and
accurate in all material respects.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;page-break-after:avoid;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The audited financial statements of the Corporation, consisting of a
balance sheet and statements of income, retained earnings and cash flows for
each of the three years ended December&nbsp;31, 2007, 2006 and 2005, together
with the reports of Deloitte and Touche LLP, chartered accountants, thereon and
the notes thereto (collectively, the &#147;<b>Audited Financial
Statements</b>&#148;), and the unaudited balance sheet as of December&nbsp;31,
2008 (the &#147;<b>Latest Balance Sheet</b>&#148;) and the
related statements of income, retained earnings and cash flows for the
twelve-month period ending December&nbsp;31, 2008 (the &#147;<b>Interim
Financial Statements</b>&#148;, and together with the Audited Financial
Statements, collectively, the &#147;<b>Financial Statements</b>&#148;),
copies of which are attached hereto as <b>Schedule 3.02(5)(b)</b>:</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>are in all material respects in accordance with the accounting and
financial books and records of the Corporation as at the respective dates then
ended;</p>

<p align="left" style="margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>are true and correct in all material respects and present fairly in
all material respects the financial position of the Corporation as at the
respective dates then ended, and the results of operations and cash flows of
the Corporation for the periods covered thereby, all in accordance with Canadian
generally accepted accounting principles consistently applied (except as may be
noted therein); and</p>

<p align="left" style="margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>have been prepared in accordance with Canadian generally accepted
accounting principles consistently applied (except as may be noted therein);</p>

<p align="left" style="margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">provided,
however, that the Interim Financial Statements are subject to normal year-end
audit adjustments (which are not expected to be material) and do not contain
footnotes required under Canadian generally accepted accounting principles.</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Absence of Undisclosed Liabilities</u>.
Except as disclosed in <b>Schedule&nbsp;3.02(6)</b>,
the Corporation has not incurred any liabilities or obligations required in
accordance with Canadian generally accepted accounting principles to be
reflected on the Corporation&#146;s balance sheet which continue to be outstanding,
except (a)&nbsp;as disclosed on the Latest Balance Sheet, (b)&nbsp;for the
Transaction Expenses paid prior to the Time of Closing or reflected on the
Estimated Closing Balance Sheet, (c)&nbsp;as incurred in the ordinary course of
business since the date of the Latest Balance Sheet or (d)&nbsp;which are not
individually or in the aggregate reasonably expected to have a Material Adverse
Effect.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Absence of Changes and Unusual
Transactions</u>. Except as set forth on <b>Schedule&nbsp;3.02(7)</b>,
since December&nbsp;31, 2007, the Corporation has operated its business
in all material respects in the ordinary course of business (except with
respect to the transactions contemplated hereby and except for confidentiality
agreements or other agreements entered into </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=32,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=710438,FOLIO='29',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-05_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:32 2009' -->



<div style="font-family:Times New Roman;">

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">by the Corporation in the context of the sale of the Shares, the
ViroChem Shares and the ESOP Shares) and has not:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>experienced
any change in its financial condition or operations other than changes in the
ordinary course of business, none of which individually or in the aggregate has
had or would reasonably be anticipated to result in a Material Adverse Effect;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>transferred,
assigned, sold or otherwise disposed of any of the material assets shown or
reflected in the Latest Balance Sheet or cancelled any material debts or
entitlements or released or relinquished any material contractual rights;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>made
any change in its accounting principles, policies, practices or methods;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>cancelled
or waived any debt, claim or other right;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>incurred
or assumed any liabilities or obligations of any nature, whether absolute,
accrued, contingent or otherwise, except unsecured current liabilities incurred
in the ordinary course of business;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>mortgaged,
pledged, granted a security interest in or otherwise created a lien on any of
its property or assets, except in the ordinary course of business and in
amounts which, individually and in the aggregate are not material to the
financial condition of the Corporation or operation of the business;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>entered
into any contract or any other transaction that was not in the ordinary course
of business, except with respect to the transactions contemplated hereby and
except for confidentiality agreements or other agreements entered into by the
Corporation in the context of the sale of the Shares, the ViroChem Shares and
the ESOP Shares;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>terminated,
cancelled, modified or amended in any material respect or received notice or a
request for termination, cancellation, modification or amendment of any
Material Contract or taken or failed to take any action that would entitle any
party to a Material Contract to terminate, modify, cancel or amend any Material
Contract;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>made
any capital expenditure or authorized any capital expenditure or made any
commitment for the purchase, construction or improvement of any capital assets
except in the ordinary course of business; or</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>authorized,
agreed or otherwise become committed to do any of the foregoing.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Employees.</u></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Schedule&nbsp;3.02(8)(a)&nbsp;</b>sets forth, as of the date hereof, a complete and accurate list of
the directors, officers, employees, consultants and independent contractors of
the Corporation, including their position/title; their status (i.e., full time,
part time, temporary, casual, seasonal, co-op student); their total length of
employment; and </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=33,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=847554,FOLIO='30',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-07_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:33 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">whether any employees are on any approved or statutory
leave of absence, and, if so, the reason for such absence and the expected date
of return.</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>As of
the date hereof, the Corporation does not have any employment, consulting or
independent contractor agreement with any person whomsoever except those
agreements listed in <b>Schedule&nbsp;3.02(8)(b)</b>,
copies of which have been delivered or made available to the Purchaser. All
past and current<b>  </b>employees of and consultants and
independent contractors to the Corporation who have contributed to the Owned
Intellectual Property have executed invention and discovery agreements as are
customary for the business of the Corporation whereby each of them agrees to
assign to the Corporation all of their right, title and interests to
inventions, discoveries and other intellectual property created in the course
of their employment or consulting with the Corporation and in connection with
the business of the Corporation.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Corporation is in all material respects in compliance with all Applicable Laws
relating to employees, consultants and independent contractors.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>As of
the date hereof, there is no proceeding, action, suit, claim, complaint or
application for certification pending or, to the Knowledge of the Corporation,
threatened by any current or former director, employee, consultant or
contractor against the Corporation that would reasonably be expected to have a
Material Adverse Effect.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>As of
the date hereof, the Corporation is not a party, either directly, voluntarily
or by operation of law, to any collective agreement, letter of understanding,
letter of intent or other similar agreement or undertaking with any bargaining
agent, trade union or association which may qualify as a trade union, which
would apply to any of its employees.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All
unused vacation days for the Corporation&#146;s employees as of the date of the
Latest Balance Sheet are properly reflected in the employee records of the
Corporation.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>There
is no pending labour dispute, strike, lock-out, slowdown, work stoppage&nbsp;or
other labour conflict that would reasonably be expected to have a Material
Adverse Effect.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=34,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=325111,FOLIO='31',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-07_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:33 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(9)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Benefit
Plans.</u></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except
for the ESOP and the Trust ESOP and such other agreements and plans as are
listed in <b>Schedule 3.02(9)(a)&nbsp;</b>(the &#147;<b>Benefit Plans</b>&#148;), as of the date hereof, the Corporation is
not bound by or a party to any benefit plan including, without limitation, any
pension plan or any arrangement providing for the payment of benefits after the
employee&#146;s retirement maintained by or on behalf of the Corporation for any of
its employees.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Corporation has made available to the Purchaser a copy of each Benefit Plan, as
well as any funding agreements and service provider contracts or other
contracts related to each such the Benefit Plan in respect of which the
Corporation would be reasonably expected to have liability, and any other material
document that supports each Benefit Plan and no promises or commitments have
been made by the Corporation to amend any Benefit Plan.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All Benefit Plans have been
established, registered and qualified, and are being administered and funded in
all material respects in accordance with the terms of such Benefit Plans and
all Applicable Laws.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>None
of the Benefit Plans provide for benefit increases, or the acceleration of
vesting or funding obligations or an increase thereof that are contingent solely
upon, or will be triggered solely by, the completion of the transactions
contemplated herein.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>None
of the Benefit Plans provide benefits beyond retirement or other termination of
service to employees or former employees or to the beneficiaries or dependants
of such employees.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>As of
the date hereof, there is no proceeding, action, suit or claim (other than
routine claims for payments of benefits) pending or, to the Knowledge of the
Corporation, threatened involving any Benefit Plan or its assets.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(10)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Intellectual
Property.</u></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All of
the Owned Intellectual Property that (i)&nbsp;is registered or granted or (ii)&nbsp;applied
for and pending is set out on <b>Schedule&nbsp;3.02(10)(a)(i)</b>.
Except as disclosed in <b>Schedules&nbsp;3.02(10)(a)(ii)&nbsp;</b>and
<b>3.02(10)(g)</b>, the Corporation holds the
entire right, title and interest in and to all of the Owned Intellectual
Property free and clear of any Encumbrances, except such Encumbrances as could
not reasonably be expected to have a Material Adverse Effect.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Owned Intellectual Property has been duly registered or applications to
register the same have been filed in all appropriate offices, as set forth on <b>Schedule&nbsp;3.02(10)(a)(i)</b>, consistent with the prevailing
intellectual property practices of the Corporation or its predecessors, and any
such applications or registrations are in good administrative standing. Except
as disclosed in <b>Schedule&nbsp;3.02(10)(b)</b>, all
necessary registration, maintenance or annuity, and </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=35,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=176468,FOLIO='32',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-07_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:33 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">renewal fees in connection with the Owned Intellectual
Property have been timely made (having regard to any available periods of
extension, reinstatement, restoration or late payment) and are current, except
where any deficiency could not reasonably be expected to have a Material
Adverse Effect.</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>As of
the date hereof, the Corporation has the right and license to use the Licensed
Intellectual Property from the purported licensors thereof in the manner used
in the business of the Corporation as currently conducted.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All agreements relating to the license or
sublicense of the Owned Intellectual Property or Licensed Intellectual Property
(the &#147;<b>License Agreements</b>&#148;) have been made
available to Parent as of the date hereof; <i>provided, however</i>,
that confidentiality agreements and other agreements entered into by the
Corporation in the context of the sale of the Shares, the ViroChem Shares and
the ESOP Shares have been provided to Parent in redacted form. All agreements
relating to the license to the Corporation from others of the Licensed
Intellectual Property as it pertains to the development, manufacture or use of
the VCH-759 or VCH-222 products as same are being developed, manufactured or
used by the Corporation as of the date hereof are set forth in <b>Schedule 3.02(10)(d)</b>. All royalty-bearing agreements
relating to the license or sublicense by the Corporation to others of the Owned
Intellectual Property or Licensed Intellectual Property are set forth on <b>Schedule 3.02(10)(d)</b>.&#160;
The Corporation is not a party to any contract to pay any ongoing
royalty or other fee to use the Licensed Intellectual Property except as set
out in <b>Schedule 3.02(10)(d)</b>.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except
as set out in <b>Schedule&nbsp;3.02(10)(e)</b>, as of
the date hereof, no consents from the purported licensors thereof are required
in order for the Licensed Intellectual Property to be licensed or sub-licensed
to a third party in the manner such licensing or sub-licensing has been
effected to date in the conduct of the business of the Corporation.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except
as set out in <b>Schedule&nbsp;3.02(10)(f)</b>, to the
Knowledge of the Corporation, and as of the date hereof, the Owned Intellectual
Property and the Licensed Intellectual Property constitute all of the material
Intellectual Property used in, held for use in, or required (i)&nbsp;to carry
on, the business of the Corporation as currently conducted or (ii)&nbsp;if the
HCV Products were to be commercialized as of the date hereof, to develop,
manufacture or use the HCV Products as same are being developed, manufactured
or used by the Corporation, and to sell the HCV Products as so developed,
manufactured or used.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except
as set out in <b>Schedule 3.02(10)(g)</b>, to the
Knowledge of the Corporation and as of the date hereof, neither the use of the
Owned Intellectual Property or the Licensed Intellectual Property, as same are
used in the business of the Corporation as currently conducted, nor the conduct
of the business of the Corporation as currently conducted nor, if the HCV
Products were to be commercialized as of the date hereof, the development,
manufacture or use of the HCV Products as same are being developed,
manufactured or used by the </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=36,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=529161,FOLIO='33',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-07_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:33 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporation or the sale of the HCV Products as so
developed, manufactured or used, infringes or misappropriates the Intellectual
Property rights of any other person, and the Corporation has not received any
written demand or claim by any person (except from a government intellectual
property office in the course of ordinary prosecution of the Owned Intellectual
Property) that any of the Owned Intellectual Property or Licensed Intellectual
Property is, or may be, invalid or that the Corporation or any of its
technology or the use by the Corporation of any Intellectual Property infringes
upon or misappropriates any patent or other intellectual property right of any
third party. None of the Owned Intellectual Property has been or is the subject
of any interference or opposition proceedings, nor, to the Knowledge of the
Corporation, are there any threatened interference or opposition proceedings in
respect of same.</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except
as set out in <b>Schedule 3.02(10)(h)</b>, to the
Knowledge of the Corporation, no infringement of the Owned Intellectual
Property is occurring.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except
as disclosed in <b>Schedule 3.02(10)(i)</b>, to the Knowledge
of the Corporation, (i)&nbsp;the Owned Intellectual Property that has been
issued is valid, (ii)&nbsp;there is no prior art other than has been made of
record or otherwise revealed during prosecution of the Owned Intellectual
Property that would materially adversely affect the patentability of any Owned
Intellectual Property that is pending or issued, and (iii)&nbsp;all of the
rights of the Corporation in the Owned Intellectual Property that is issued are
enforceable.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>To
the Knowledge of the Corporation, all named inventors under the Owned
Intellectual Property listed in <b>Schedule&nbsp;3.02(10)(a)(i)&nbsp;</b>and
that pertains to the VCH-759 or VCH-222 products were under obligation to
assign their inventions to their respective employers. To the Knowledge of the Corporation, all
named inventors for U.S. application Serial No.&nbsp;10/166,030 filed&nbsp;on June&nbsp;11th
2002, now U.S. patent No.&nbsp;&nbsp;6,887,877, were under an obligation to
assign their inventions therein&nbsp;to their respective employers.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(11)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Real Property</u>. Except as set forth in the lease agreement, together with all
amendments, subleases, extensions, renewals, guaranties, licenses, concessions
and other agreement (whether written or oral) relating thereto,<b>  </b>copies of which are attached hereto as <b>Schedule&nbsp;3.02(11)</b>,
the Corporation does not own, lease or otherwise have any rights in or to any
real or immovable<b>  </b>property, and the Corporation is
not a lessor or sublessor under any lease or sublease. There are no amounts
disputed by the Corporation and not paid to the landlord with respect to the
said lease and the lease and its contractual terms are legal, valid, binding,
enforceable and in full force and effect. Neither the Corporation nor, to the
Knowledge of the Corporation, any other party to said lease is in breach or
default under the lease, and, to the Knowledge of the Corporation, no event has
occurred or circumstance exists which, with the delivery of notice, the passage
of time or both, could reasonably be expected to constitute such a breach or
default, or permit the termination of the lease, or the modification or
acceleration of rent under the lease. There are no oral leases of the
Corporation.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=37,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=219777,FOLIO='34',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-07_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:33 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(12)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Insolvency</u>. The Corporation is not insolvent within the meaning of the <i>Bankruptcy and Insolvency Act </i>(Canada)<i>  </i>and
has not committed any act of bankruptcy, proposed any compromise or arrangement
or taken any proceedings with respect thereto and no encumbrance or receiver
has taken possession of any of the Corporation&#146;s property nor is any of the
foregoing pending or threatened.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(13)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Legal Proceedings</u>. There is no Legal Proceeding (whether or not purportedly on behalf
of the Corporation) in progress, pending or, to the Knowledge of the
Corporation, threatened against or affecting the Corporation or any of its
property or assets or title thereto, nor, to the Knowledge of the Corporation,
is there any basis on which any such Legal Proceeding might be commenced. There
is no order, directive, judgment, decree, injunction, decision, ruling, award
or writ of any Governmental Authority outstanding against or, to the Knowledge
of the Corporation, affecting the Corporation or any of its property or assets.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Insurance.</u>  <b>Schedule&nbsp;3.02(14)</b> contains a
list indicating all insurance policies maintained by the Corporation, as of the
date hereof, which list specifies the insurer, the amount of the coverage, the
type of insurance and the policy number and any claims thereunder, and true,
correct and complete copies of such insurance policies have been provided or
made available to the Purchaser. To the Knowledge of the Corporation, no event has occurred or
circumstance exists which would provide the insurer grounds to rescind, cancel,
or non-renew the insurance policies listed in <b>Schedule&nbsp;3.02(14)</b>.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(15)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Contracts
and Commitments.</u></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Other
than (i)&nbsp;the Asset Purchase Agreement and any contracts or commitments
assigned or assumed thereunder, (ii)&nbsp;the lease disclosed on<b> Schedule 3.02(11), </b>(iii)&nbsp;the employment and consulting
agreements listed on<b> Schedule 3.02(8)(b)</b>,
(iv)&nbsp;the License Agreements relating to the license to the Corporation from others
of the Licensed Intellectual Property as it pertains to the development,
manufacture or use of the VCH-759 or VCH-222 products as same are being
developed, manufactured or used by the Corporation as of the date hereof<b>,</b> and (v)&nbsp;the contracts disclosed on<b> Schedule
3.02(15)(a)&nbsp;</b>(collectively, the &#147;<b>Material
Contracts</b>&#148;), the Corporation is not a party to any contract or
commitment that is not cancellable by the Corporation without penalty (and by
the Purchaser following the Time of Closing) on less than twelve
(12)&nbsp;months&#146; notice or that would require expenditures by the Corporation
in the aggregate to be made thereunder in excess of CN$50,000.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Corporation is not in default or breach in any material respect of any Material
Contract and, to the Knowledge of the Corporation, there exists no condition,
event or act which, with the giving of notice or lapse of time or both, would
constitute a default or breach by any party to a Material Contract, and all the
Material Contracts are in all material respects in good standing and in full
force and effect.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except
as set forth in <b>Schedule 3.02(8)(b)&nbsp;</b>or for
the Trusts, Trust ESOP, ESOP and Shareholders Agreement, no officer, director
or Affiliate of the Corporation is </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=38,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=518823,FOLIO='35',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-07_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:33 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a party to any transaction with the Corporation,
including any contract, agreement or other arrangement providing for the
employment of, furnishing of services by, rental of real or personal property
from or otherwise requiring payments to or payments from any such Person, other
than employment-at-will arrangements in the ordinary course of business.</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Asset Purchase Agreement is valid, binding and enforceable upon the Corporation
in accordance with its terms and is in full force and effect, subject to
bankruptcy, insolvency, reorganization and other laws of general application
limiting the enforcement of creditors&#146; rights generally and to the fact that
specific performance is an equitable remedy available only in the discretion of
the court. Neither the Corporation nor, to the Knowledge of the Corporation,
Shire, is in default of any of its obligations under the Asset Purchase
Agreement. The Corporation has not waived any rights or defaults under the
Asset Purchase Agreement, and, to the Knowledge of the Corporation, no event
has occurred which, after the giving of notice or the lapse of time or both,
would constitute a default or breach by the Corporation under the Asset
Purchase Agreement or, to the Knowledge of the Corporation, would constitute a
default or breach by Shire. The Corporation has not received any notice that
the Asset Purchase Agreement has been or will be terminated or that the Corporation
is in material default of its obligations under the Asset Purchase Agreement.
The Corporation has no intention of terminating the Asset Purchase Agreement
and, to the Knowledge of the Corporation, there is no event, circumstances or
grounds upon which the Asset Purchase Agreement may be terminated by either
party for breach.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(16)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Regulatory.</u></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Schedule&nbsp;3.02(16)(a)&nbsp;</b>hereto sets forth a true, complete and accurate list, as of the date
hereof, of all the HCV Products and HIV Products (collectively, the &#147;<b>Products</b>&#148;). The Corporation is not developing any other drug candidates
or products other than the Products, and the Corporation has not conducted and
is not conducting or planning to conduct, as of the date hereof, any
preclinical development studies or clinical trials in respect of drug
candidates or products other than the Products. The Corporation does not commercially market any products.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Corporation has obtained such approvals or authorizations of Governmental
Authorities, including: (i)&nbsp;all such permits required by Health Canada and
the FDA as are currently required under Applicable Law to manufacture, possess,
transport, package, label, test, import, export the Products in order to carry
out each of the preclinical development studies and clinical trials that have
been conducted or, if still pending, are being conducted, with respect to the
Products, and (ii)&nbsp;all such permits required from Health Canada or the FDA
to otherwise conduct its business in the manner in which it is currently
conducted (collectively, the &#147;<b>Product</b>  <b>Permits</b>&#148;), except for any of the foregoing that could not,
individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. The Corporation has satisfied all of the requirements of and </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=39,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=505100,FOLIO='36',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-07_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:33 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">fulfilled and performed all of its obligations with
respect to the Product Permits, and, to the Knowledge of the Corporation, no
event has occurred that allows, or after notice or lapse of time would allow,
revocation or termination thereof or results in any other impairment of the
rights of the holder of any such Product Permits, except for any of the
foregoing that could not reasonably be expected to have a Material Adverse
Effect.</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Corporation has submitted to Health Canada a clinical trial application for
each clinical trial that it has conducted or sponsored in Canada and has
submitted to the FDA an investigational new drug application for each Product
for which a clinical trial has been or is being conducted or sponsored in the
United States, each of which is listed on <b>Schedule&nbsp;3.02(16)(c)</b><b>(i)</b>. All such submissions and
applications were made in compliance in all material respects with all
Applicable Laws and no material deficiencies have been asserted to the
Corporation by Health Canada or the FDA with respect to any such submission or
application. The Corporation has not conducted or sponsored and is not
conducting or sponsoring any clinical trials with respect to the Products in
any country other than in Canada and the United States. <b>Schedule&nbsp;3.02(16)(c)</b><b>(ii)&nbsp;</b>includes
a list of all clinical trials and the countries in which such clinical trials
are currently planned or contemplated to be conducted or sponsored by the
Corporation with respect to the Products.<b> Schedule&nbsp;3.02(16)(c)</b><b>(iii)&nbsp;</b>includes
the protocols for all clinical trials listed in <b>Schedule&nbsp;3.02(16)(c)</b><b>(i)&nbsp;</b>and
all clinical trials listed in <b>Schedule&nbsp;3.02(16)(c)</b><b>(ii)</b>.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All tests, preclinical development
studies and clinical trials conducted by or, to the Knowledge of the
Corporation, on behalf of the Corporation were and, if still pending, are being
conducted in all material respects in accordance with Applicable Laws and
experimental protocols, procedures and controls pursuant to, where applicable,
accepted professional and scientific standards for drugs comparable to the
Products being developed by the Corporation. The
Products that were the subject of any
such tests, preclinical development studies and clinical trials conducted by or, to the Knowledge of the
Corporation, on
behalf of the Corporation were and, if still pending, are being manufactured
in&nbsp;all material respects in accordance with Applicable Laws and procedures
and controls pursuant to, where applicable, accepted professional and
scientific standards for drugs comparable to the Products being developed by
the Corporation. Except as disclosed in <b>Schedule
3.02(16)(d)</b>, the Corporation has never been inspected by Health Canada, the FDA or
any Governmental Authority exercising comparable authority or entity acting on
their behalf or received any correspondence with respect to an inspection. The
Corporation has disclosed to the Parent in all material respects: (i)&nbsp;all
notices or communications of investigations, inquiries, adverse findings or other
material notices alleging violation of or deviations from Applicable Laws and
all response to such notices; and (ii)&nbsp;any regulatory audit reports by an
outside auditor received by the Corporation in respect of the Products (&#147;<b>Audits</b>&#148;) and all responses to such Audits by the Corporation
or an outside auditor. For purposes of (i)-(ii)&nbsp;above, true, correct and
completes copies of all notices or communications of investigations, inquiries,
adverse findings or</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=40,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=729496,FOLIO='37',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-07_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:33 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">other material notices
alleging violation of or deviations from Applicable Laws received by the
Corporation prior to the date hereof and all responses to such notices have
been delivered or made available to Parent. <b>Schedule
3.02(16)(d) </b>contains a list of all notices or communications of
investigations, inquiries, adverse findings or other material notices that were
so disclosed or made available to Parent.</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Corporation maintains records that provide, in all material respects, true,
complete and accurate information about its research and development of the
Products, relating to tests, preclinical development studies and clinical
trials conducted by or on behalf of the Corporation. As of the date hereof,
such records relating to preclinical development studies, clinical trials,
clinical trial results and all associated adverse events and serious adverse
events as such terms are used in each of the clinical protocols, and tests
forming part of the Corporation&#146;s clinical trial applications or
investigational new drug applications as well as relevant available data to
support planned clinical trials and clinical trial applications or
investigational new drug applications relating to the Products have been fully
disclosed or made available to the Purchaser with the exception of laboratory
notebooks.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Corporation has not received any written notices or correspondence from Health
Canada, the FDA or any Governmental Authority exercising comparable authority
or the institutional review board at any site at which a preclinical
development study or a clinical trial was or is being performed requiring the
termination, suspension or material modification of any preclinical development
studies or clinical trials conducted by or on behalf of the Corporation, nor,
to the Knowledge of the Corporation, is any such notice expected to be
received.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>To the
Knowledge of the Corporation, no person or entity providing services of any
type with regard to any Product and no officer or director of the Corporation
has been convicted of any crime or engaged in any conduct that could result in
debarment or disqualification by Health Canada, the FDA or any other
Governmental Authority<b>  </b>exercising
comparable authority<b>  </b>and there are
no proceedings pending or, to the Knowledge of the Corporation<b>  </b>threatened that reasonably might be expected to result in
criminal liability or debarment or disqualification by Heath Canada, the FDA or
any other Governmental Authority<b>  </b>exercising
comparable authority.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All
material filings, renewals, declarations, listings, registrations, reports,
documents, responses, claims, submissions and notices required to be filed,
maintained, or furnished by the Corporation or, to the Knowledge of the Corporation, on behalf of the Corporation to Health Canada, the FDA or any other
applicable Governmental Authority exercising comparable authority with respect
to Products have been so filed, maintained or furnished and were complete and
correct in all material respects on the date filed.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=41,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=678777,FOLIO='38',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-07_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:33 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(17)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Environmental
Matters.</u></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
business and the property and assets as carried on or used currently by the
Corporation are carried on and used in material compliance with all
Environmental Laws and the Environmental Permits listed in <b>Schedule&nbsp;3.02(17)(a)&nbsp;</b>constitute
all Environmental Permits held and required by the Corporation for the
operation of its business or any of the property and assets used in the
business and such permits are valid and in full force and effect.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Corporation has<b>  </b>not used any of its premises
described in the lease agreement set forth in <b>Schedule&nbsp;3.02(11)</b>,
property or assets, or permitted them to be used, to generate, manufacture,
refine, treat, transport, store, handle, dispose of, transfer, produce or
process any Hazardous Substance except in all material respects in compliance
with all Environmental Laws; no Hazardous Substance is present on or in the
said property or assets, except in compliance with all Environmental Laws.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(18)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Compliance with Laws.</u> The Corporation is conducting its business in material compliance
with all Applicable Laws; and the Corporation has conducted its business in
compliance with all Applicable Laws, except for such non-compliance as has not
or could not reasonably be expected to individually or in
the aggregate have a Material Adverse Effect. The
Corporation is duly licensed, registered or qualified, and duly possesses all
material Permits required to enable its business to be carried on as now conducted
and its assets to be owned, leased and operated, and all such licences,
registrations, qualifications and Permits are valid and subsisting and in good
standing and none of the same contains or is subject to any terms, provisions,
conditions or limitations which, individually or in the aggregate, have or
would reasonably be expected to have a Material Adverse Effect on the
Corporation.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(19)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Tax
Matters.</u></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="line-height:normal;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as disclosed in <b>Schedule&nbsp;3.02(19)</b>:</font></p>

<p style="line-height:normal;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Tax
Filings</i>. The Corporation has prepared and filed on
time with all appropriate Governmental Authority all Tax Returns required to be
filed by or on behalf of the Corporation for all fiscal periods ending on or
before the Closing Date. All such Tax Returns are correct and complete in all
material respects. No extension of time in which to file any such Tax Return is
in effect. All Taxes shown on all such Tax Returns, or on any assessments or
reassessments in respect of any such returns have been paid in full.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Taxes
Paid.</i> The Corporation has paid in full all material
Taxes required to be paid on or prior to the date hereof and has made adequate
provision in the Closing Balance Sheet in accordance with generally accepted
accounting principles for the payment of all Taxes in respect of all fiscal
periods ending on or before the Closing Date which are not required to be paid
on or prior to the Closing Date</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=42,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=861852,FOLIO='39',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-07_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:33 2009' -->



<div style="font-family:Times New Roman;">

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Reassessments
of Taxes</i>. There are no material reassessments of
the Corporation&#146;s Taxes that have been issued and are outstanding and there are
no outstanding issues which have been raised and communicated in writing, or,
to the Knowledge of the Corporation, otherwise, by any Governmental Authority
for any taxation year in respect of which a Tax return of the Corporation has
been audited. No Governmental Authority has challenged, disputed or questioned
in writing, or, to the Knowledge of the Corporation, otherwise, the Corporation
in respect of Taxes or of any returns, filings or other reports filed under any
statute providing for Taxes. The Corporation is not negotiating any draft
assessment or draft reassessment with any Governmental Authority. The Corporation
has not received any indication in writing, , or, to the Knowledge of the
Corporation, otherwise, from any Governmental Authority that an assessment or
reassessment of the Corporation is proposed in respect of any Taxes, regardless
of its merits. The Corporation has not executed or filed with any Governmental
Authority any agreement or waiver extending the period for assessment,
reassessment or collection of any Taxes.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Withholding
and Remittances</i>. The Corporation has withheld from
each payment made to any of its present or former employees, officers and
directors, and to all persons who are non-residents of Canada for the purposes
of the Tax Act all amounts required by law to be withheld, and furthermore, has
remitted such withheld amounts within the prescribed periods to the appropriate
Governmental Authority. The Corporation has withheld all Canada Pension Plan
contributions, provincial pension plan contributions, employment insurance
premiums, employer health taxes and other Taxes payable by it in respect of its
employees and has remitted such amounts to the proper Governmental Authority
within the time required under the applicable legislation. The Corporation has
charged, collected and remitted on a timely basis all Taxes as required under applicable
legislation on any sale, supply or delivery whatsoever, made by the
Corporation. The Corporation does not have a permanent establishment in any
country or jurisdiction where it has not filed Tax Returns.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>There
are no circumstances existing which could result in the application of sections
78, 160, 80, 80.01, 80.02, 80.03 or 80.04 of the Tax Act or any equivalent
provincial or territorial provision to the Corporation. The Corporation has not
directly or indirectly transferred property to or acquired property from a
Person with which the Corporation did not deal at arm&#146;s length within the
meaning of the Tax Act other than for consideration equal to the fair market
value of such property at the time of such transfer or acquisition.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Corporation has maintained and continues to maintain at its place of business
in Canada all books and records required to be maintained under the Tax Act and
any applicable analogous provincial or territorial legislation.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All Canadian, federal and
provincial research and development investment tax credits claimed (and refunds
received) by the Corporation were claimed (and refunds received) in accordance,
in all material respects, with the relevant rules&nbsp;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=43,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=1014014,FOLIO='40',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-09_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:36 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and conditions under
the Tax Act and applicable analogous provincial or territorial legislation.</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Corporation is duly registered under the <i>Excise Tax Act</i>
(Canada) for purposes of the goods and services tax (&#147;<b>GST</b>&#148;)
and under An Act Respecting the Quebec Sales Tax for the purpose of the Quebec
Sales Tax (&#147;<b>QST</b>&#148;). All input tax credits and
refunds claimed by any such company for GST and QST purposes were calculated in
accordance with Applicable Law. The Corporation has complied with all
registration, reporting, payment, collection and remittance requirements in
respect of GST and QST and other provincial sales tax or harmonized tax
legislation in all material respects.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(20)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Financial
Advisor.</u> Except as set forth on <b>Schedule&nbsp;3.02(20)</b>, no broker, finder
or investment banker is entitled to any brokerage, finder&#146;s or other fee or
commission in connection with the transactions contemplated pursuant to this
Agreement.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.03</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Representations and
Warranties of the Purchaser and Parent</u></b></p>

<p align="left" style="font-size:10.0pt;font-weight:normal;margin:0in 0in .0001pt .5in;page-break-after:auto;text-align:left;text-indent:-.5in;">&nbsp;</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Purchaser and Parent solidarily
represent and warrant to the Vendors as follows, and acknowledge and confirm
that the Vendors are relying on the representations and warranties contained
herein in connection with the sale of by the Vendors of the Shares and the
issuance by Parent of the Consideration Shares:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Parent is a corporation duly incorporated, organized and subsisting in good
standing under the laws of<b>  </b>The
Commonwealth of Massachusetts; and the Purchaser is a corporation duly
incorporated, organized and subsisting in good standing under the laws of the
Province of British Columbia, Canada. The Purchaser is a wholly-owned
subsidiary of Parent;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each
of the Parent and the Purchaser has good and sufficient power, authority and
right to enter into and deliver this Agreement and to complete the transactions
to be completed by it hereunder;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
authorized capital stock of Parent consists of 1,000,000 shares of preferred
stock, $.01 par value per share, 300,000,000 shares of common stock, $.01 par
value per share, of which<b>  </b>162,229,475 shares of common stock are the only issued and outstanding
shares of the capital stock of Parent as of February&nbsp;24, 2009;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><strong><b><font face="Times New Roman" style="font-weight:normal;">At the Time of Closing</font></b></strong>, all necessary corporate action <strong><b><font face="Times New Roman" style="font-weight:normal;">will have</font></b></strong>&nbsp;been
taken by <strong><b><font face="Times New Roman" style="font-weight:normal;">Parent</font></b></strong> to validly create and issue the
Consideration Shares and to register such shares with <strong><b><font face="Times New Roman" style="font-weight:normal;">Parent&#146;s transfer agent</font></b></strong>
in the names of the Vendors, the ViroChem Employees and the ESOP Holders;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>When
issued in accordance with this Agreement, the Consideration Shares will be
validly issued, fully paid and non-assessable and, subject to Section&nbsp;2.03(1)&nbsp;and
the Holdback Escrow Agreement or the Escrow Agreement, issued in the name of
the applicable Vendor, ViroChem Employee and ESOP Holder;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=44,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=981563,FOLIO='41',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-09_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:36 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Upon
effectiveness of the Shelf Registration Statement, the Consideration Shares
registered thereby will be freely tradable in the United States without
restrictions on transfer and will not be subject to any hold period or escrow
conditions except as provided in the Registration Rights Agreement, the
Holdback Escrow Agreement and the Escrow Agreement;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Parent
has filed or furnished to the SEC all forms, reports, statements,
certifications and other documents (including all exhibits, amendments and
supplements thereto) required to be filed or furnished, as applicable, by it
with the SEC since January&nbsp;1, 2008 (the &#147;<b>SEC Reports</b>&#148;).
All reports and disclosure documents filed by Parent with the SEC, as of their
respective dates, complied to form in all material respects with the
requirements of Applicable Law and did not contain any untrue statement of
material fact or omit to state a material fact required to be stated therein or
necessary in order to make the statements therein, in light of the circumstance
under which these were made, not misleading. The financial statements contained
in the SEC Reports were prepared in accordance with U.S. generally acceptable
accounting principles consistently applied and present fairly the consolidated
financial position and results of operations of the Purchaser and its
subsidiaries for the periods and as of the dates specified therein. Since December&nbsp;31,
2008, there has not been any material change to the business of Parent except
to the extent required to be disclosed and so disclosed in the SEC Reports;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This
Agreement constitutes a valid and legally binding obligation of each of the
Purchaser and Parent, enforceable against each of the Purchaser and Parent in
accordance with its terms, subject to applicable bankruptcy, insolvency,
reorganization and other laws of general application limiting the enforcement
of creditors&#146; rights generally and to the fact that specific performance is an
equitable remedy available only in the discretion of the court;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Neither
the entering into nor the delivery of this Agreement nor the completion of the
transactions contemplated hereby by the Purchaser or the Parent will result in
a violation of:</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any
of the provisions of the constating documents or by-laws of the Purchaser or
the Parent;</p>

<p align="left" style="margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any agreement or other instrument to which
the Purchaser or the Parent is a party or by which the Purchaser or the Parent
is bound, except as could not<b>  </b>reasonably
be expected to individually or in the aggregate have a Material Adverse Effect; or</p>

<p align="left" style="margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any
Applicable Law in respect of which the Purchaser or the Parent must comply,
except as could not<b>  </b>reasonably be
expected to individually or in the aggregate have a Material Adverse Effect.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=45,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=612670,FOLIO='42',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-09_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:36 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No
approval, order or consent of, waiver from or filing with any Governmental
Authority (including under the<i> Investment Canada Act</i>)
is required on the part of the Purchaser or the Parent in connection with the execution and delivery of this
Agreement or the consummation of the transactions contemplated hereunder, other
than post-transaction securities law and other filings which are due following
the Closing Date;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Parent currently has on hand sufficient immediately available funds and will on
the Closing Date have sufficient immediately available funds to pay the
Purchase Price; and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Parent is a WTO investor within the meaning of the Investment Canada Act.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-decoration:underline;text-transform:uppercase;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">ARTICLE&nbsp;4 - COVENANTS</font></u></b></p>

<p style="font-size:10.0pt;font-weight:normal;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.01</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Covenants
of the Vendors and of the Corporation</u></b></p>

<p align="left" style="font-size:10.0pt;font-weight:normal;margin:0in 0in .0001pt .5in;page-break-after:auto;text-align:left;text-indent:-.5in;">&nbsp;</p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Conduct
of Business by the Corporation Pending Closing</u>.
Except as otherwise contemplated by this Agreement or consented to in writing
by the Purchaser (which consent shall not be unreasonably withheld or delayed),
from the date of this Agreement until the Time of Closing, the Corporation
will, except as required by Applicable Law:</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>carry
on its business in all material respects in the ordinary course, consistent
with past practice and in compliance in all material respects with Applicable
Law;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>use
all reasonable commercial efforts to maintain and preserve intact its business,
organization, intellectual property and goodwill, to keep available the
officers, employees, consultants and independent contractors of its business as
a group and to maintain satisfactory relationships with suppliers and others
with whom the Corporation has business relationships;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>use
all reasonable commercial efforts to cause its current insurance policies not
to be cancelled or terminated or any other coverage thereunder to lapse, unless
simultaneously with such terminations, cancellation or lapse, replacement
policies underwritten by insurance companies of nationally recognized standing
providing coverage equal to or greater than the coverage under the cancelled,
terminated or lapsed policies, and where possible, for substantially similar
premiums, are in full force and effect;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>promptly
advise the Purchaser of the occurrence of any material event, change,
occurrence or circumstance or the planned abandonment, expiry or lapse of any
material matter relating to the Corporation&#146;s research and development
activities or intellectual property;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>promptly
advise the Purchaser in writing of the occurrence of any event, change,
occurrence or circumstance that individually or in the aggregate with any such
events, changes, occurrences or circumstances, has had or is reasonably likely
to </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">43</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=46,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=127307,FOLIO='43',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-09_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:36 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">have a Material Adverse Effect in respect of the
Corporation or of any facts that come to the attention of the Corporation which
would cause any of the Vendors and/or the Corporation&#146;s representations and
warranties herein contained to be untrue in any material respect;</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>maintain
the books, records and accounts of the Corporation in all material respects in
the ordinary course, consistent with past practice and record all transactions
on a basis consistent with past practice;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>maintain
in effect its Material Contracts (subject to the expiration of any contract
pursuant to its terms or termination of such contract by a party other than the
Corporation); and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>not
enter into any transaction and refrain from doing any action that, if effected
before the date of this Agreement, would constitute a breach of any representation,
warranty, covenant or other obligation of the Corporation or the Vendors in
this Agreement.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Access
to Information</u>. Prior to the Time of Closing and
upon reasonable notice, the Corporation shall, and the Vendors will use their
best efforts to cause the Corporation to, subject to any confidentiality
obligations to third parties:</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>afford
to the officers, employees, accountants, counsel and other representatives of
the Parent who have agreed to be bound by the confidentiality obligations set
forth in Section&nbsp;4.06(1)&nbsp;reasonable access during normal working
hours and without interference to the ordinary conduct of the business to all
of its properties, books, contracts and records;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>furnish
promptly to the Parent all information concerning its business, properties,
books, contracts, records and personnel as the Purchaser may reasonably
request; and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>make
available to the officers, employees, accountants, counsel and other
representatives of the Parent upon the reasonable request of the Parent and
during normal working hours and without interference to the ordinary conduct of
the business all officers, accountants, counsel and other representatives or
agents of the Corporation with knowledge about the Corporation for discussion
of the Corporation&#146;s businesses, properties or personnel as the Parent may
reasonably request.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Financial
Statements</u>. The Corporation shall, and the Vendors
will use their commercially reasonable efforts to cause the Corporation to, use
commercially reasonable efforts to prepare and deliver to Parent the 2008
Audited Financial Statements and the Form&nbsp;8-K Financial Statements as
promptly as practicable after the date hereof; provided, however, that the
obligations of Purchaser and Parent hereunder, other than as specified in Section&nbsp;4.02(1),
shall not be conditional upon, or subject to, the delivery to Parent of the Form&nbsp;8-K
Financial Statements.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=47,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=380433,FOLIO='44',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-09_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:36 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.02</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Covenants of Parent</u></b></p>

<p align="left" style="font-weight:bold;margin:0in 0in .0001pt .5in;page-break-after:auto;text-align:left;text-indent:-.5in;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Parent
shall file the Shelf Registration Statement with the U.S. Securities Exchange
Commission, and cause the Shelf Registration Statement to become effective, as
of one (1)&nbsp;Business Day after the Closing Date unless both (a)&nbsp;the &#147;cost
of the Corporation&#148;, determined as of the Closing Date in accordance with U.S.
generally accepted accounting principles (and after giving effect to any
adjustment pursuant to Section&nbsp;2.05(4)), would exceed, with respect to
Parent, the condition of significance in the definition of significant
subsidiary in Rule&nbsp;1-02(w)(1)&nbsp;of Regulation&nbsp;S-X under the
Securities Act at the 50% percent level and (b)&nbsp;the Corporation has not
delivered to Parent the Form&nbsp;8-K Financial Statements at least three (3)&nbsp;Business
Days prior to Closing Date.&#160; In the event
that Parent does not file with the U.S. Securities Exchange Commission and
cause the Shelf Registration Statement to become effective one (1)&nbsp;Business
Day after the Closing Date by reason of clauses&nbsp;(a)&nbsp;and (b)&nbsp;above,
Parent and the Corporation shall cooperate, at the expense of Parent, to cause
the Form&nbsp;8-K Financial Statements to be completed as promptly as
practicable after the Time of Closing and Parent shall file the Shelf
Registration Statement, and cause the Shelf Registration Statement to become
effective, no later than three (3)&nbsp;Business Days after completion of the Form&nbsp;8-K
Financial Statements.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>From
the date of this Agreement until the Time of Closing, Parent shall:</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>promptly
advise the Vendors and the Securityholders&#146; Representative of any event,
change, occurrence or circumstance that individually or in the aggregate with
any such events, changes, occurrences or circumstances, has had or is
reasonably likely to have a Material Adverse Effect in respect of Parent,
including in respect to the intellectual property protection for telaprevir,
data from telaprevir clinical trials, or any material legal proceeding in
relation to the Parent or its hepatitis&nbsp;C program, or of any facts that
come to the attention of Parent which would cause any of the Parent&#146;s and/or
Purchaser&#146;s representations and warranties herein contained to be untrue in any
material respect; and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>not
enter into any transaction and refrain from doing any action that, if effected
before the date of this Agreement, would constitute a breach of any representation,
warranty, covenant or other obligation of the Parent or the Purchaser in this
Agreement.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.03</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Covenants of all Parties</u></b></p>

<p align="left" style="font-weight:bold;margin:0in 0in .0001pt .5in;page-break-after:auto;text-align:left;text-indent:-.5in;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Cooperation</u>. Upon the terms and subject to the conditions set forth in this
Agreement, each party hereto shall use commercially reasonable efforts to take,
or cause to be taken, all actions, and do, or cause to be done, and to assist
and cooperate with the other party or parties in doing, all things necessary,
proper or advisable to consummate and make effective, in the most expeditious
manner practicable, the transactions contemplated by this Agreement and to
satisfy or cause to be satisfied all of the conditions precedent that are set
forth in Article&nbsp;5&nbsp;(<i>Conditions and Termination</i>),
as applicable to each of them. Each party hereto, at the reasonable request of
another party hereto, shall execute and deliver such other instruments and do
and perform such other acts and things as may be necessary or desirable for
effecting </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">45</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=48,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=768278,FOLIO='45',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-09_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:36 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">completely the
consummation of this Agreement and the transactions contemplated hereby. The
parties agree that irreparable damage (for which monetary damages would not be
an adequate remedy) would occur in the event that any of the Purchaser, the
Corporation or any Vendor fails to consummate the transactions contemplated
hereby as a result of any breach of any representation or warranty, or breach
of covenant or other obligation by such party under this Agreement or to give
effect to the transactions contemplated hereby. It is accordingly agreed that,
in addition to any other remedies, upon the occurrence of any such event, any
other party shall have the right to obtain a decree of specific performance or
other injunctive relief (without the necessity of proving the inadequacy of
monetary damages as a remedy) to prevent the continuation of any such event.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notice
of Certain Events</u>. Each of the Corporation and the
Parent shall promptly notify the other of (a)&nbsp;any event, condition, fact,
circumstance, occurrence, transaction or other item of which such party becomes
aware after the date hereof and prior to the Time of Closing that would
constitute a violation or breach of this Agreement (or a breach of any
representation or warranty contained herein) or, if the same were to continue
to exist as of the Closing Date, would constitute the non-satisfaction of any
of the conditions set forth in Article&nbsp;5 hereof (<i>Conditions
and Termination</i>), and (b)&nbsp;any event, condition, fact,
circumstance, occurrence, transaction or other item of which such party becomes
aware which would have been required to have been disclosed pursuant to the
terms of this Agreement had such event, condition, fact, circumstance,
occurrence, transaction or other item existed as of the date hereof.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.04</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Directors&#146; and Officers&#146;
Liability Insurance</u></b></p>

<p align="left" style="font-weight:bold;margin:0in 0in .0001pt .5in;page-break-after:auto;text-align:left;text-indent:-.5in;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Purchaser shall purchase &#147;tail&#148;
insurance coverage from the Corporation&#146;s current directors and officers
liability insurers, or from other insurers, that provides for a period of six (6)&nbsp;years
that is substantially equivalent to the Corporation&#146;s existing directors and
officers liability insurance program, or if substantially equivalent insurance
coverage is not available, the best available coverage. From and after the
Closing Date, the Purchaser or the Parent will, and will cause the Corporation
(or its successor) to, indemnify the current and former directors and officers
of the Corporation to the fullest extent that the Corporation would be
permitted under Applicable Law for actions or omissions taken or failed to be
taken by them in their respective capacities as directors or officers of the
Corporation. This Section&nbsp;4.04 shall inure to the benefit of the current
directors and officers of the Corporation who are express third party
beneficiaries of and entitled to enforce this Section&nbsp;4.04 against the
Purchaser.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.05</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Tax Matters</u></b></p>

<p align="left" style="font-weight:bold;margin:0in 0in .0001pt .5in;page-break-after:auto;text-align:left;text-indent:-.5in;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Purchaser does not assume and will not be liable for any Taxes which may be or
become payable by the Vendors, the ViroChem Employees or the ESOP Holders, as
the case may be, including any Taxes payable by the ViroChem Employees or ESOP
Holders or required to be deducted, withheld or remitted by the Corporation or
the ViroChem Trust resulting from or arising as a consequence of the exercise
of options held by ViroChem Employees and ESOP Holders or the sale by the
Vendors, the ViroChem Employees or the ESOP Holders, as the case may be, to the
Purchaser of the Shares, the ViroChem Shares or the ESOP Shares.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=49,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=303453,FOLIO='46',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-09_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:36 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Corporation
shall withhold from each payment or distribution to or for the benefit of the
ViroChem Employees or ESOP Holders from the date hereof through the Closing
Date, including from payments of the Purchase Price hereunder, all amounts
required by law to be withheld on account of Taxes with respect to each such
payment or distribution made or deemed to be made to any of its present or
former employees, officers and directors, and with respect to such payment or
distribution made to all persons who are non-residents of Canada for the
purposes of the Tax Act, all amounts required by law to be withheld, and shall
remit such withheld amounts within the prescribed periods to the appropriate
Governmental Authority. The Corporation shall also, after the date hereof,
remit to the proper Government Authority all Canada and Quebec Pension Plan
contributions, employment, insurance premiums, employer health taxes and other
Taxes payable by it in respect of its employees within the time required under
the applicable legislation.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Purchaser shall cause to be prepared and filed on a timely basis all Tax
Returns for the Corporation for any period which ends on or before the Closing
Date and for which Tax Returns have not been filed as of such date. The
Purchaser shall also cause to be prepared and filed on a timely basis all Tax
Returns for the Corporation for all Straddle Periods (all such Tax Returns
together with the Tax Returns referred to in the first sentence of this
paragraph being referred to herein as &#147;<b>Stub Period Returns</b>&#148;).
The Vendors and the Purchaser shall co-operate fully with each other and make
available to each other in a timely fashion such personnel, data and other
information as may reasonably be required for the preparation of all Stub
Period Returns including, without limitation, all personnel and data related to
Canadian and Quebec research and development investment tax credit claims and
shall preserve such data and other information until the expiration of any
applicable limitation period under any Applicable Law with respect to such Stub
Period Returns. At least thirty (30)<b>  </b>days prior to
the date on which a Stub Period Return is due to be filed, the Purchaser shall
provide to the Auditor and the Vendors a reasonable opportunity to review and
comment on a copy of such Stub Period Returns.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If,
except as required by Applicable Law or as agreed to by the two-thirds in
interest of the Vendors (based on the Shares
listed in Column 1 of <b>Schedule 2.02(2)</b>), the Purchaser causes the Corporation to take any action on or
after the Closing Date, make any election or deemed election or make or change
any Tax election, amend any Tax Return or take any position on any Tax Return
that results in or increases the amount of Taxes payable by the Corporation in
respect of any period ending on or before the Closing Date, the Purchaser
agrees that the Vendors are to have no liability for any Tax resulting from any
such action. The Purchaser and the Parent will solidarily (hereby waiving the
benefit of divisibility) indemnify and save harmless the Vendors, the ViroChem
Employees, the ESOP Holders and the directors of the Corporation (where such
action pertains to a Tax for which such directors may incur a personal
liability), from and against all such Taxes arising out of or resulting from
such action.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Purchaser will provide notice to the Vendors of any inquiries made by,
discussions with or representations or submissions proposed to be made to any
Taxation Authority to the extent that the subject matter thereof relates to
representations, covenants or obligations of the Vendors hereunder and could
reasonably give rise to a right of indemnity hereunder. The Purchaser will
forthwith advise the Vendors of the substance of any such inquiries or
discussions and provide the Vendors with copies of any written communications </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">47</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=50,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=674569,FOLIO='47',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-09_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:36 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">from any
Taxation Authority relating to such inquiries or discussions. The Purchaser
will provide the Vendors a reasonable opportunity to comment on any such
representations or submissions and to attend any meeting with any such Taxation
Authority with respect to such matters.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Upon request of a Vendor,
the Purchaser and the Corporation will effect the election described in
subsection 256(9)&nbsp;of the Tax Act.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.06</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Confidentiality</u></b></p>

<p align="left" style="font-weight:bold;margin:0in 0in .0001pt .5in;page-break-after:auto;text-align:left;text-indent:-.5in;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Both
prior to the Closing Date and, if the sale and purchase of the Shares, the ESOP
Shares and ViroChem Shares hereunder fails to occur for whatever reason,
thereafter, the Parent and the Purchaser will not disclose to anyone or use for
its own or for any purpose other than the purpose contemplated by this
Agreement any confidential information concerning the Vendors or the
Corporation obtained by the Parent and the Purchaser pursuant hereto, will hold
all such information in the strictest confidence and, if the sale and purchase
of the Shares, the ESOP Shares and the ViroChem Shares hereunder fails to occur
for whatever reason, will return all documents, records and all other
information or data relating to the Vendors or to the Corporation which the
Parent and the Purchaser obtained pursuant to this Agreement or in connection
with the transactions contemplated hereby. Such return of documents shall be
certified in writing by a senior officer of the Parent or the Purchaser. The
Parent and the Purchaser agree and acknowledge that remedies at law for any
breach of its obligations under this Section&nbsp;4.06 may be inadequate and
that, in addition thereto, the Vendors and the Corporation shall be entitled to
seek equitable relief, including injunction and, to the extent practicable,
specific performance, in the event of any such breach; and</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Vendors, ViroChem Employees and
ESOP Holders agree to, and shall cause their agents, representatives,
Affiliates, partners, employees, officers and directors to: (i)&nbsp;treat
and hold as confidential (and not disclose or provide to any person access to)
all confidential information (whether oral or written) concerning the Parent and the Purchaser if marked or disclosed as such or
the Corporation, except as may be required to be disclosed by Applicable Laws, (ii)&nbsp;in
the event that any Vendor, ViroChem Employee or ESOP Holder or any
such agent, representative, Affiliate, partner, employee, officer or director
becomes legally compelled to disclose any such confidential information to the
extent practicable, provide the Parent and the Purchaser with prompt written notice of such requirement so that the Parent and the Purchaser or the Corporation or any of
their respective Affiliates may seek a protective order or other remedy or
waive compliance with this Section&nbsp;4.06, and (iii)&nbsp;in the event that
such protective order or other remedy is not obtained, or the Parent or the Purchaser waives compliance with this Section&nbsp;4.06,
furnish only that portion of such confidential information which it is legally
required to provide and exercise its commercially reasonable efforts to obtain
assurances that confidential treatment will be accorded all such confidential
information. Each Vendor, ViroChem Employee and ESOP Holder agrees and
acknowledges that remedies at law for any breach of its obligations under this Section&nbsp;4.06
may be inadequate and that, in addition thereto, the Parent
and the Purchaser shall be entitled to seek equitable relief,
including injunction and specific performance, in the event of any such breach.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">48</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=51,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=190465,FOLIO='48',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-09_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:36 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.07</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Release of Claims</u></b></p>

<p align="left" style="font-weight:bold;margin:0in 0in .0001pt .5in;page-break-after:auto;text-align:left;text-indent:-.5in;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each Vendor, on behalf of it and its
successors and assigns, hereby releases and forever discharges the Corporation,
the Parent and the Purchaser and each of their officers and directors, from any
and all actions, accounts, agreements, bonds, causes of action, claims,
contracts, damages, debts, demands, doings, dues, executions, extents,
omissions, promises, reckonings, specialties, suits, sum(s), variances and
liabilities whatever, in law or equity, which such Vendor, in its capacity as a
shareholder of the Corporation ever had, now has, or ever will have against the
Corporation, the Parent or the Purchaser and their respective officers and
directors, upon or by reason of or in connection with any matter, cause or
thing related to the Corporation arising out of any act or omission prior to
the Time of Closing, other than Claims for receipt of the Purchase Price
pursuant to this Agreement or any other Claims pursuant to this Agreement and,
with respect to Shire, with respect to payments owing to or to become owed
under the Asset Purchase Agreement.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-decoration:underline;text-transform:uppercase;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">ARTICLE&nbsp;5- CONDITIONS AND
TERMINATION</font></u></b></p>

<p style="font-size:10.0pt;font-weight:normal;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.01</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Conditions to Closing of
Each Party</u></b></p>

<p align="left" style="font-size:10.0pt;font-weight:normal;margin:0in 0in .0001pt .5in;page-break-after:auto;text-align:left;text-indent:-.5in;">&nbsp;</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The respective obligations of each party to
effect the completion of the transactions contemplated hereunder is subject to
the following conditions which are to be performed or complied with at or prior
to the Time of Closing:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governmental
Approvals</u>. All approvals of, or declarations or
filings with, any Governmental Authority required to be obtained or made in
order to consummate the transactions contemplated by this Agreement, if any,
shall have been obtained or made; and</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Injunctions
or Restraints; Illegality</u>. No order or injunction
(whether temporary, preliminary or permanent) issued by any U.S. or Canadian
court or Governmental Authority of competent jurisdiction shall be in effect
which prevents the consummation of the transactions contemplated by this
Agreement, nor shall any law or order applicable to the transactions
contemplated by this Agreement make the consummation of such transactions
illegal.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.02</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Conditions for the Benefit
of the Purchaser and the Parent</u></b></p>

<p align="left" style="font-weight:bold;margin:0in 0in .0001pt .5in;page-break-after:auto;text-align:left;text-indent:-.5in;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The completion of the transactions
contemplated hereunder is subject to the following conditions, which are for
the exclusive benefit of the Purchaser and the Parent and which are to be
performed or complied with at or prior to the Time of Closing:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Vendor
Representations and Warranties</u>. (i)&nbsp;Each of
the representations and warranties of the Vendors set forth in Sections 3.01(1)&nbsp;<i>(Vendor&#146;s Shares)</i>, 3.01(2)&nbsp;<i>(Power, Authority, Right)</i>, 3.01(3)&nbsp;<i>(Establishment
and Incorporation)</i>, 3.01(4)&nbsp;<i>(No Agreements)</i>,
3.01(5)&nbsp;<i>(No Conflict, Violation, Consents),</i>
3.01(6)&nbsp;<i>(No Insolvency)</i>, 3.01(7)&nbsp;(<i>Legal Proceedings</i>), and 3.01(8)&nbsp;<i>(Binding
Obligation)</i> shall be true and correct at and as of the date of this
Agreement and at and as of the Time of Closing as though then made (provided that
any such representation and warranty that addresses matters only as of a
certain date shall be so true and correct as of that </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=52,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=505973,FOLIO='49',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-09_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:36 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">certain date); and</font>
(ii)&nbsp;each of </font>the other representations and warranties of
the Vendors set forth in Section&nbsp;3.01 shall be true and correct at and as
of the date of this Agreement and at and as of the Time of Closing as though
then made (provided that any such representation and warranty that addresses
matters only as of a certain date shall be so true and correct in all respects
as of that certain date),<b>  </b>in each case
determined without regard to qualifications as to materiality or Material
Adverse Effect, except, for purposes of this sub-clause&nbsp;(ii), for any
failure of any such representations and warranties being true and correct which
would not adversely affect the ability of the Vendors to deliver title and
ownership of the Shares to the Purchaser or otherwise comply in any material
respect with the obligations hereunder.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Corporation
Representations and Warranties</u>. (i)&nbsp;Each of
the representations and warranties of the Corporation set forth in
Sections&nbsp;3.02(1)&nbsp;(<i>Establishment,
Incorporation and Corporate Power</i>), 3.02(2)&nbsp;(<i>Capitalization</i>), 3.02(3)&nbsp;(<i>No Conflict,
Violation, Consents</i>), 3.02(4)&nbsp;(<i>Subsidiaries</i>),
3.02(12)&nbsp;(<i>No Insolvency</i>) and 3.02(20) (<i>Financial Advisor</i>) shall be true and correct at and as of
the date of this Agreement and at and as of the Time of Closing as though then
made (provided that any such representation and warranty that addresses matters
only as of a certain date shall be so true and correct as of that certain
date); and (ii)&nbsp;each of the other representations and warranties of the
Corporation set forth in Section&nbsp;3.02 shall be true and correct at and as
of the date of this Agreement and at and as of the Time of Closing as though
then made (provided that any such representation and warranty that addresses
matters only as of a certain date shall be so true and correct in all respects
as of that certain date), in each case determined without regard to
qualifications as to materiality or Material Adverse Effect, except for
purposes of this subclause&nbsp;(ii), for any failure of any such
representations and warranties being true and correct which has not resulted
in, and is not reasonably likely to result in, individually or in the
aggregate, a Material Adverse Effect.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>ViroChem
Employees and ESOP Holders Representations and Warranties</u>. Each of the representations and warranties of the ViroChem Employees
and ESOP Holders set forth in the interventions provided for in <b>Schedules 6.02(2)(a)&nbsp;</b>and<b> 6.02(2)(b)&nbsp;</b>hereto shall be true and correct at and as of the Time of Closing (provided that
any such representation and warranty that addresses matters only as of a
certain date shall be so true and correct as of that certain date);</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Agreements
and Covenants.</u> Each of the Vendors, ViroChem
Employees, ESOP Holders and the Corporation will have performed or complied in
all material respects with all of the obligations and covenants pursuant to
this Agreement to be performed or complied with by them at or prior to the Time
of Closing;</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Absence
of a Material Adverse Effect</u>. There shall not have
been or occurred any event, change, occurrence or circumstance that
individually or in the aggregate with any such events, changes, occurrences or
circumstances has had or is reasonably likely to have a Material Adverse Effect
in respect of the Corporation from the date of this Agreement to the Time of
Closing;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">50</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=53,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=630267,FOLIO='50',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-09_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:36 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination
and Cancellation of Certain Agreements.</u></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Shareholders Agreement shall have been terminated and be of no further force or
effect;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Corporation shall furnish satisfactory evidence to the Purchaser that each
holder of options under the Trust ESOP has validly exercised his or her options
under the Trust ESOP or received notice from the Corporation and/or the
ViroChem Trust that any unexercised options under the Trust ESOP will be
terminated and no longer exercisable as of the Time of Closing; and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
ESOP, any options under the ESOP and any other option, warrant or other right
to acquire (by purchase, conversion or otherwise) any shares of capital stock
or other securities of the Corporation shall have been terminated and be of no
further force or effect as of the Time of Closing, and the Corporation shall
furnish satisfactory evidence to the Purchaser (i)&nbsp;to such effect and that
(ii)&nbsp;each holder of the options under the ESOP has (A)&nbsp;validly
exercised his or her options under the ESOP prior to the Time of Closing, (B)&nbsp;consented
in writing to the cancellation of his or her options prior to the Time of
Closing, or (C)&nbsp;the Corporation has included in the Estimated Final Net
Amount the <strong><b><font face="Times New Roman" style="font-weight:normal;">aggregate amount set forth in Column 14 of </font></b></strong><b><font style="font-weight:bold;">Schedule 2.02(2)</font><strong><b><font face="Times New Roman">&nbsp;</font></b></strong></b><strong><b><font face="Times New Roman" style="font-weight:normal;">payable to holders of
options under the ESOP who have not exercised their options under the ESOP for
ESOP Shares prior to the Time of the Closing</font></b></strong>;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Transfer
of Shares</u>. All necessary steps and proceedings will
have been taken to permit the Shares, the ViroChem Shares (including the
transfer of all Shares held by the ViroChem Trust to the ViroChem Employees)
and the ESOP Shares, to be duly and regularly transferred to and registered in
the name of the Purchaser; and</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Closing
Deliveries</u>. The Corporation, Vendors, ViroChem
Employees and the ESOP Holders shall deliver the certificates, instruments and
documents required to be delivered by them pursuant to Article&nbsp;6 hereof.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.03</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Conditions for the Benefit
of the Vendors</u></b></p>

<p align="left" style="font-size:10.0pt;font-weight:normal;margin:0in 0in .0001pt .5in;page-break-after:auto;text-align:left;text-indent:-.5in;">&nbsp;</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The completion of the transactions
contemplated hereunder is subject to the following conditions, which are for
the exclusive benefit of the Vendors and which are to be performed or complied
with at or prior to the Time of Closing:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Representations
and Warranties</u>. Each of the representations and
warranties of the Purchaser and the Parent set forth in Section&nbsp;3.03 will
be true and correct in all material respects at and as
of the date of this Agreement and at and as of the Time of Closing as though then
made (provided that any such representation and warranty that addresses matters
only as of a certain date shall be so true and correct as of that certain date);</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Agreements
and Covenants</u>. The Purchaser and the Parent will
have performed or complied in all material respects with all of the obligations
and covenants pursuant to this </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=54,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=1010638,FOLIO='51',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-09_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:36 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement to
be performed or complied with by them at or prior to the Time of Closing
including, without limitation, the capital contribution contemplated by Section&nbsp;2.04(4);</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Closing
Deliveries</u>. The Purchaser and the Parent shall
deliver the certificates, instruments and documents required to be delivered by
it pursuant to Article&nbsp;6 hereof;</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Absence
of a Material Adverse Effect</u>. There shall not have
been or occurred any Material Adverse Effect in respect of the Parent from the
date of this Agreement to the Time of Closing that relates to the intellectual property
protection for telaprevir, data from telaprevir clinical trials, or any
material legal proceeding in relation to the Parent or its hepatitis C program;</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Consideration
Shares.</u> The Consideration Shares shall have been
approved for listing on The NASDAQ Stock Market, subject to official notice of
issuance; and</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.04</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Waiver of Condition</u></b></p>

<p align="left" style="font-size:10.0pt;font-weight:normal;margin:0in 0in .0001pt .5in;page-break-after:auto;text-align:left;text-indent:-.5in;">&nbsp;</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Purchaser, in the case of conditions
set out in Sections&nbsp;5.01 and 5.02 applicable to the Corporation or the
Vendors, the ViroChem Employees or the ESOP Holders, and the Vendors, in the
case of conditions set out in Sections&nbsp;5.01 and 5.03 applicable to the
Corporation or the Purchaser and the Parent, will have the exclusive right to
waive the performance or compliance of such conditions in whole or in part and
on such terms as may be agreed upon without prejudice to any of its rights in
the event of non-performance of or non-compliance with any condition in whole
or in part. Any such waiver will not constitute a waiver of any other
conditions in favour of the waiving party.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.05</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination</u></b></p>

<p align="left" style="font-size:10.0pt;font-weight:normal;margin:0in 0in .0001pt .5in;page-break-after:auto;text-align:left;text-indent:-.5in;">&nbsp;</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement may be terminated, by notice
given prior to or at the completion of the transactions herein contemplated:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>by the
Purchaser and the Parent if a breach of any representation, warranty or
covenant of this Agreement has been committed by the Vendors and/or the Corporation,
in each case such that the conditions set forth in Sections&nbsp;5.02(1),
5.02(2), 5.02(3)&nbsp;or 5.02(4)&nbsp;would not be satisfied and such breach
has not been waived or is incapable of being cured or, if capable of being
cured, shall not have been cured within thirty (30) days following the date on
which the Purchaser and the Parent notify the Vendors and the Corporation of
such breach;</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>by the
Vendors if a breach of any representation, warranty or covenant of this
Agreement has been committed by the Purchaser or the Parent, in each case such
that the conditions set forth in Sections&nbsp;5.03(1)&nbsp;or 5.03(2)&nbsp;would
not be satisfied and such breach has not been waived or is incapable of being
cured or, if capable of being cured, shall not have been cured within thirty
(30) days following the date on which the Vendors notify the Purchaser and the
Parent of such breach;</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>by
written agreement of the Purchaser, the Parent, the Corporation and the
Vendors;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">52</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=55,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=94833,FOLIO='52',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-09_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:36 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>by the
Purchaser and the Parent, if any event, change, occurrence or circumstance that
individually or in the aggregate with any such events, changes, occurrences or
circumstances<b>  </b>has had or is reasonably likely
to have<b>  </b>a Material Adverse Effect in respect
of the Corporation after the date of this Agreement;</p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>by the
Vendors, if there has been any Material Adverse Effect in respect of Parent
from the date of this Agreement to the Time of Closing that relates to the
intellectual property protection for telaprevir, data from telaprevir clinical
trials, or any material legal proceeding in relation to Parent or its hepatitis
C program;</p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>by
either the Purchaser, the Parent, the Corporation or the Vendors, if a court or
Governmental Authority shall have issued an order or taken any other action, in
each case, which has become final and non-appealable and which restrains,
enjoins or otherwise prohibits the transactions contemplated by this Agreement;
<i>provided,
however</i>, that the right to terminate this Agreement under
this Section&nbsp;5.05(4)&nbsp;shall not be available to any party whose
failure to fulfill any obligation or condition under this Agreement has been
the cause of, or resulted in, such order or other action; or</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>by the
Vendors or the Purchaser and the Parent if the completion of the transactions
herein contemplated has not occurred (other than as a result of a failure by
the party seeking to terminate this Agreement to satisfy a closing condition in
favour of the other party which is within its reasonable control and subject to
the party seeking to terminate this Agreement not being otherwise in default or
breach) on or before the date which is one hundred and twenty (120) days from
the date of this Agreement, or such later date as the Purchaser, the Parent and
the Corporation may agree upon.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.06</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Effect of Termination</u></b></p>

<p align="left" style="font-weight:bold;margin:0in 0in .0001pt .5in;page-break-after:auto;text-align:left;text-indent:-.5in;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If
this Agreement is terminated pursuant to Section&nbsp;5.05, this Agreement
(except for Sections&nbsp;4.06 (<i>Confidentiality</i>)
and 8.03 (<i>Fees and Commissions</i>), which shall
survive such termination) will then be null and void and have no further force
and effect, and no party shall have any Claim to performance of any nature
whatsoever against any other party under this Agreement. Notwithstanding the
foregoing, if (i)&nbsp;termination rights arise as contemplated by Section&nbsp;5.05(1)&nbsp;or
5.05(2)&nbsp;and the party which is seeking termination of this Agreement is
not itself in default or (ii)&nbsp;in the case of a termination right arising
under Section&nbsp;5.05(7), the failure of the closing to occur results from a
default by the other party to satisfy a closing condition which is within its
reasonable control, then the parties agree in either case (x)&nbsp;that
irreparable damage (for which monetary damages would not be an adequate remedy)
would occur, and (y) in addition to any other remedies, upon the occurrence of
any such event, the non-breaching party shall have the right to obtain a decree
of specific performance or other injunctive relief (without the necessity of
proving the inadequacy of monetary damages as a remedy) to prevent the
continuation of any such event.</p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Nothing
in this Article&nbsp;5 shall relieve or have the effect of relieving a party
from liability for damages incurred or suffered by another party as a result of
a breach of this Agreement by such party acting in bad faith with a clear
intent and design to prevent the conditions precedent to this Agreement&#146;s
completion from being satisfied.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=56,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=411722,FOLIO='53',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-09_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:36 2009' -->



<div style="font-family:Times New Roman;">

<p style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-decoration:underline;text-transform:uppercase;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">ARTICLE&nbsp;6- CLOSING ARRANGEMENTS</font></u></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.01</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Closing</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The sale and purchase of the Shares, the
ViroChem Shares and the ESOP Shares will be completed at the Time of Closing at
the offices of McCarthy T&#233;trault LLP, 1000 De La Gaucheti&#232;re Street West, Suite&nbsp;2500,
Montreal, Qu&#233;bec, H3B 0A2.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.02</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Deliveries</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>By the Vendors.</u> At the Time of
Closing:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Delivery of Share Certificates</i>. Each Vendor shall deliver to the Purchaser share certificates
representing the Shares identified on <b>Schedule A</b> as
being held by each such Vendor, duly endorsed, or with a stock power attached,
in favour of the Purchaser;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Officer Certificates</i>.
Each Vendor shall furnish the Purchaser with a certificate of such Vendor or an
officer of such Vendor, in form and substance reasonably satisfactory to the
Purchaser, as to the satisfaction of the conditions set forth in
Sections&nbsp;5.02(1)&nbsp;and 5.02(4)&nbsp;(with respect to the Vendor&#146;s
obligations only);</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Registration Rights Agreement</i>. Each Vendor shall deliver or cause to be delivered to the Purchaser
the Registration Rights Agreement set forth on <b>Schedule&nbsp;6.02(1)(c)&nbsp;</b>executed
by such Vendor;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Holdback Escrow Agreement</i>. Each Vendor, the Securityholders&#146; Representative and the ViroChem
Trust shall deliver or cause to be delivered to the Purchaser the Holdback
Escrow Agreement set forth in <b>Schedule&nbsp;6.02(1)(d)</b>,
executed by such Vendor, the Securityholders&#146; Representative, the ViroChem
Employees and the ViroChem Trust;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Escrow Agreement.</i> Each
Non-Resident Vendor shall deliver or cause to be delivered to the Purchaser the
Escrow Agreement set forth in <b>Schedule&nbsp;6.02(1)(e)</b>,
executed by such Non-Resident Vendor; and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Other Documents</i>. The
Vendors shall furnish all other documents, instruments or certificates required
to be delivered by the Vendors at or prior to the Time of Closing pursuant to
this Agreement.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>By the Corporation.</u> At the
Time of Closing:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Intervention by ViroChem Employees</i>. The Corporation shall deliver or cause to be delivered to the
Purchaser an intervention to this Agreement executed by all of the ViroChem
Employees, who will have exercised their options under the Trust ESOP, prior to
the Time of Closing in the form of <b>Schedule&nbsp;6.02(2)(a)</b>;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">54</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=57,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=197896,FOLIO='54',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-11_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:38 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Intervention by ESOP Holders.</i> The Corporation shall deliver or cause to be delivered to the
Purchaser an intervention to this Agreement executed by all of the ESOP
Holders, who will have exercised their options under the ESOP prior to the Time
of Closing, in the form of <b>Schedule 6.02(2)(b)</b>;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Delivery of ViroChem Share Certificates.</i> The Corporation shall cause each ViroChem Employee having exercised
their options in the Trust ESOP prior to the Time of Closing to deliver the
share certificates representing the ViroChem Shares, duly endorsed, or with a
stock power attached, in favour of the Purchaser;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Delivery of ESOP Share Certificates</i>. The Corporation shall cause each ESOP Holder having exercised
their options in the ESOP prior to the Time of Closing to deliver the share
certificates representing the ESOP Shares, duly endorsed, or with a stock power
attached, in favour of the Purchaser;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Officer Certificate</i>.
The Corporation shall furnish the Purchaser with a certificate of the President
and Chief Operating Officer of the Corporation, in form and substance
reasonably satisfactory to the Purchaser, as to the satisfaction of the
conditions set forth in Sections&nbsp;5.02(2),<b>  </b>5.02(4),
5.02(5)&nbsp;and 5.02(6);</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Secretary Certificate</i>.
The Corporation shall furnish copies of resolutions, certified by the Secretary
of the Corporation, as to the authorization of this Agreement and all of the
transactions contemplated hereby;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Good Standing Certificate</i>. The Corporation shall furnish to the Purchaser a certificate of
good standing from the Governmental Authority of its jurisdiction of
incorporation;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Closing Balance Sheet and Transaction Expenses</i>. The Corporation shall have delivered to the Purchaser (A)&nbsp;the
Estimated Closing Balance Sheet, (B)&nbsp;pay-off letters or final invoices in
respect of Transaction Expenses, and (C)&nbsp;a certificate of the Corporation
setting forth an estimate of the aggregate amount of Transaction Expenses
(whether or not paid as of such date) incurred as of the Time of Closing or
expected to be incurred following the Time of Closing;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Directors and Officers Resignations</i>. All directors and officers of the Corporation shall have delivered
to the Corporation letters of resignation effective at the Time of Closing;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Opinion of the
Corporation&#146;s Counsel</i>. The Corporation shall
furnish to the Purchaser an opinion from the Corporation&#146;s counsel
substantially in the form set out in <b>Schedule&nbsp;6.02(2)(j)</b>;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Registration Rights Agreement</i>. The Corporation shall deliver or cause to be delivered to the
Purchaser the Registration Rights Agreement executed by each ViroChem Employee
and ESOP Holder;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">55</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=58,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=623016,FOLIO='55',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-11_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:38 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Escrow Agreement</i>. The
Corporation shall deliver or cause to be delivered to the Purchaser the Escrow
Agreement, executed by each Non-Resident Vendor who is a ViroChem Employee or
an ESOP Holder;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(m)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Allocation of Purchase Price</i>. The Corporation shall deliver or cause to be delivered to the
Purchaser and the Escrow Agent a final version of Schedule 2.02, with any changes
from the date of this Agreement to be mutually agreed by the Corporation, the
Parent and the Purchaser;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(n)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Financial Statements</i>.
The Corporation shall deliver or cause to be delivered to the Purchaser the
2008 Audited Financial Statements; and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(o)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Other Documents</i>. All
other documents, instruments or certificates required to be delivered by the
Corporation, the ViroChem Employees and the ESOP Holders at or prior to the
Time of Closing pursuant to this Agreement.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>By the Purchaser and the Parent.</u>
At the Time of Closing:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Purchase Price.</i> The
Purchaser shall deliver to the Vendors, the ViroChem Employees, the ESOP
Holders, the Holdback Escrow Agent and the Escrow Agent the portions of the
Purchase Price payable to them pursuant to Section&nbsp;2.03.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Officer Certificate.</i>
The Purchaser shall furnish the Corporation with a certificate of a senior
officer of the Purchaser, in form and substance reasonably satisfactory to the
Corporation, as to the satisfaction of the conditions set forth in
Sections&nbsp;5.03(1), 5.03(2)&nbsp;and 5.03(3).</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Secretary Certificate</i>.
The Purchaser and the Parent shall furnish the Corporation copies of
resolutions, certified by the Secretary of the Purchaser and the Parent,
respectively, as to the authorization of this Agreement and all of the
transactions contemplated hereby;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Good Standing Certificate</i>. The Purchaser and the Parent shall furnish to the Corporation a
certificate of good standing from the Governmental Authority of their
respective jurisdiction of incorporation.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Opinion of the
Purchaser&#146;s Counsel</i>. The Purchaser will deliver to
the Vendors an opinion from the Purchaser&#146;s counsel substantially in the form
set out in <b>Schedule 6.02(3)(e)</b>;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Registration Rights Agreement</i>. The Parent shall deliver or cause to be delivered to the Vendors,
the ViroChem Employees and the ESOP Holders the Registration Rights Agreement,
executed by the Parent;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Escrow Agreements.</i> The
Purchaser and the Parent shall deliver or cause to be delivered to the Vendors
and the Securityholders&#146; Representative the Holdback Escrow Agreement, executed
by the Purchaser and the Parent; and the Purchaser </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">56</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=59,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=199949,FOLIO='56',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-11_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:38 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shall deliver or cause to be delivered to
the Non-Resident Vendors and Vitus the Escrow Agreement, executed by the
Purchaser;</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Delivery of Consideration Shares Certificates.</i> The Parent will have delivered to the Vendors, ViroChem Trust, for
and on behalf of the ViroChem Employees, and the ESOP Holders the share
certificates representing the Consideration Shares payable to each such party
on the Closing Date, other than shares to be held in escrow pursuant to this
Agreement, the Holdback Escrow Agreement or the Escrow Agreement, which shall
be delivered to the Holdback Escrow Agent as provided therein; and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Other Documents</i>. All
other documents, instruments or certificates required to be delivered by the
Purchaser or the Parent at or prior to the Time of Closing pursuant to this
Agreement.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-decoration:underline;text-transform:uppercase;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">ARTICLE&nbsp;7 &#151; SURVIVAL OF REPRESENTATIONS AND WARRANTIES AND
INDEMNIFICATION</font></u></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.01</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Survival of Representations and Warranties</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Survival of Representations and
Warranties of the Vendors, ViroChem Employees and ESOP Holders.</u></font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The representations and warranties of the
Vendors, ViroChem Employees and ESOP Holders contained in this Agreement or in
any certificate or other document delivered or given pursuant to this Agreement
shall survive the completion of the transactions contemplated by this Agreement
and shall continue in full force and effect for the benefit of the Purchaser
and the Parent:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>for a period equivalent to sixty (60) days following the statute of
limitations with respect to the particular matter that is the subject matter
thereof for (i)&nbsp;representations and warranties contained in, or incorporated
through an intervention hereto, Sections&nbsp;3.01(1)&nbsp;<i>(Vendor&#146;s
Shares)</i>, 3.01(2)&nbsp;<i>(Power, Authority, Right)</i>,
3.01(3)&nbsp;<i>(Establishment and Incorporation)</i>,
3.01(4)&nbsp;<i>(No Agreements)</i>, 3.01(5)&nbsp;<i>(No Conflict, Violation, Consents)</i> (but in the latter case
only to the extent that a breach thereof has the same effect on title to the
Shares as a breach of Sections 3.01(1)&nbsp;or 3.01(2)&nbsp;would have), 3.01(6)&nbsp;<i>(No Insolvency)</i>, 3.01(7)&nbsp;(<i>Legal Proceedings</i>),<i>  </i>3.01(8)&nbsp;<i>(Binding Obligation)</i>
and, with respect to the Vendors only (ii)&nbsp;representations and warranties
in the certificate referred to in Section&nbsp;6.02(1)(b)&nbsp;to the extent
relating to such representations and warranties; and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>for a period of twelve (12)<b>  </b>months from
the Closing Date for all other representations and warranties.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">57</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=60,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=547542,FOLIO='57',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-11_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:38 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Survival of Representations and
Warranties of the Corporation.</u></font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The representations and warranties of the
Corporation contained in this Agreement or in any certificate or other document
delivered or given pursuant to this Agreement shall survive the completion of
the transactions contemplated by this Agreement and shall continue in full
force and effect for the benefit of the Purchaser and the Parent:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>for a period equivalent to sixty (60) days following the statute of
limitations with respect to the particular matter that is the subject matter
thereof for (i)&nbsp;representations and warranties contained in
Sections&nbsp;3.02(1)(a)&nbsp;and 3.02(1)(c)&nbsp;<i>(Establishment,
Incorporation, Corporate Power)</i>, 3.02(2)&nbsp;<i>(Capitalization)</i>,
3.02(3)&nbsp;<i>(No Conflict, Violation, Consents)</i>
and 3.02(19) <i>(Tax Matters)</i> and (ii)&nbsp;the
representations and warranties in the certificate referred to in Section&nbsp;6.02(2)(e)&nbsp;to
the extent relating to such representations and warranties; and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>for a period of<b>  </b>twelve (12)
months from the Closing Date for all other representations and warranties.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Survival of Representations and
Warranties of the Purchaser.</u></font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The representations and warranties of the
Purchaser contained in this Agreement or in any certificate or other document
delivered or given pursuant to this Agreement shall survive the completion of
the transactions contemplated by this Agreement and shall continue in full
force and effect for the benefit of the Vendors, the ViroChem Employees and the
ESOP Holders:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>for a period equivalent to sixty (60) days following the statute of
limitations with respect to the particular matter that is the subject matter
thereof for (i)&nbsp;representations and warranties contained in Sections 3.03(a)&nbsp;<i>(Incorporation)</i>, 3.03(b)&nbsp;<i>(Authority)</i>,
3.03(c)&nbsp;<i>(Capitalization)</i>, 3.03(d)&nbsp;and
3.03(e)&nbsp;<i>(Consideration Shares)</i>, 3.03(c)&nbsp;<i>(Enforceability)</i>, 3.03(i)&nbsp;<i>(No
Conflict)</i> and (ii)&nbsp;the representations and warranties in the
certificate referred to in Section&nbsp;6.02(3)(b)&nbsp;to the extent relating
to such representations and warranties; and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>for a period of twelve (12) months from the Closing Date for all
other representations and warranties.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Survival Following Notice of Loss</u></font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding
anything to the contrary in this Section&nbsp;7.01, any obligations under this Article&nbsp;7
shall not terminate with respect to any losses as to which the Person to be
indemnified shall have given written notice (stating in reasonable detail the
basis of the claim for indemnification) to the indemnifying party in accordance
with Article&nbsp;7 before the termination of the applicable survival period
under this Section&nbsp;7.01.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.02</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Indemnification by the Vendors and ViroChem Employees</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subject to the provisions of this Article&nbsp;7,
each of the Vendors and ViroChem Employees (excluding, for avoidance of doubt,
the ESOP Holders), individually and separately </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=61,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=278861,FOLIO='58',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-11_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:38 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">as related to Sections 7.02(1)(a)&nbsp;and 7.02(1)(b)&nbsp;and
jointly as related to Sections 7.02(1)(c)&nbsp;and 7.02(1)(d)&nbsp;(and in no
case solidarily), will indemnify and save harmless the Purchaser, the Parent
and each of its directors, officers, employees and agents (collectively, the &#147;<b>Purchaser Indemnitees</b>&#148;) from and against all Claims incurred
by or asserted against any of them directly or indirectly arising out of or
resulting from:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any inaccuracy or misrepresentation in any representation or
warranty of the Vendors or the ViroChem Employees in this Agreement or in any
certificate or other document delivered or given by such Vendor or ViroChem
Employee pursuant to this Agreement;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any breach of any covenant of the Vendors or the ViroChem Employees
in this Agreement not caused by a breach by the Purchaser or the Parent of any
of its representations, warranties and covenants under this Agreement or in any
certificate or other document delivered or given by such Vendor or ViroChem
Employee pursuant to this Agreement;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any inaccuracy or misrepresentation in any representation or
warranty of the Corporation in this Agreement or in any certificate or other
document delivered or given by the Corporation pursuant to this Agreement; and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any breach of any covenant of the Corporation in this Agreement not
caused by a breach by the Purchaser or the Parent of any of its
representations, warranties and covenants under this Agreement or in any
certificate or other document delivered or given by the Corporation pursuant to
this Agreement.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding the provisions of Section&nbsp;7.02(1),
in case of any Claims arising out of or resulting from the events contemplated
in Sections&nbsp;7.02(1)(a)&nbsp;or 7.02(1)(b), any such Claims may only be
made against the Vendor or ViroChem Employee having made the inaccuracy,
misrepresentation or breach.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No Claim seeking indemnification may
be made pursuant to Section&nbsp;7.02(1)&nbsp;unless a written notice
describing such Claim in reasonable detail in light of the circumstances then
known to the Purchaser Indemnitees is delivered to the relevant Vendor or
ViroChem Employee with respect to Claims under Sections&nbsp;7.02(1)(a)&nbsp;or
7.02(1)(b)&nbsp;and to the Vendors and the Securityholders&#146; Representative with
respect to Claims under Sections&nbsp;7.02(1)(c)&nbsp;or 7.02(1)(d). Such
notice may be delivered at any time after the Closing Date but prior to the end
of the applicable survival period set forth in Section&nbsp;7.01.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The obligations of indemnification
set forth in Sections&nbsp;7.02(1)(a)&nbsp;or 7.02(1)(b)&nbsp;shall be subject
to the following monetary limitations:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>that the relevant Vendor or ViroChem Employee shall not be required
to pay any amount in respect of such Claims in excess of an aggregate amount
equal to the sum of the amounts set forth in Columns&nbsp;18 and 30 of <b>Schedule 2.02(2)</b>, except (i)&nbsp;for a breach of the
representation and warranty set forth in, or incorporated through an
intervention hereto, Section&nbsp;3.01(9)&nbsp;<i>(Not a
Non-Resident)</i>, in which case the limit shall be increased to an
amount equal to 25% of the Canadian </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">59</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=62,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=41589,FOLIO='59',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-11_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:38 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase Price allocated to such
Non-Resident Vendor (and an additional amount of 12% of the Canadian Purchase
Price allocated to Vitus), and (ii)&nbsp;for a breach of the representations
and warranties contained in, or incorporated through an intervention hereto,
Sections&nbsp;3.01(1)&nbsp;<i>(Vendor&#146;s Shares)</i>,
3.01(2)&nbsp;<i>(Power, Authority, Right)</i>, 3.01(3)&nbsp;<i>(Establishment and Incorporation)</i>, 3.01(4)&nbsp;<i>(No Agreements)</i>, 3.01(5)&nbsp;<i>(No
Conflict, Violation, Consents)</i> (but in the latter case only to the
extent that a breach thereof has the same effect on title to the Shares as a
breach of Sections 3.01(1)&nbsp;or 3.01(2)&nbsp;would have),</font> 3.01(6)&nbsp;<i>(No Insolvency)</i>, 3.01(7)&nbsp;(<i>Legal Proceedings</i>)<i>  </i>and<i>  </i>3.01(8)&nbsp;<i>(Binding Obligation),</i> in which case the obligation to
indemnify for all such Claims shall be limited to an amount in the aggregate
equal to 100% of the portion of the Purchase Price received by such Vendor or
ViroChem Employee (as set forth on Column 13 of <b>Schedule
2.02(2)</b>), minus any amount
previously paid for any Claim resulting from obligations of indemnification of
such Vendor or ViroChem Employee pursuant to Sections 7.02(1)(c)&nbsp;or
7.02(1)(d)&nbsp;of this Agreement.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The obligations of indemnification
set forth in Sections&nbsp;7.02(1)(c)&nbsp;or 7.02(1)(d)&nbsp;shall be subject
to the following monetary limitations:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>that the Vendors and ViroChem Employees shall not be required to pay
any amount in respect of indemnification obligations relating to such Claims
until the aggregate amount of all such Claims exceeds an amount equal to 0.5%
of the Purchase Price and upon the aggregate amount of all such Claims
exceeding such amount, the Vendors and ViroChem Employees shall only be
required to pay all such amounts in excess of such amount, except in the event
of Claims that arise out of any breach of the provisions of this Agreement
referred to in (i)&nbsp;Section&nbsp;7.01(2)(a)&nbsp;or (ii)&nbsp;7.02(1)(d)&nbsp;with
respect to only the covenants contained in Section&nbsp;4.05, in which either
case the Vendors and ViroChem Employees shall be required to pay all such
amounts; and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>that the Vendors and ViroChem Employees shall not be required to pay
any amount in respect of all such Claims in excess of the sum of the amounts
set forth in Columns&nbsp;18 and 30 of <b>Schedule 2.02(2)&nbsp;</b>(minus
any amount previously paid for any Claim resulting from obligations of such
Vendor or ViroChem Employee under Section&nbsp;7.02(1)&nbsp;of this Agreement),
except in the event of Claims that arise out of any breach of the provisions of
this Agreement referred to in Section&nbsp;7.01(2)(a), in which case the
obligation to indemnify for all such Claims shall be limited to an amount in
the aggregate equal to 100% of the portion of the Purchase Price received by
such Vendor or ViroChem Employee (as set forth on Column 13 of <b>Schedule 2.02(2)</b>) (minus any amount previously paid for any
Claim resulting from obligations of such Vendor or ViroChem Employee under Section&nbsp;7.02(1)&nbsp;of
this Agreement), it being understood that the liability of any Vendor or
ViroChem Employee for any Claim made pursuant to 7.02(1)(c)&nbsp;or 7.02(1)(d)&nbsp;shall
be limited to such Vendor&#146;s or ViroChem Employee&#146;s proportionate share of such
Claim as set forth in Column 4 of <b>Schedule 2.02(a)</b>;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">60</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=63,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=503363,FOLIO='60',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-11_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:38 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Any Claims relating to the
obligations of indemnification set forth in Sections&nbsp;7.02(1)(c)&nbsp;or
7.02(1)(d)&nbsp;shall first be satisfied by deduction from the Holdback Amount
or any balance thereof in compliance with the terms and conditions of the
Holdback Escrow Agreement. No Claims relating to the obligations of
indemnification set forth in Sections&nbsp;7.02(1)(a)&nbsp;or 7.02(1)(b)&nbsp;or
for fraud, intentional misrepresentation or wilful misconduct may be satisfied
against the Holdback Amount or any balance thereof except if there remains a
balance of Holdback Amount at the date on which such balance is to be released
to the Vendors and ViroChem Employees in compliance with the terms and
conditions of the Holdback Escrow Agreement, and then only to the extent of the
portion of such balance which is otherwise owed to the Vendor and ViroChem
Employees against which the Purchaser Indemnitees have a Claim.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The value to be used for calculating
the number of any Consideration Shares to be released to the Purchaser and
Parent pursuant to the Holdback Escrow Agreement shall be the same value used
in calculating the number of Consideration Shares to be issued in Section&nbsp;2.03(1)&nbsp;of
this Agreement.</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.03</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Indemnification by the ESOP Holders</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subject to the provisions of this Article&nbsp;7,
each of the ESOP Holders, individually and separately, not jointly or
solidarily, will indemnify and save harmless the Purchaser Indemnitees from and
against all Claims incurred by or asserted against any of them directly or
indirectly arising out of or resulting from:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any inaccuracy or misrepresentation in any representation or
warranty of the ESOP Holder in its intervention to this Agreement or in any
certificate or other document delivered or given by such ESOP Holder pursuant
to this Agreement; and</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any breach of any covenant of the ESOP Holders in this Agreement not
caused by a breach by the Purchaser of any of its representations, warranties
and covenants under this Agreement or in any certificate or other document
delivered or given by such ESOP Holder pursuant to this Agreement.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding the provisions of Section&nbsp;7.03(1),
in case of any Claims arising out of or resulting from the events contemplated
in Sections&nbsp;7.03(1)(a)&nbsp;or 7.03(1)(b)&nbsp;any such Claims may only be
made against the ESOP Holder having made the inaccuracy, misrepresentation or
breach.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No Claim seeking indemnification may
be made pursuant to Section&nbsp;7.03(1)&nbsp;unless a written notice
describing such Claim in reasonable detail in light of the circumstances then
known to the Purchaser Indemnitees is delivered to the relevant ESOP Holder.
Such notice may be delivered at any time after the Closing Date but prior to
the end of the applicable survival period set forth in Section&nbsp;7.01.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The obligations of indemnification
set forth in Section&nbsp;7.03(1)(a)&nbsp;shall be subject to the following
monetary limitations:</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">61</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=64,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=887394,FOLIO='61',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-11_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:38 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>that the relevant ESOP Holder shall not be required to pay any
amount in respect of such Claims in the aggregate in excess of an amount equal
to 10% of the Purchase Price received by such ESOP Holder except (i)&nbsp;for a
breach of the representation and warranty set forth in, or incorporated through
an intervention hereto, Section&nbsp;4 of Schedule&nbsp;6.02(2)(b), in which
case the limit shall be increased to an amount equal to 25% of the Canadian
Purchase Price allocated to such Non-Resident Vendor and (ii)&nbsp;for a breach
of the representations and warranties contained in, or incorporated through an
intervention hereto, Sections&nbsp;3.01(1)&nbsp;<i>(Vendor&#146;s
Shares)</i>, 3.01(2)&nbsp;<i>(Power, Authority, Right)</i>,
3.01(3)&nbsp;<i>(Establishment and Incorporation)</i>,
3.01(4)&nbsp;<i>(No Agreements)</i>, 3.01(5)&nbsp;<i>(No Conflict, Violation, Consents)</i> (but in the latter case
only to the extent that a breach thereof has the same effect on title to the
ESOP Shares as a breach of Sections 3.01(1)&nbsp;or 3.01(2)&nbsp;would have), 3.01(6)&nbsp;<i>(No Insolvency)</i>, 3.01(7)&nbsp;(<i>Legal Proceedings</i>)<i>  </i>and<i>  </i>3.01(8)&nbsp;<i>(Binding Obligation),</i> in which case the obligation to
indemnify shall be limited to an amount in the aggregate equal to 100% of the
portion of the Purchase Price received by such ESOP Holder (as set forth on
Column 13 of <b>Schedule 2.02(2)</b>).</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.04</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Indemnification by the Purchaser and the Parent</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subject to the provisions of this Article&nbsp;7,
the Purchaser and the Parent will solidarily (thereby waiving the benefit of
divisibility) indemnify and save harmless the Vendors, the ViroChem Employees<b>  </b>and the ESOP Holders and their respective directors,
officers, employees and agents (the &#147;<b>Vendor Indemnitees</b>&#148;)
from and against all Claims incurred by or asserted against any of them
directly or indirectly arising out of or resulting from:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any inaccuracy or misrepresentation in any representation or
warranty of the Purchaser in this Agreement or in any certificate or other
document delivered or given pursuant to this Agreement,</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any breach of any covenant of the Purchaser in this Agreement or in
any certificate or other document delivered or given pursuant to this Agreement
not caused by a breach by the Vendors, the ViroChem Employees, the ESOP Holders
or the Corporation of any of their representations, warranties and covenants
under this Agreement or in any certificate or other document delivered or given
pursuant to this Agreement, or</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Claims against the Vendor Indemnitees by creditors of the
Corporation or Claims against any of the directors of the Corporation by third
parties arising out of or resulting from the reduction of the Corporation&#146;s
stated capital pursuant to section 38(1)(b)&nbsp;of the <i>Canada
Business Corporations Act</i>&nbsp; and/or the&nbsp;dividend,
respectively, effected immediately before the Time of Closing pursuant to Section&nbsp;2.04(3).</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No Claim seeking indemnification may
be made pursuant to Section&nbsp;7.04(1)&nbsp;unless a written notice
describing such Claim in reasonable detail in light of the circumstances then
known to the Vendor Indemnitees is delivered to the Purchaser and the Parent.
Such notice </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">62</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=65,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=814107,FOLIO='62',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-11_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:38 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">may be delivered at any time after the Closing Date
but prior to the end of the applicable survival period set forth in Section&nbsp;7.01.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The obligations of indemnification
set forth in Section&nbsp;7.04(1)(a), to the extent that they arise out of any
breach of the provisions of this Agreement referred to in Section&nbsp;7.01(3)(b),
shall be subject to the following monetary limitations:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>that the Purchaser or the Parent shall not be required to pay any
amount in respect of such Claim in excess of an amount equal to 10% of the
Purchase Price.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.05</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Claims for Fraud</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding any of the other provisions
of this Article&nbsp;7, all Claims for fraud, intentional misrepresentation or
wilful misconduct or Claims arising out or resulting from Section&nbsp;7.04(1)(c)&nbsp;shall
not become time-barred and shall continue indefinitely and shall not be subject
to any monetary limitation.&#160; </font>For avoidance of
doubt, the obligations of any Vendor or ViroChem
Employee&nbsp; pursuant to this Section&nbsp;7.05 with respect to and Claim for fraud,
intentional misrepresentation or wilful misconduct by
the Corporation is joint and not solidary (in which case, such
Vendor&#146;s or such ViroChem Employee&#146;s&nbsp;liability shall be limited to such
Vendor&#146;s or ViroChem Employee&#146;s proportionate share of such Claim as set forth
in Column 4 of <b>Schedule 2.02(a)</b>), and with respect to
such Vendor&#146;s or ViroChem Employee&#146;s own fraud,
intentional misrepresentation or wilful misconduct is
individual and separate and not joint or solidary (in which case such Vendor or&nbsp;ViroChem Employee shall be solely liable for the full amount of
such Claim).</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.06</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Indemnification Procedures</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; A claim for indemnification for any
matter not involving a Third Party Claim (as defined below) may be asserted by
written notice to the party from whom indemnification is sought stating in
reasonable detail the nature of the claim and the amount claimed or demanded
therewith within ten (10)&nbsp;Business Days after first having actual
knowledge of the matter; provided that no failure to provide such written
notice shall excuse the indemnifying party from any of its obligations under
this Article&nbsp;7 except to the extent that the indemnifying party can
demonstrate actual loss and prejudice as a result of such failure. Prior to
receipt of a Third Party Claim (as defined below), neither the Parent, the
Purchaser nor any Purchaser Indemnitee shall undertake to compromise or offer
to settle any potential claims of third parties for which Claims might be
indemnifable under this Article&nbsp;7.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the event that any action shall be
instituted or that any claim or demand shall be asserted by any third party in
respect of which indemnification may be sought under Article&nbsp;7 hereof
(regardless of the limitations set forth therein) (each, a &#147;<b>Third Party Claim</b>&#148;), the indemnified party shall promptly
cause written notice of the assertion of any Third Party Claim of which it has
knowledge which is covered by this indemnity to be forwarded to the
indemnifying party. The failure of the indemnified party to give reasonably
prompt notice of any Third Party Claim shall not release, waive or otherwise
affect the indemnifying party&#146;s obligations with respect thereto except to the
extent that the indemnifying party can demonstrate actual loss and prejudice as
a result of such failure. Subject to the provisions of this Section&nbsp;7.06, </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">63</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=66,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=1038482,FOLIO='63',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-11_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:38 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the indemnifying party shall have the right, at its
sole expense, to be represented by counsel of its choice, which must be
reasonably satisfactory to the indemnified party, and to defend against,
negotiate, settle or otherwise deal with any Third Party Claim which relates to
any Claims indemnified against hereunder, including but not limited to
asserting claims and affirmative defenses and impleading or pursuing claims
against other Persons who may have been responsible for all or part of the
Claims associated with such Third Party Claim. If the indemnifying party elects
to defend against, negotiate, settle or otherwise deal with any Third Party
Claim which relates to any Claims indemnified by it hereunder, it shall within
thirty (30) days of the indemnified party&#146;s written notice of the assertion of
such Third Party Claim (or sooner, if the nature of the Third Party Claim so
requires) notify the indemnified party of its intent to do so; <u>provided</u>,
that the indemnifying party must conduct the defense of the Third Party Claim
actively and diligently thereafter in order to preserve its rights in this
regard. If the indemnifying party elects not to defend against, negotiate,
settle or otherwise deal with any Third Party Claim which relates to any Claims
indemnified against hereunder, fails to notify the indemnified party of its
election as herein provided or contests its obligation to indemnify the
indemnified party for such Claims under this Agreement, the indemnified party
may defend against, negotiate, settle or otherwise deal with such Third Party
Claim at its own expense. If the indemnified party defends any Third Party
Claim, then the indemnifying party shall reimburse the indemnified party for
the expenses of defending such Third Party Claim upon submission of periodic
bills. If the indemnifying party shall assume the defense of any Third Party
Claim, the indemnified party may participate, at his or its own expense, in the
defense of such Third Party Claim; <u>provided</u>, <u>however</u>, that such
indemnified party shall be entitled to participate in any such defense with separate
counsel at the expense of the indemnifying party if (i)&nbsp;so requested by
the indemnifying party to participate or (ii)&nbsp;in the reasonable opinion of
counsel to the indemnified party, a conflict or potential conflict exists
between the indemnified party and the indemnifying party that would make such
separate representation advisable; and <u>provided</u>, <u>further</u>, that
the indemnifying party shall not be required to pay for more than one such
counsel for all indemnified party in connection with any Third Party Claim. The
parties hereto agree to provide commercially reasonable access to the other to
such documents and information as may be reasonably requested in connection
with the defense, negotiation or settlement of any such Third Party Claim.
Notwithstanding anything in this Section&nbsp;7.06 to the contrary, neither the
indemnifying party nor the indemnified party shall, without the written consent
of the other party, settle or compromise any Third Party Claim or permit a
default or consent to entry of any judgment unless the claimant or claimants
and such party provide to such other party an unqualified release from all
liability in respect of the Third Party Claim. If the indemnifying party makes
any payment on any Third Party Claim, the indemnifying party shall be
subrogated, to the extent of such payment, to all rights and remedies of the
indemnified party to any insurance benefits or other claims of the indemnified
party with respect to such Third Party Claim.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; After any final decision, judgment or
award shall have been rendered by a Governmental Authority of competent
jurisdiction and the expiration of the time in which to appeal therefrom, or a
settlement shall have been consummated, or the indemnified party and the
indemnifying party shall have arrived at a mutually binding agreement, in each
case with respect to a Third Party Claim hereunder, the indemnified party shall
forward to the indemnifying party notice of any sums due and owing by the
indemnifying party pursuant to this Agreement with respect to such matter and
the indemnifying party shall pay all of such remaining sums so due </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">64</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=67,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=171988,FOLIO='64',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-11_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:38 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and owing to the indemnified party by wire transfer of
immediately available funds within five (5)&nbsp;Business Days after the date
of such notice; <u>provided</u>, <u>however</u>, that any amounts owed by a
Vendor or ViroChem Employee shall be paid out of the Holdback Escrow Fund in
accordance with this Agreement and the Holdback Escrow Agreement, if
applicable.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Vendors, ViroChem Employees and
ESOP Holders shall have no right of contribution or other recourse against the
Corporation or its directors, officers, employees, Affiliates, agents,
attorneys, representatives, assigns or successors for any Third Party Claims
asserted by the Purchaser Indemnitees, it being acknowledged and agreed that
the covenants and agreements of the Corporation are solely for the benefit of
the Purchaser Indemnitees.</font></p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Any actions on behalf of or with
respect to the ViroChem Employees and ESOP Holders under this Section&nbsp;7.06
shall be taken by or directed to the Securityholders&#146; Representative under the
authority set forth in Section&nbsp;7.09 of this Agreement.&#160; In addition, in the event of any disagreement
or dispute among the Vendors with respect to (i)&nbsp;the negotiation,
settlement or compromise of any Claim under this Section&nbsp;7.06 or the
Holdback Escrow Agreement or (ii)&nbsp;any dispute arising under this Agreement
or the Holdback Escrow Agreement, the Purchaser, the Parent and the Purchaser
Indemnitees shall be entitled to rely upon the written direction of two-thirds
in interest of the Vendors&#160; </font>(based on the Shares listed in Column 1 of <b>Schedule 2.02(2)</b>).</p>

<p align="left" style="margin:0in 0in .0001pt 6.0pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.07</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Exclusive Remedy</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From and after the completion of the
transactions herein contemplated, except for specific performance and
injunctive relief in the case of a breach of Sections&nbsp;4.03 through 4.07,
the rights of indemnity set forth in this Article&nbsp;7 are the sole and
exclusive remedies of each party in respect of any inaccuracy or
misrepresentation in any representation or warranty, or breach of covenant or
other obligation by another party under this Agreement or the other documents
or agreements executed by the parties in connection with or to give effect to
the transactions contemplated hereby other than in respect of claims based on
conduct constituting fraud, intentional misrepresentation or wilful misconduct.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.08</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Adjustment to Purchase Price</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All amounts payable by the Vendors,
ViroChem Employees and ESOP Holders to a Purchaser Indemnitee pursuant to Article&nbsp;7
will be deemed to be a decrease to the Purchase Price. All amounts payable by
the Purchaser to a Vendor Indemnitee pursuant to Article&nbsp;7 will be deemed
to be an increase to the Purchase Price.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.09</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Securityholders&#146; Representative</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Appointment of Representative</u>.
The Securityholders&#146; Representative is hereby appointed, authorized and
empowered to be the exclusive proxy, representative, agent and attorney-in-fact
of each of the ViroChem Employees and ESOP Holders, with full power of
substitution, to make all decisions and determinations and to act and execute,
deliver and receive all documents, instruments and consents on behalf of the
ViroChem Employees and ESOP Holders at any time, in connection with, and that
may be necessary or appropriate to accomplish the intent and implement the
provisions of, this Agreement and the Holdback Escrow</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">65</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=68,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=579803,FOLIO='65',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-11_ZAU43502.CHC",USER="LPALLES",CD='Mar  6 18:38 2009' -->



<div>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement, and
to facilitate the consummation of the transactions contemplated hereby and
thereby, and in connection with the activities to be performed by or on behalf
of such ViroChem Employees and ESOP Holders under this Agreement, and each
other agreement, document, instrument or certificate referred to herein or
therein (including, without limitation, in connection with any and all claims
for remedies brought pursuant to this Agreement). By executing this Agreement,
the Securityholders&#146; Representative accepts such appointment, authority and
power. Without limiting the generality of the foregoing, the Securityholders&#146;
Representative shall have the power to take any of the following actions on
behalf of such ViroChem Employees and ESOP Holders: (i)&nbsp;to give and
receive notices, communications and consents under this Agreement; (ii)&nbsp;to
receive and distribute payments pursuant to this Agreement and the Holdback
Escrow Agreement; (iii)&nbsp;to waive any provision of this Agreement and the
Holdback Escrow Agreement; (iv)&nbsp;to assert any claim or institute any
action; (v)&nbsp;to investigate, defend, contest or litigate any action
initiated by any Person against the Securityholders&#146; Representative; (vi)&nbsp;to
receive process on behalf of any or all such ViroChem Employees and ESOP
Holders in any such action; (vii)&nbsp;to negotiate, enter into settlements and
compromises of, resolve and comply with orders of courts and awards of
arbitrators or other third party intermediaries with respect to any disputes
arising under this Agreement and the Holdback Escrow Agreement; (viii)&nbsp;to
agree to any offsets or other additions or subtractions of amounts to be paid
under this Agreement and the Holdback Escrow Agreement; and (ix)&nbsp;to make,
execute, acknowledge and deliver all such other agreements, guarantees, orders,
receipts, endorsements, notices, requests, instructions, certificates, stock
powers, letters and other writings, and, in general, to do any and all things
and to take any and all action that the Securityholders&#146; Representative, in its
sole and absolute discretion, may consider necessary or proper or convenient in
connection with or to carry out the activities described in this Section&nbsp;7.09
and the transactions contemplated hereby.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Authority</u>. The appointment of
the Securityholders&#146; Representative by each such ViroChem Employee and ESOP
Holder is coupled with an interest and may not be revoked in whole or in part
(including, without limitation, upon the death or incapacity of such ViroChem
Employees and ESOP Holders). Such appointment shall be binding upon the heirs,
executors, administrators, estates, personal representatives, officers,
directors, security holders, successors and assigns of each such ViroChem
Employee and ESOP Holder. All decisions of the Securityholders&#146; Representative
shall be final and binding on all of the ViroChem Employees and ESOP Holders,
and no such ViroChem Employees and ESOP Holders shall have the right to object,
dissent, protest or otherwise contest the same. The Parent and the Purchaser
shall be entitled to rely upon, without independent investigation, any act,
notice, instruction or communication from the Securityholders&#146; Representative
and any document executed by the Securityholders&#146; Representative on behalf of
any such ViroChem Employees and ESOP Holders and shall be fully protected in
connection with any action or inaction taken or omitted to be taken in reliance
thereon absent wilful misconduct. The Securityholders&#146; Representative shall not
be responsible for any loss suffered by, or liability of any kind to, such
ViroChem Employees and ESOP Holders arising out of any act done or omitted by
the Securityholders&#146; Representative in connection with the acceptance or
administration of the Securityholders&#146; Representative&#146;s duties hereunder,
unless such act or omission involves gross negligence or wilful misconduct.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Limitations on Authority</u>.
Notwithstanding anything to the contrary in Section&nbsp;7.09(2)&nbsp;or any
other provision of this Agreement or the Holdback Escrow Agreement, the
Securityholders&#146; Representative shall have no authority with respect to Claims
for </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">66</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=69,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=471508,FOLIO='66',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-13_ZAU43502.CHC",USER="LPALLES",CD='Mar 12 15:43 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">indemnification
against an individual ViroChem Employee or ESOP Holder pursuant to
Sections&nbsp;7.02(1)(a), 7.02(1)(b)&nbsp;or 7.03 of this Agreement or with
respect to any other Claims against an individual ViroChem Employee or ESOP
Holder, and the Purchaser and Parent shall deal exclusively with the relevant
ViroChem Employee or ESOP Holder, or such Person&#146;s authorized representative,
with respect to such matters.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Resignation</u>. The
Securityholders&#146; Representative may resign by providing thirty (30) days prior
written notice to each ViroChem Employee, ESOP Holder and the Parent. Upon the
resignation of the Securityholders&#146; Representative, a majority-in-interest of
the Vendors shall appoint a replacement Securityholders&#146; Representative to
serve in accordance with the terms of this Agreement; provided, however, that
such appointment shall be subject to such newly-appointed Securityholders&#146;
Representative notifying the Parent in writing of his, her or its appointment
and appropriate contact information for purposes of this Agreement, and the
Parent shall be entitled to rely upon, without independent investigation, the
identity of such newly-appointed Securityholders&#146; Representative as set forth
in such written notice.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-decoration:underline;text-transform:uppercase;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">ARTICLE&nbsp;8 - GENERAL</font></u></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman">&nbsp;</font></b></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.01</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Further
Assurances</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each of the Vendors, ViroChem Employees,
ESOP Holders, the Vendors&#146; Representative, the Corporation, the Parent and the
Purchaser will from time to time execute and deliver all such further documents
and instruments and do all acts and things as the other party may, either
before or after the Closing Date, reasonably require to effectively carry out
or better evidence or perfect the full intent and meaning of this Agreement.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.02</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Time of the Essence</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Time is of the essence of this Agreement.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.03</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Fees and Commissions</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each of the Vendors, ViroChem Employees,
ESOP Holders, the Vendors&#146; Representative, the Corporation, the Parent and the
Purchaser will pay its respective legal and accounting costs and expenses
incurred in connection with the preparation, execution and delivery of this
Agreement and all documents and instruments executed pursuant to this Agreement
and any other costs and expenses whatsoever and howsoever incurred and will
indemnify and save harmless the other from and against any Claim for any broker&#146;s,
finder&#146;s or placement fee or commission alleged to have been incurred as a
result of any action by it in connection with the transactions under this
Agreement. The Transaction Expenses shall be paid in accordance with Section&nbsp;2.03(3).</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.04</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Public Announcements</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Purchaser, the Parent and the
Corporation shall consult with and obtain the approval of each other (which
shall not be unreasonably withheld) before issuing any press release or other
public announcement with respect to this Agreement, and no party hereto shall
issue or </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">67</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=70,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=263267,FOLIO='67',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-13_ZAU43502.CHC",USER="LPALLES",CD='Mar 12 15:43 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">cause to be
issued any such press release prior to such consultation and approval, except
to the extent required by Applicable Law, </font>stock exchange or securities market rules&nbsp;or
the rules&nbsp;of any self-regulatory body having competent jurisdiction, in which case the party proposing to issue such press release or
make such public announcement shall use commercially reasonable efforts to
consult in good faith with the other parties before issuing any such press
release or making any such public announcement to attempt to agree upon
mutually satisfactory text. The parties acknowledge that the Parent will be
required by the rules&nbsp;of the SEC to disclose in publicly available filings
with the SEC this Agreement, details regarding the transactions contemplated by
this Agreement and historical and pro forma financial information with respect
to the Corporation, and consent to such disclosures. Notwithstanding anything to the contrary in
this Agreement or the Confidentiality Agreement, from and after the public
announcement of the transactions contemplated by this Agreement, Parent may
disclose information about the HCV Products that it deems, in its sole
discretion, is&nbsp;of material interest to Parent&#146;s investors, including but
not limited to releasing top-line data from the&nbsp;Phase&nbsp;1 clinical
trial of VCH-222.</p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.05</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Benefit of the Agreement</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement will inure to the benefit of
and be binding upon the respective heirs, executors, administrators, other
legal representatives, successors and permitted assigns of the parties hereto.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.06</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Entire Agreement</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement, together with the Holdback
Escrow Agreement, the Escrow Agreement, the Registration Rights Agreement and
the Confidentiality Agreement, including all Schedules thereto and hereto,
constitute the entire agreement between the parties hereto (and the ViroChem
Employees and ESOP Holders) with respect to the subject matter hereof and
cancels and supersedes any prior understandings and agreements between the
parties hereto with respect thereto. There are no representations, warranties,
terms, conditions, undertakings or collateral agreements, express, implied or
statutory, between the parties other than as expressly set forth in this
Agreement and the aforementioned agreements.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.07</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Amendments and Waivers</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No amendment to this Agreement will be
valid or binding unless set forth in writing and duly executed by all of the
parties hereto. No waiver of any breach of any provision of this Agreement will
be effective or binding unless made in writing and signed by the party
purporting to give the same and, unless otherwise provided, will be limited to
the specific breach waived.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.08</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Assignment</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement may not be assigned by any
of the parties hereto without the written consent of the Purchaser, the Parent,
the Corporation, the Vendors and the Securityholders&#146; Representative, <i>provided, however</i>, (i)&nbsp;that this Agreement may be
assigned by the Purchaser or the Parent without the consent of the Vendors or
Securityholders&#146; Representative to an Affiliate of the Purchaser or the Parent,
<i>provided, however,</i> that the Purchaser or
the Parent will remain solidarily bound by the terms of this Agreement with any
such Affiliate; and (ii)&nbsp;that this Agreement may be assigned by Fonds
without the consent of the other Vendors or </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">68</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=71,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=50693,FOLIO='68',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-13_ZAU43502.CHC",USER="LPALLES",CD='Mar 12 15:43 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Securityholders&#146;
Representative to an Affiliate of Fonds or a limited partnership of which Fonds
holds all the units, <i>provided, however,</i>
that (A)&nbsp;such assignee agrees in writing to be bound by the terms of this
Agreement, the Holdback Escrow Agreement, the Registration Rights Agreement
and, if applicable, the Escrow Agreement, and (B)&nbsp;Fonds will remain
solidarily bound by the terms of this Agreement,&#160; the Holdback Escrow Agreement, the
Registration Rights Agreement and, if applicable, the Escrow Agreement, with
any such Affiliate or limited partnership.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.09</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notices</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any demand, notice or other communication
to be given in connection with this Agreement must be given in writing and will
be given by personal delivery, by registered mail or by electronic means of
communication addressed to the recipient as follows:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">To
the Vendors:</font></b></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">To CDPQ</font></u>:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CAISSE DE D&#201;P&#212;T ET PLACEMENT DU QU&#201;BEC</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4258398 Canada Inc.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">1001 de Maisonneuve Blvd. </font>West</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Montreal,
Qu&#233;bec</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">H2A 3C8</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (514) 849-5191</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Louis
Lacasse</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">To the Fonds</font></u>:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">FONDS DE SOLIDARIT&#201; DES TRAVAILLEURS DU QU&#201;BEC (F.T.Q.)</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">545 Cr&#233;mazie Blvd. East</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Suite&nbsp;200</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Montreal, Qu&#233;bec</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">H2M 2W4</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (514) 383-2500</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Vice President, Legal Affairs</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">To BDC</font></u>:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BDC CAPITAL
INC.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BDC Building</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5 Place Ville-Marie</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Suite&nbsp;400</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Montreal, Qu&#233;bec</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">H3B 5E7</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (514) 283-5455</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Jean-Francois Parizeau</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">69</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=72,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=800388,FOLIO='69',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-13_ZAU43502.CHC",USER="LPALLES",CD='Mar 12 15:43 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">To Dr.&nbsp;Francesco
Bellini</font></u>:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DR. FRANCESCO
BELLINI</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">920 - 5th
Avenue SW</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Calgary, Alberta</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T2P 5P6</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (403) 262-1117</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">To Dr.&nbsp;Gervais Dionne</font></u>:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DR. GERVAIS DIONNE</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2702 Place Guy-Sanche</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">St-Laurent, Qu&#233;bec</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">H4R 2T5</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (514) 333-8458</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">To IFML</font></u>:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">LES INVESTISSEMENTS F.M. LEGAULT INC.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33 Glencoe Avenue,</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Outremont, Qu&#233;bec</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">H3T 1R1</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (514) 342-6764</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Fran&#231;ois Legault</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">To
Shire</font></u>:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SHIRE CANADA
INC.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2250
Alfred-Nobel</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Suite&nbsp;500</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">St-Laurent, Qu&#233;bec</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">H4S 2C9</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (514) 787-2470</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Claude Perron</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">To
Franklin M. Berger</font></u>:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">MR. FRANKLIN
M. BERGER</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">257 Park
Avenue South</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15th Floor</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New York, NY
10010</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">USA</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (212) 213-4447</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">70</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=73,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=701937,FOLIO='70',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-13_ZAU43502.CHC",USER="LPALLES",CD='Mar 12 15:43 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">To the
Corporation</font></u>:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">VIROCHEM PHARMA INC.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">275 Armand-Frappier Blvd.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Laval, Qu&#233;bec</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">H7V 4A7</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (514) 342-6764</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Fran&#231;ois Legault</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">To
Power</font></u>:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">POWER
CORPORATION OF CANADA</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">751 Victoria
Square</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Montreal, Qu&#233;bec</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">H2Y&nbsp;2J3</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (514) 286-7476</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Senior Vice President and General
Counsel</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">To
Vitus</font></u>:</p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">VITUS INVESTMENTS III LTD.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">80 Raffles Place</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">UOB Plaza 1 #25-01</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Singapore 048624</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>(86) 21 6881 7668</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Ban
Su-Mei</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With a copy
to: Roberto Bellini</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">To
Therapeutic Trust</font></u></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">and
ViroChem Trust</font></u></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any notice or
other communication to be given to the Trustees shall be addressed as follows:</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DANIEL JOHNSON</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1321
Sherbrooke Street West</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Apt. D-61</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Montreal, Qu&#233;bec</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">H3G 1J4</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">FRAN&#199;OIS LEGAULT</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33 Glencoe Avenue</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Outremont, Qu&#233;bec</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">H3T 1R1</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">71</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=74,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=934577,FOLIO='71',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-13_ZAU43502.CHC",USER="LPALLES",CD='Mar 12 15:43 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">GERVAIS DIONNE</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2702 Place Guy-Sanche</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">St-Laurent, Qu&#233;bec</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">H4R 2T5</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">With a
copy to</font></u>:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">MCCARTHY T&#201;TRAULT LLP</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1000 de la Gaucheti&#232;re St. West</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Suite&nbsp;2500</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Montreal, Qu&#233;bec</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">H3B 0A2</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (514) 875-6246</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Mireille Fontaine </font>and Clemens Mayr</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">To
the ViroChem Employees or ESOP Holders:</font></b></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
Securityholders&#146; Representative (as set forth below)</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">With a
copy to</font></u>:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">MCCARTHY
T&#201;TRAULT LLP</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1000 de la Gaucheti&#232;re St. West</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Suite&nbsp;2500</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Montreal, Qu&#233;bec</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">H3B 0A2</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (514) 875-6246</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Mireille
Fontaine and Clemens Mayr</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">To
the Securityholders&#146; Representative:</font></b></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">FRAN&#199;OIS
LEGAULT</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33 Glencoe
Avenue</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Outremont,
Qu&#233;bec</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">H3T&nbsp;1R1</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (514) 342-6764</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">With a
copy to</font></u>:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">MCCARTHY
T&#201;TRAULT LLP</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1000 de la Gaucheti&#232;re St. West</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Suite&nbsp;2500</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Montreal, Qu&#233;bec</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">H3B 0A2</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (514) 875-6246</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Mireille
Fontaine and Clemens Mayr</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">72</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=75,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=876849,FOLIO='72',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-13_ZAU43502.CHC",USER="LPALLES",CD='Mar 12 15:43 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">To
the Parent or the Purchaser:</font></b></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vertex
Pharmaceuticals Incorporated</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">130 Waverly Street</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cambridge, Massachusetts 02139</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (617) 444-6483</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Office
of General Counsel</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">With a copy to</font></u>:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">One Financial Center</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Boston, Massachusetts, 02111</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (617)
542-2241</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Michael
L. Fantozzi,&nbsp;Esq.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">or to such other street address, individual
or electronic communication number or address as may be designated by notice
given by any of the parties to the others. Any demand, notice or other
communication given by personal delivery will be presumed to have been given on
the day of actual delivery thereof and, if given by registered mail, on the
third Business Day following the deposit thereof in the mail and, if given by
electronic communication, on the day of transmittal thereof if given during the
normal business hours of the recipient and on the Business Day during which
such normal business hours next occur if not given during such hours on any
day. If the party giving any demand, notice or other communication knows or
ought reasonably to know of any difficulties with the postal system that might
affect the delivery of mail, any such demand, notice or other communication may
not be mailed but must be given by personal delivery or by electronic
communication.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.10</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Remedies Cumulative</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to Section&nbsp;7.07, the right and
remedies of the parties under this Agreement are cumulative and are in addition
to, and not in substitution for, any other rights and remedies available at law
or in equity or otherwise. No single or partial exercise by a party of any
right or remedy precludes or otherwise affects the exercise of any other right
or remedy to which that party may be entitled.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.11</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Third Party Beneficiaries</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as provided in Sections&nbsp;4.04
and 8.04, this Agreement is solely for the benefit of:</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Vendors and the Securityholders&#146; Representative, and their
heirs, executors, administrators, other legal representatives, successors and
permitted assigns, with respect to the obligations of the Purchaser and the
Parent under this Agreement;</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Corporation, the ViroChem Employees and the ESOP Holders, and
each of their heirs, executors, administrators, other legal representatives,
successors and </p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">73</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=76,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=137738,FOLIO='73',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-13_ZAU43502.CHC",USER="LPALLES",CD='Mar 12 15:43 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">permitted assigns, with respect to the obligations
of the Purchaser and the Parent under this Agreement; and</font></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Purchaser and the Parent, and each of their heirs, executors,
administrators, other legal representatives, successors and permitted assigns,
with respect to the obligations of the Corporation, Vendors, the
Securityholders&#146; Representative, the ViroChem Employees and ESOP Holders under
this Agreement.</p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and this Agreement will not be deemed to
confer upon or give to any other person any remedy, claim, liability,
reimbursement, cause of action or other right.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.12</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governing Law</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement is governed by and will be
construed in accordance with the laws of the Province of Qu&#233;bec and the laws of
Canada applicable therein.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.13</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Attornment</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For the purpose of all legal proceedings,
this Agreement will be deemed to have been performed in the Province of Qu&#233;bec
and the courts of the Province of Qu&#233;bec will have jurisdiction to entertain
any action arising under this Agreement. The Vendors, the ViroChem Employees,
the ESOP Holders, the Vendors&#146; Representative, the Parent and the Purchaser
each attorns to the jurisdiction of the courts of the Province of Qu&#233;bec.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.14</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Severability</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If any term or other provision of this
Agreement is invalid, illegal or incapable of being enforced by any rule&nbsp;of
Applicable Law, or public policy, all other conditions and provisions of this
Agreement shall nevertheless remain in full force and effect.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.15</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Representation by Counsel</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each party hereto acknowledges that it has
been advised by legal and any other counsel retained by such party in its sole
discretion. Each party acknowledges that such party has had a full opportunity
to review this Agreement and all related exhibits, schedules and ancillary
agreements and to negotiate any and all such documents in its sole discretion,
without any undue influence by any other party hereto or any third party.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.16</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Construction</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The parties have participated jointly in
the negotiations and drafting of this Agreement and in the event of any
ambiguity or question of intent or interpretation, no presumption or burden of
proof shall arise favoring or disfavoring any party by virtue of the authorship
of any of the provisions of this Agreement.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">74</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=77,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=988816,FOLIO='74',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-13_ZAU43502.CHC",USER="LPALLES",CD='Mar 12 15:43 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.17</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Counterparts</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement may be executed in any
number of counterparts, each of which will be deemed to be an original and all
of which taken together will be deemed to constitute one and the same
instrument.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.18</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Electronic Execution</u></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Delivery of an executed signature page&nbsp;to
this Agreement by any party by electronic transmission will be as effective as
delivery of a manually executed copy of this Agreement by such party.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">75</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=78,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=571558,FOLIO='75',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-13_ZAU43502.CHC",USER="LPALLES",CD='Mar 12 15:43 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS
WHEREOF the parties have executed this Agreement.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">VIROCHEM
  PHARMA INC.</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="332" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">/s/
  Fran</font>&#231;</font>ois Legault</p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">Name:
  Fran</font>&#231;</font>ois Legault</p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: President</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CAISSE DE D&#201;P&#212;T ET PLACEMENT DU QU&#201;BEC</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="332" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Louis
  Lacasse</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:
  Louis Lacasse</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:
  President, 4258398 Canada Inc</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="332" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SHIRE
  CANADA INC.</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="332" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/
  Tatjana May</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:
  Tatjana May</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:
  EVP, General Counsel</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FONDS DE SOLIDARIT&#201; DES TRAVAILLEURS DU <br>
  QU&#201;BEC (F.T.Q.)</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="332" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Serge
  Lapointe</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:
  Serge Lapointe</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:
  Directeur des investissements</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt .6in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;Sciences
  de la vie</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Signature Page to Share
Purchase Agreement</font></i></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=79,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=720595,FOLIO='1',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-13_ZAU43502.CHC",USER="LPALLES",CD='Mar 12 15:43 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BDC
  CAPITAL INC.</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="336" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.5in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Denis Ho</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="336" valign="top" style="padding:0in 0in 0in 0in;width:3.5in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:
  Denis Ho</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="336" valign="top" style="padding:0in 0in 0in 0in;width:3.5in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:
  Managing Director</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="336" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.5in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Jean
  Francois Pariseau</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="336" valign="top" style="border:none;padding:0in 0in 0in 0in;width:3.5in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: Jean
  Francois Pariseau</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="336" valign="top" style="padding:0in 0in 0in 0in;width:3.5in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:
  Director</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/
  Dr.&nbsp;Francesco Bellini</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DR.
  FRANCESCO BELLINI</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/
  Dr.&nbsp;Gervais Dionne</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DR. GERVAIS DIONNE</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LES INVESTISSEMENTS F.M. LEGAULT INC.</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="336" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.5in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Fran&#231;ois
  Legault</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="336" valign="top" style="padding:0in 0in 0in 0in;width:3.5in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:
  Fran&#231;ois Legault</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="336" valign="top" style="padding:0in 0in 0in 0in;width:3.5in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:
  President</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Franklin
  M. Berger</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FRANKLIN
  M. BERGER</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">POWER
  CORPORATION OF CANADA</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="336" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.5in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Peter
  Kruyt</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="336" valign="top" style="padding:0in 0in 0in 0in;width:3.5in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: Peter
  Kruyt</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="336" valign="top" style="padding:0in 0in 0in 0in;width:3.5in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:
  Vice-President</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="336" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.5in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Stephane
  Lemay</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="336" valign="top" style="padding:0in 0in 0in 0in;width:3.5in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:
  Stephane Lemay</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="336" valign="top" style="padding:0in 0in 0in 0in;width:3.5in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:
  Vice-President and Assistant General Counsel</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Signature Page to Share
Purchase Agreement</font></i></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=80,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=755367,FOLIO='2',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-13_ZAU43502.CHC",USER="LPALLES",CD='Mar 12 15:43 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">VITUS
  INVESTMENTS III PRIVATE LIMITED</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="332" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Ban
  Su-Mei</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: Ban
  Su-Mei</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:
  Director</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">VIROCHEM
  RENAISSANCE TRUST, FOR AND ON BEHALF OF THE BENEFICIARIES THEREUNDER</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="332" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Fran&#231;ois
  Legault</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="border:none;padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Trustees:
  Fran&#231;ois Legault</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="332" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/
  Dr.&nbsp;Gervais Dionne</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="border:none;padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Trustees:
  Dr.&nbsp;Gervais Dionne</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THERAPEUTIC
  RENAISSANCE TRUST, FOR AND ON BEHALF OF THE BENEFICIARIES THEREUNDER</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="332" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/
  Dr.&nbsp;Gervais Dionne</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Trustees:
  Dr.&nbsp;Gervais Dionne</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="332" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Fran&#231;ois
  Legault</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="border:none;padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Trustees:
  Fran&#231;ois Legault</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Fran&#231;ois
  Legault</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FRAN&#199;OIS
  LEGAULT,</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AS
  SECURITYHOLDERS&#146; REPRESENTATIVE</font></b></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Signature Page to Share
Purchase Agreement</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=81,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=318582,FOLIO='3',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-13_ZAU43502.CHC",USER="LPALLES",CD='Mar 12 15:43 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">VERTEX
  PHARMACEUTICALS INCORPORATED</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="332" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Ian F.
  Smith</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: Ian F.
  Smith</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:
  Executive Vice President and Chief Financial Officer</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">VERTEX
  PHARMACEUTICALS (CANADA) INCORPORATED</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per:</font></p>
  </td>
  <td width="332" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Ian F.
  Smith</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: Ian F.
  Smith</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28" valign="top" style="padding:0in 0in 0in 0in;width:20.7pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="332" valign="top" style="padding:0in 0in 0in 0in;width:249.3pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:
  Executive Vice President and Chief Financial Officer</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt 3.75in;text-indent:-30.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Signature
Page to Share Purchase Agreement</font></i></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&nbsp;</font></i></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=82,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=485179,FOLIO='4',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-13_ZAU43502.CHC",USER="LPALLES",CD='Mar 12 15:43 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATTACHMENT
TO THE SHARE PURCHASE AGREEMENT:</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AGREEMENT
TO FURNISH OMITTED SCHEDULES UPON REQUEST AND LIST OF OMITTED SCHEDULES</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AGREEMENT:&nbsp;&nbsp;&nbsp;The
Registrant hereby agrees to furnish supplementally a copy of any omitted
schedule to the Commission upon request.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">LIST OF
OMITTED SCHEDULES:</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:.5in;width:93.0%;">
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule A</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Share
  Ownership of the Corporation</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  2.02(2)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Allocation
  of Purchase Price</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  2.03(1)(a)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Holdback
  Escrow Agent Trust Account</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  2.03(2)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">McCarthy
  T&#233;trault Trust Account</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  2.03(2)(c)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Escrow Agent
  Trust Account</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.01(5)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No Conflict,
  Violation, Consents</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.01(10)(a)(i)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Definition
  of U.S. Person</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.01(10)(b)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Definition
  of an Accredited Investor</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(1)(b)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Articles of
  Incorporation and By-Laws of the Corporation, as Amended</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(2)(e)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ESOP</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(5)(b)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financial
  Statements</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(6)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Undisclosed
  Liabilities</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule 3.02(7)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Changes and
  Unusual Transactions</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(8)(a)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">List of
  Directors, Officers, Employees, Consultants and Independent Contractors of
  the Corporation</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(8)(b)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">List of
  Employment, Consulting and Independent Contractor Agreements</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(9)(a)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Benefit
  Plans</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(a)(i)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registered
  and Applied for Owned Intellectual Property</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(a)(ii)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rights of
  Others in the Owned Intellectual Property</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(b)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registration,
  Maintenance and Fees for Owned Intellectual Property</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(d)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">License
  Agreements</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(e)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consents
  Required to License or Sub-License</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(f)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sufficiency
  of Intellectual Property</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(g)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Infringement
  of Third Party Intellectual Property Rights</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(h)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Infringement
  of Corporation Owned Intellectual Property</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(10)(i)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Validity and
  Enforceability of Owned Intellectual Property</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(11)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Lease
  Agreement and Related Agreements</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(14)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Insurance
  Policies</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(15)(a)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Material
  Contracts</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(16)(a)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">List of
  Products</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(16)(c)(i)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">List of
  Clinical Trials Conducted or Being Conducted in Canada or the United States</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(16)(c)(ii)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">List of
  Other Clinical Trials Planned or Contemplated</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(16)(c)(iii)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Protocols
  for Clinical Trials</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(16)(d)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">List of
  Notices Disclosed to Purchaser</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(17)(a)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Environmental
  Permits</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(19)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tax Matters</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  3.02(20)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financial
  Advisor</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule
  6.02(1)(c)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of
  Registration Rights Agreement</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule 6.02(1)(d)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of
  Holdback Escrow Agreement</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule 6.02(1)(e)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of
  Escrow Agreement</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule 6.02(2)(a)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of
  Intervention of the ViroChem Employees</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=83,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=328577,FOLIO='',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-13_ZAU43502.CHC",USER="LPALLES",CD='Mar 12 15:43 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:.5in;width:93.0%;">
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule 6.02(2)(b)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of
  Intervention of the ESOP Holders</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule 6.02(2)(j)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of
  Legal Opinion of McCarthy T&#233;trault LLP</font></p>
  </td>
 </tr>
 <tr>
  <td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.48%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule 6.02(3)(e)</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>
  </td>
  <td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of
  Legal Opinion of Purchaser&#146;s Counsel</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=84,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2",CHK=920922,FOLIO='',FILE="DISK132:[09ZAU2.09ZAU43502]7135-2-KC-13_ZAU43502.CHC",USER="LPALLES",CD='Mar 12 15:43 2009' -->


<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=LPALLES,SEQ=,EFW="2191551",CP="VERTEX PHARMACEUTICALS INC.",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
